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Summary 
Food contact materials (FCMs) are sources of food contamination and human chemical exposure. Some 
chemicals in these materials are known to cause adverse effects, but many are poorly characterized for their 
potential toxicological hazards making risk assessment a challenge. 
The aim of the project was to obtain knowledge on the potential hazards posed by chemicals present in 
FCMs through examining compounds with known usages or suspected of being used in these materials, 
namely bisphenol A (BPA), BPA analogues and fluorinated substances. Furthermore, we developed a 
strategy to identify problematic compounds present in these materials. Specific focus was placed on in vitro 
endpoints assessing endocrine activity. 
BPA, five BPA analogues, and 19 fluorinated substances including fluorochemical containing technical 
mixtures (TMs) were investigated. The in vitro assays included the androgen receptor (AR), estrogen 
receptor (ER), aryl hydrocarbon receptor, retinoic acid receptor, glucocorticoid receptor, p53, and nuclear 
factor (erythroid-derived 2)-like 2 reporter gene assays, and the H295R steroidogenesis assay. The FCM 
strategy was a step-by-step procedure in which extracts from FCMs of paper and board were tested in vitro, 
active extracts were fractionated and tested in vitro, tentative identification was performed in active fractions, 
and tentatively identified compounds were tested in vitro and quantified in the extract.  
BPA analogues generally led to similar estrogenic and antiandrogenic effects in vitro compared to BPA. 
However, the BPA analogue BPS caused less marked effects on most of these endpoints, but led to a more 
pronounced effects on progestagen levels compared to BPA. Likewise, the effects on corticoid levels in the 
H295R steroidogenesis assay differed between the six compounds. These data suggest that the tested 
analogues overall have similar effects on the parameters investigated, though some differed. Therefore 
based on the presented data, the BPA analogues may not be suitable BPA alternatives.  
The fluorinated chemicals exhibited endocrine activities distinct from one another, but subgroups of 
fluorinated chemicals had similar profiles. Polyfluoroalkyl phosphate ester surfactants (PAPs) generally 
decreased progestagen and androgen levels, fluorotelomer alcohols (FTOHs) generally increased ER 
activity, and long-chained perfluorinated alkyl carboxylic acids (PFCAs) generally increased 17β-estradiol 
levels. Two TMs caused estrogenicity in vitro, whereas none of the short-chained PFCAs caused effects. It is 
recommended to conduct further studies on polyfluorinated chemicals as well as TMs to obtain more 
information on the implications of these differences in effect. 
The developed FCM strategy proved useful for identifying potential problematic compounds in FCMs of 
paper and board. All extracts from FCMs led to effects in at least one of the applied in vitro assays and we 
successfully identified five causative agents in two FCMs when applying the full strategy. It is recommended 
to test more FCMs of paper and board with the strategy to obtain information on other potentially problematic 
compounds present in these materials. 
  
The presented data overall suggest that some compounds present in FCMs or suspected of being used can 
exert endocrine activities in vitro, though the implications of these findings with respect to effects in humans 
and exposure to humans remain largely unknown. Nevertheless, it is of concern that so many of the 
materials and compounds led to effects and calls for further studies to be conducted. The data obtained in 
this PhD can be used as a prioritization tool for these purposes. 
  
  
Resumé (summary in Danish) 
Fødevarekontaktmaterialer (FKM’er) er kilder til forurening af fødevarer og menneskelig kemisk eksponering. 
Nogle af de kemikalier, der er tilstede i disse materialer, har kendte toksikologiske effekter, men der findes 
dog stadig mange stoffer, som er dårligt karakteriseret for deres potentielle toksikologiske effekter, hvilket 
gør risikovurdering til en udfordring. 
Formålet med projektet var at få viden om de potentielle toksikologiske effekter forbundet med kemikalier i 
FKM'er ved at undersøge kemikalier, hvis anvendelse er kendt eller som er mistænkt for at blive anvendt i 
disse materialer, såsom bisphenol A (BPA), BPA-analoger og fluorstoffer. Endvidere blev der udviklet en 
strategi til at identificere problematiske kemiske stoffer i disse materialer. Fokus blev i særlig grad lagt på in 
vitro karakterisering af endokrin aktivitet. 
BPA, fem BPA analoger, og 19 fluorerede stoffer, herunder fluorholdige tekniske blandinger (TB’er), blev 
undersøgt in vitro. De anvendte in vitro assays omfattede androgen receptor (AR), østrogen receptor (ER), 
aryl hydrocarbon receptor, retinoic acid receptor, glucocorticoid receptor, p53, and nuclear factor (erythroid-
derived 2)-like 2 reporter gene assays, og H295R steroidogenese assayet. FKM-strategien bestod af en trin-
for-trin procedure, hvor ekstrakter fra FKM'er af papir og pap blev testet in vitro, aktive ekstrakter blev 
fraktioneret og testet in vitro, aktive fraktioner blev tentativt identificeret, og tentativt identificerede stoffer blev 
derefter testet in vitro og kvantificeret i ekstraktet. 
Analogerne til BPA udviste generelt lignende østrogene og antiandrogene effekter in vitro sammenlignet 
med BPA. Dog forårsagede BPA analogen, BPS, mindre markante effekter på de fleste af disse effektmål, 
men førte til en mere udtalt effekt på niveauet af progestagener i forhold til BPA. Effekterne på niveauerne af 
kortikosteroiderne, i H295R assayet, var forskellig for de seks stoffer. Overordnet tyder data dog på, at de 
testede analoger samlet set har effekter som lignede BPAs. Baseret på de konkrete undersøgelser ser 
analogerne derfor ikke ud til at være bedre alternativer til BPA. 
De fluorerede kemikalier udviste forskellige endokrine aktiviteter, omend undergrupper af fluorstoffer havde 
lignende profiler. De polyfluorerede alkyl phosphate ester surfaktanter (PAPs) medførte generelt et fald i 
progestagen og androgen niveauer, hvor fluortelomeralkoholer (FTOHs) generelt medførte forøget ER 
aktivitet og de langkædede perfluoralkyl carboxylsyrer (PFCA'er) forøgede 17β-østradiol niveauer. To TB’er  
udviste østrogenicitet in vitro, mens ingen af de kortkædede PFCA'er forårsagede effekter. Det anbefales at 
foretage yderligere undersøgelser af polyfluorerede kemikalier samt TB’er for at få mere information om 
konsekvenserne af disse forskelle i effekt. 
Den udviklede FKM strategi viste sig nyttig til at identificere potentielle problematiske stoffer i FKM'er af papir 
og pap. Alle ekstrakter fra FKM'er udviste effekt i mindst et af de anvendte assays og ved anvendelse af 
strategien var det muligt at identificere fem stoffer i to FKM’er, som kunne forklare de observerede effekter. 
  
Det anbefales at bruge den udviklede strategi til at teste flere FKM'er af papir og pap for bedre at forstå 
omfanget, såvel som identiteten, af potentielt problematiske forbindelser. 
De præsenterede data tyder samlet set på, at stoffer der anvendes eller mistænkes anvendt i FKM’er, kan 
have endokrine aktiviteter in vitro. Selvom konsekvenserne af disse resultater med hensyn til effekter på 
mennesker, og eksponering af mennesker i nogle tilfælde er ukendte, er det bekymrende, at så mange af de 
testede materialer og kemikalier medførte effekter. Derfor opfordres der til, at der gennemføres yderligere 
undersøgelser af denne type materialer, hvor data fra dette PhD projekt kan bruges som en 
prioriteringsredskab til dette formål.  
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1. Introduction  
Ideally, foods for human consumption are free from chemical contamination. In the modern 
world this has become practically impossible and the efforts are instead put towards minimizing 
human exposure as much as possible to problematic substances that can cause adverse health 
effects. However, potential sources of food contamination are many and include environmental 
toxicants, pesticide residues, packaging materials and many more (Borchers et al. 2010). Thus, 
continued monitoring and testing to assure food safety is both a challenge and an obligation.  
Food contact materials (FCMs), which include packaging and any material the foods come into 
contact with during production, are potential sources of chemical exposure (Borchers et al. 
2010; Grob et al. 2006). Many chemicals are used for FCMs and to date more than 3000 
indirect food additives, including chemicals used in FCMs, have been catalogued (Neltner et al. 
2013). Notably, these catalogues do not differentiate between substances presently in use in 
the production of FCMs with those that are not (Geueke et al. 2014). Furthermore, it is 
estimated that more than 70% of the catalogued substances are not tested for toxicological 
effects to an extent which allows for appropriate risk assessment (Neltner et al. 2013).  
Paper and board FCMs are of particular interest, as no specific regulation exists within the EU 
for these materials. A general framework directive (Article 3) for FCMs exist, which states that 
substances in FCMs should not transfer to foods in amounts that could endanger human health 
(The European Commission 2004). However, in practical terms such guidelines are empty 
promises if the potential toxicity of the substances is unknown. Thus, there is a clear need for 
an approach that gives empirical data on the compounds used in FCMs, especially those of 
paper and board, as well as a strategy on how to prioritize a toxicological investigation of these 
compounds. 
Bisphenol A (BPA) and fluorinated compounds are examples of chemicals or chemical groups 
used in FCMs (EFSA 2006; Geens et al. 2011; Kissa 2001) and that also have been measured 
in humans. For instance, BPA has been measured in human urine from the general US 
population (Calafat et al. 2008), and also in human amniotic fluid (Edlow et al. 2012; Yamada et 
al. 2002), umbilical cord blood (Chou et al. 2011; Lee et al. 2008), and in the placenta (Cao et 
al. 2012; Jimenez-Diaz et al. 2010). Similarly, fluorinated compounds have been measured in 
human sera (D'eon et al. 2009; EFSA 2008; Houde et al. 2006), umbilical cord blood (Kim et al. 
2011; Monroy et al. 2008), and breast milk (So et al. 2006). These studies clearly show that the 
general population, including unborn babies, is exposed to these compounds. Foetal exposure 
is of particular concern, as endocrine disruptors (EDs) have been implicated in impaired foetal 
development, which can manifest as disease or developmental disorders at birth or later in life 
  
(UNEP/WHO 2013) and the endocrine disruptive potential of these compounds have been 
demonstrated by numerous studies (Biegel et al. 1995; Biegel et al. 2001; Bookstaff et al. 1990; 
Cook et al. 1992; Feng et al. 2009; Gould et al. 1998; Grignard et al. 2012; Kitamura et al. 2005; 
Krishnan et al. 1993; Lee et al. 2003; Liu et al. 2009; Liu et al. 2010a; Liu et al. 2010b; Paris et 
al. 2002; Zhang et al. 2011a). 
In recent years the public awareness of BPA and its potential effects has increased and several 
BPA-free products are on the market. BPA has been prohibited in the manufacture of 
polycarbonate baby feeding bottles within the EU (The European Commission 2011) and in 
Canada the import, sale and advertisement of polycarbonate baby bottles containing BPA has 
been prohibited (Government of Canada 2010). This inevitably will lead to the introduction of 
alternative compounds to replace the use of BPA. A growing concern is that structural 
analogues could be used as substitutions and that these may exert similar effects as BPA.  
The toxicology of some fluorinated chemicals is fairly well established, however a range of 
fluorinated alternatives are being produced (Wang et al. 2013) for which little information on the 
structures, usages, and toxicology is publically available (Scheringer et al. 2014). There is some 
evidence that longer-chained perfluorinated alkyl carboxylic acids (PFCAs) have endocrine 
disruptive activities both in vivo and in vitro, itself warranting further investigations. Furthermore, 
many of the alternatives are shorter-chained (Scheringer et al. 2014), which potentially break-
down to short-chained PFCAs, however almost nothing is currently known about their potential 
endocrine activities. Therefore, it is imperative to conduct further studies on fluorinated 
alternatives and their degradation products to ascertain that these do not exhibit similar 
activities as the long-chained PFCAs. 
1.1 Study objectives, hypotheses, and methodology 
Objectives 
The overall aim was to understand the potential toxicology of chemicals present in FCMs by, 
1. expanding on toxicological knowledge of BPA analogues to understand if these would 
be good alternatives to BPA. 
2. characterizing the endocrine activity of fluorinated compounds for which little is known, 
as well as compare the endocrine disruptive potential across groups of fluorinated 
compounds. 
3. developing a strategy to identify problematic compounds used in FCMs of paper and 
board. 
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Hypotheses 
The following hypotheses were tested to fulfil the aim of the project, 
1. The endocrine mechanisms-of-action of structural analogues to BPA are comparable to 
that of BPA. 
2. Alternative fluorinated chemicals, including short-chained fluorinated compounds, 
harbour endocrine activity in vitro through similar mechanism-of-action as long-chained 
PFCAs. 
3. Biodirected analysis in combination with analytical chemical tools can be used to 
identify problematic compounds present in food packaging materials of paper and 
board. 
Study methodology 
A panel of in vitro assays was applied. The data presented in this PhD mainly focus on the 
endocrine endpoints covered in this panel including estrogen receptor (ER) and androgen 
receptor (AR) activities, and interferences with steroid hormone synthesis. 
Two approaches were applied,  
- The bottom-up approach was used to test for effects of single compounds to elucidate 
the toxicological potential of single chemicals known to be present or suspected of 
being present in food packaging. We investigated BPA and five analogues, as well as 
nineteen fluorinated substances by this approach. 
 
- The top-down approach was used to test extracts from FCMs of paper and board of 
unknown composition to characterize the hazard posed by these as well as identify 
potential causative agents. We investigated 20 extracts from paper and board food 
packaging materials.  
1.2 Contribution to publications 
My expertise is within in vitro assays for endocrine activity and knowledge on fluorinated 
chemicals, BPA and BPA analogues. Collaborative partners have been responsible for high 
pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis of steroid 
hormones, Quantitative Structure-Activity Relationship (QSAR) modelling, in vitro activity in the 
retinoic acid receptor (RAR), nuclear factor (erythroid-derived 2)-like 2 (nrf2), p53, and 
glucocorticoid receptor (GR) CALUX reporter gene assays, and the extraction, fractionation, 
identification, and quantification in FCMs of paper and board. Thus these methods are not my 
areas of expertise.   
  
2. Background 
The experimental work of this PhD project centred around three areas; BPA analogues, 
fluorinated substances, and complex mixtures extracted from FCMs. This chapter will give a 
brief introduction to the field of endocrine disruption, as well as give insight into the two known 
groups of compounds used or suspected of being used in FCMs; fluorinated substances, BPA, 
and BPA analogues. It will also outline some methods previously applied to obtain information 
on the potential toxicology of chemicals used in FCMs. 
2.1 Endocrine disruption 
Endocrine disruptors (EDs) are compounds that, by affecting the hormone system, lead to 
adverse health effects in the exposed individual or its offspring and is defined in the Global 
assessment of the state-of-the-science of endocrine disruptors report (IPCS 2002) as, 
“An endocrine disruptor is an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse health 
effects in an intact organism, or its progeny, or (sub) populations.” 
Endocrine related diseases in humans have increased such as genital malformations, endocrine 
related cancers, neurodevelopmental disorders, and obesity (UNEP/WHO 2013). These 
increases occur at a rate that exclude genetic changes as the sole origin of disease, and thus it 
has been proposed that other factors might play a role, including chemical exposures. 
Associations between some of these diseases and chemical exposure have been shown in 
epidemiological studies (UNEP/WHO 2013). Similarly, some of these effects have been induced 
in vivo with exposure to compounds (Diamanti-Kandarakis et al. 2009), such as changes in 
mammary gland development with exposure to a known estrogenic compound (Mandrup et al. 
2012) and malformations of male sex organs with exposure to known antiandrogenic 
compounds (Kim et al. 2010; McIntyre et al. 2001).  
2.1.1 The endocrine system and mechanisms of endocrine disruption 
Hormones control processes such as organ formation and cell differentiation during 
development, but also maintain adult organ and tissue function. Due to this critical role during 
development, it is believed that the foetus and neonate are particularly sensitive to exposure to 
EDs, as it may lead to permanent damage manifesting at birth or later in life (UNEP/WHO 
2013). In order to understand how EDs can exert their effect on the endocrine system a brief 
introduction to the system will be given here. 
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The endocrine system consists of tissues and glands, such as the gonads, the thyroid gland, 
the adrenal gland, and the pituitary gland, that communicate with one another and other parts of 
the body by producing and secreting hormones, which are transported throughout the body 
through the vasculature. Many different hormones exist, such as insulin, androgens, estrogens, 
leptin, and thyroid hormones, however as this thesis examines effects on the estrogen and 
androgen receptors as well as steroidogenesis, steroid hormones will be the main focus of this 
chapter. 
Steroidogenesis is the process by which steroid hormones are synthesized. The synthesis 
mainly takes place in the adrenal gland and the gonads; albeit the major hormone products 
differ between these tissues. The adrenal gland synthesises aldosterone, cortisol, 
corticosterone, as well as adrenal androgens. The testes synthesise androgens, foremost 
testosterone, whereas the ovaries synthesise estrogens (UNEP/WHO 2013). Figure 1 gives an 
overview of steroidogenesis.  
 
Figure 1: Steroidogenesis. Boxes = proteins involved in conversion or transport. 
  
The step-by-step synthesis of steroid hormones starts with cholesterol, which is transported to 
the inner mitochondrial membrane by steroidogenic acute regulatory (StAR) protein and 
peripheral-type benzodiazepine receptor (Bzrp). Here cholesterol side-chain cleavage enzyme 
(CYP11A) converts cholesterol into pregnenolone, which diffuse to the smooth endoplasmatic 
reticulum where the conversion into androgens and estrogens takes place. Several enzymes 
are involved in this process including CYP17, 3β-hydroxysteroid dehydrogenase (3β-HSD2), 
17β-HSD, and aromatase (CYP19A1). In the adrenal gland the synthesis of the corticoids is 
catalysed by CYP21A2 and CYP11B1. The conversion of testosterone into its more potent form 
dihydrotestostesterone mainly takes place in the target tissue catalysed by 5α-reductase 
(Maglich et al. 2014; Scott et al. 2009). Steroidogenesis is regulated by the hypothalamus and 
the anterior pituitary, and the hormones produced in the adrenal gland and testes exert negative 
feedback on these glands (IPCS 2002). 
After synthesis, steroid hormones are secreted 
into the bloodstream where they are transported 
bound to proteins to their respective target 
tissues, where non-bound hormone diffuse 
across the cell membrane and act by binding to 
their respective receptors, Figure 2. The 
androgen and estrogen receptors are located in 
the cytosol of cells. Upon ligand binding, the 
receptor translocate to the nucleus where it 
binds to specific DNA sequences to regulate 
transcription of target genes, which ultimately 
lead to changes in cell function (Porcher et al. 
2009).  
Endocrine disruption can occur through interference with any of the above processes, Figure 3, 
and EDs can interfere with several of these mechanisms simultaneously. Interferences can 
occur through receptor-mediated and non-receptor-mediated mechanisms, of which the latter 
cover mechanisms such as interferences with synthesis, protein bound transport, or causing 
increased/decreased metabolism of endogenous hormones. At the receptor level EDs can exert 
agonistic or antagonistic effects leading to induced or inhibited receptor activity (Porcher et al. 
2009). Many xenobiotics have shown the ability to decrease the activity of the AR and increase 
the activity of the ERs (Kojima et al. 2004; Vinggaard et al. 2008). 
 
Figure 2: Steroid hormone receptor 
activation (from UNEP/WHO 2013). 
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Figure 3: Mechanisms of an endocrine disruptor (ED) (Adapted from Porcher et al., 2009). 
2.2 Bisphenol A and its structural analogues 
Bisphenol A is widely investigated for its endocrine disruptive potential and the literature on the 
use, exposure, toxicokinetics and effects of this compound is extensive. BPA analogues are 
much less studied, and thus this chapter will give an introduction to BPA and the analogues 
based on currently available information.  
The term bisphenol is used for compounds containing two hydroxyphenyls attached to one 
another by a bridge. In BPA the hydroxyl groups are placed in the para position and the bridge 
consists of one carbon to which two methyl groups are attached. Many other bisphenols exists, 
in which the bridge can be more or less polar and which vary with respect to the placement of 
the hydroxyl groups. BPA and the analogues included in this PhD project are shown in Figure 4. 
In this thesis, the term BPA analogues also covers compounds not containing two 
hydroxyphenyl groups, but rather refers to compounds that have structural similarities to BPA. 
2.2.1 Usage, exposure sources and human biomonitoring 
The primary application of BPA is as a starting material in the production of polymers such as 
polycarbonate and epoxy resins, which are used for multiple applications. In FCMs, 
polycarbonate is used for food and beverage containers, whereas epoxy resins are used as 
coating for food and beverage cans (Geens et al. 2011). Besides these applications, BPA have 
been reported in recycled paper products (Ozaki et al. 2004; Vinggaard et al. 2000), presumably 
originating from thermal paper containing BPA (Geens et al. 2011). It has been estimated that 
diet is the main source of human BPA exposure in the general population followed by exposure 
through contact with thermal paper (EFSA 2013).  
Synthesis 
Transport 
Action 
Metabolism  
ED 
  
BPB, BPF, and BPS have been detected in foods and drinks on several accounts (Cunha et al. 
2011; Gallart-Ayala et al. 2011; Grumetto et al. 2008; Liao and Kannan 2014; Vinas et al. 2010). 
In addition, BPS has been reported in thermal paper (Becerra and Odermatt 2012; Liao et al. 
2012c) and BPF as well as BPS in dust (Liao et al. 2012b). These data suggests that humans 
could be exposed to the BPA analogues through foods, drinks, dust and thermal paper. 
The majority of the human population in developed countries is exposed to BPA. Urine 
concentrations of free BPA plus conjugated BPA was measured in more than 90% of samples 
(n = 2517) in the general US population from 6 years of age and upwards in the period 2003-
2004 (Calafat et al. 2008). Similarly, total BPA was measured in human urine collected from 
seven Asian countries from 2006-2010 (Zhang et al. 
2011b), as well as in Danish children and adolescents 
(Frederiksen et al. 2013). BPA in its free or conjugated 
form have also been measured in amniotic fluid 
(Edlow et al. 2012; Yamada et al. 2002), umbilical 
cord blood (Chou et al. 2011; Lee et al. 2008) and in 
the placenta (Cao et al. 2012; Jimenez-Diaz et al. 
2010), indicating that the foetus is exposed during 
pregnancy. Since the foetus is suspected of being 
particularly sensitive to ED exposure, this could be an 
issue of concern. 
The occurrence of BPA analogues in humans is only 
described in a few studies and the studies are not 
based on large cohorts as that for BPA. Of the BPA 
analogues tested in this study three has currently 
been measured in humans. Liao and co-workers 
(2012a) found BPS both in its free and conjugated 
form in the general US population and in seven Asian 
countries (n = 315) (Liao et al. 2012a) and BPB has 
been reported in human blood from endometriotic 
women from Italy in a small cohort (n = 58) (Cobellis 
et al. 2009). Finally, BPF as well as BFS was detected 
in urine samples (n=94) collected from residents living 
near a bisphenol AF manufacturing plant, though BPF 
was only detected in a small subset of the samples, 
and BPB was not detected in any of the samples 
(Yang et al. 2014). 
Figure 4: Chemical structures and 
CAS numbers of BPA and BPA 
analogues investigated in this PhD 
project. 
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2.2.2 Toxicokinetics 
In humans, BPA is readily absorbed across the gastrointestinal tract and subsequent elimination 
is rapid (Völkel et al. 2002). Human urine elimination half-life has been reported to be between 
4-5.4 hrs after oral administration of labelled BPA in two small study populations (Völkel et al. 
2002; Völkel et al. 2005). In human urine BPA is mainly measured in its conjugated form, BPA-
glucuronide or BPA-sulfate, of which the former is the major metabolite (Vandenberg et al. 
2007).  
Only few studies have reported on the metabolism of BPA analogues and thus I here refer to 
data obtained from sea and river water, well knowing that these may not be representative of 
metabolism in humans or animals. In river water the degradation of BPA, BPB, BPE, BPF, and 
BPS was examined, and it was found that BPF degraded faster than BPA, whereas the 
remaining BPA analogues degraded at a slower rate (Ike et al. 2006). In accordance with the 
findings in river water, BPF showed slightly better degradation efficiencies than BPA in 
seawater, whereas BPS showed no degradation during the time course of the experiments 
(Danzl et al. 2009). These data suggest that the degradation at least in water systems may vary 
between these structurally similar compounds. If a similar degradation pattern takes place in 
humans, this could mean varying half-lives of the different analogues, which might affect their 
potential to exert effects in vivo. 
2.2.3 Toxicological effects 
In recent years, a debate on the potential low-dose effects of BPA has been ongoing as some in 
vivo studies have shown low-dose effects on endpoints such as changes in normal behavioural 
development (Xu et al. 2010), changes in obesity associated parameters (Miyawaki et al. 2007), 
decreased anogenital distance (Christiansen et al. 2014), and disturbed mammary gland 
development (Moral et al. 2008) with prenatal followed in some cases by postnatal exposure. 
The recently proposed tolerable daily intake of BPA of 5µg/kg/d is however based on general 
toxicity on the kidney in male mice in a two-generational toxicity study (EFSA 2014).  
2.2.4 Endocrine activity in vitro 
BPA is widely investigated for affecting several endocrine targets in vitro. The estrogenic 
potential of BPA has been reported in numerous studies, in which the values for concentrations 
causing 50% of the maximum response (EC50) ranged from 0.2-2.32 µM (Grignard et al. 2012; 
Kitamura et al. 2005; Kuruto-Niwa et al. 2005; Paris et al. 2002). In these studies the potency of 
17β-estradiol was >10,000 times more potent than BPA. Besides, antiandrogenic potential of 
BPA has been reported on the AR (Kitamura et al. 2005; Lee et al. 2003; Paris et al. 2002), as 
well as the ability to decrease androgen levels in the H295R steroidogenesis assay (Zhang et 
  
al. 2011a). This decrease in androgen levels were accompanied by increased estrogen levels 
(Zhang et al. 2011a).  
The effects of BPA analogues are not as thoroughly investigated for endocrine disruptive 
potential as BPA itself. However some studies suggest that structurally similar chemicals cause 
effects on the same endpoints in vitro. Amongst the compounds investigated were BPA, BPB, 
BPE, BPF, BPS, and 4-cumylphenol (HPP). These compounds all showed the potential to be 
estrogenic and antiandrogenic (Kitamura et al. 2005), however the potency differed between the 
compounds and also between the studies (Grignard et al. 2012; Kitamura et al. 2005). 
A few studies have examined a broad range of structural analogues to BPA for estrogenicity 
and antiandrogenicity and found some structural traits which affected the effect on these 
endpoints (Kitamura et al. 2005; Paris et al. 2002; Rivas et al. 2002). Overall the results from 
these studies suggest that estrogenicity as well as antiandrogenicity increase when the hydroxyl 
groups are placed in the para position compared to the meta and the ortho position. For 
estrogenicity at least one phenyl group is needed for effect to occur and the effect increase 
when two phenyl groups are present, whereas for antiandrogenic effects only one phenyl group 
is needed and the response does not change when a second phenyl group is introduced. 
Finally, for both estrogenicity and antiandrogenicity it seems that the introduction of a polar 
group in/on the central carbon reduces the effects (Kitamura et al. 2005; Paris et al. 2002; Rivas 
et al. 2002). 
2.3 Fluorochemicals 
Fluorinated chemicals cover a wide range of structurally diverse compounds, which are used for 
multiple applications. In FCMs of paper and board fluorinated chemicals impart repellency 
properties to the materials (Kissa 2001). Within the last couple of decades, a shift in 
fluorochemical production methods has taken place, as a consequence of voluntary phase-outs 
by the industry as well as implementation of regulations for some fluorochemicals (OECD 2013; 
Stockholm Convention 2009; US EPA 2000). These actions have in some cases led to a shift in 
the production towards short-chained chemistry (Scheringer et al. 2014). The following chapter 
will focus on the compounds investigated in this study including compounds used in coatings for 
FCMs of paper and board, polyfluoroalkyl phosphate ester surfactants (PAPs), and their 
metabolic products, fluorotelomer alcohols (FTOHs) and perfluorinated alkyl carboxylic acids 
(PFCAs). 
The term fluorochemicals or fluorinated chemicals are here defined as an aliphatic substance 
containing at least one fully fluorinated carbon atom, also called polyfluoroalkyl substances 
(PFAS). These compounds contain a fluorinated moiety and a functional head group such as an 
alcohol or carboxylic acid (Buck et al. 2011; Trier et al. 2011) and the fluorinated moiety can 
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vary in chain lengths from typically 4-15 carbons (Prevedouros et al. 2006). The degree of 
fluorination classifies the compounds as either a polyfluoroalkyl substances, defined as above, 
or perfluoroalkyl substances in which all carbons except that in the functional head group are 
fully fluorinated (Buck et al. 2011). PAPs, FTOHs, and PFCAs tested in this PhD project thus 
belong to the polyfluoroalkyl substances, whereas only the PFCAs are perfluoroalkyl 
substances. 
2.3.1 Exposure sources and human biomonitoring  
Human exposure sources to perfluorooctanoic acid (PFOA) have been estimated to be through 
intake of food and drinking water (Trudel et al. 2008; Vestergren et al. 2008), however 
fluorinated chemicals have also been measured in indoor dust (D'Hollander et al. 2010), 
suggesting this as an alternative source of human exposure. Furthermore, D’eon et al. (2011b) 
have suggested that additional sources to PFOA exposure may exist, such as exposure to 
fluorinated chemicals, for instance in FCMs of paper and board, which can be converted into 
PFCAs (D'eon and Mabury 2011b). In support of these findings, PAPs, a precursor of PFCAs, 
can migrate from FCMs of paper and board into food and food simulants (Begley et al. 2005; 
Begley et al. 2008). 
The serum half-life of PFOA in humans is long, T½ of approximately 3.8 years (Olsen et al. 
2007) and in animals the T½ generally decrease with PFCA chain length (Lau 2012). PFOA in 
serum/plasma/whole blood has been reported ranging from 3 to 213 nM in the general 
population worldwide (EFSA 2008). Furthermore, several other PFCAs have been measured in 
human serum/plasma (Calafat et al. 2007; Olsen et al. 2012), as well as homologues of diPAPs 
in a total concentration of 4.5 µg/L in one study (D'eon et al. 2009). 
Fluorinated compounds have also been measured in human body compartments of relevance 
to foetal and neonatal exposure. PFOA has in two studies been reported in 100% of umbilical 
cord blood samples (Apelberg et al. 2007; Monroy et al. 2008) and correlations between 
maternal and umbilical serum levels of PFOA and longer-chained PFCAs was found in women 
from Seoul (Kim et al. 2011). Transfer to breast milk of PFOA and diPAPs has also been 
reported (Kubwabo et al. 2013; So et al. 2006; Völkel et al. 2008). These human biomonitoring 
data suggests that not only is the general population exposed to fluorinated compounds, but the 
unborn or newborn child may also be exposed through the placenta or breast milk. 
2.3.2 Toxicokinetics 
Based on human biomonitoring data, some fluorinated compounds can pass biological barriers 
and enter the human body, as the compounds are measured in blood and other human body  
  
O
O
O
P
O
F F
FF
FF
FF
FF
FF
F
F
F
F F
RF1
RF2
O
O
O
P
O
F F
FF
FF
FF
FF
FF
F
F
F
F F
RF1
O
O
O
P
O
F F
FF
FF
FF
FF
FF
F
F
F
F F
OH
F F
FF
FF
FF
FF
FF
F
F
F
F F
H
F F
FF
FF
FF
FF
FF
F
F
F
F F O
H
F F
FF
FF
FF
FF
FF
F
F
F
F O
H
OH
F F
FF
FF
FF
FF
FF
F
F
F
F O
H
OH
F F
FF
FF
FF
FF
FF
F
F
F
O
OH
F F
FF
FF
FF
FF
FF
F
F
F
F F O
OH
F F
FF
FF
FF
FF
FF
F
F
F
F F
O
FTOH
FTOH
PO43-
Biotic hydrolysis
Biotic hydrolysis
Biotic hydrolysis
monoPAPS
triPAPS
diPAPS
FTOH
FTUALFTAL
FTCA FTUCA
-HF
-HF
Non enzymatic
elimination
Non enzymatic
elimination
Oxidation
Oxidation Oxidation
PFCA2PFCA1
Oxidation Oxidation
C
on
ju
ga
t io
n
C
on
ju
ga
t io
n
C
on
ju
ga
t io
n
 
Figure 5: Metabolic pathway of trialkylated, dialkylated, and monoalkylated polyfluoroalkyl phosphate ester 
surfactants (PAPs) into perfluorinated alkyl carboxylic acids (PFCAs) through the intermediate metabolite 
fluorotelomer alcohol (FTOH). RF = fully fluorinated carbon chains. Abbreviations: fluorotelomer aldehyde 
(FTAL), fluorotelomer carboxylic acid (FTCA), fluorotelomer unsaturated aldehyde (FTUAL), and 
fluorotelomer unsaturated carboxylic acid (FTUCA). (D'eon and Mabury 2007; D'eon and Mabury 2011a; 
Fasano et al. 2006; Kudo et al. 2005; Martin et al. 2005).  
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compartments. These findings have also been corroborated by animal studies where animals 
subjected to oral exposure of PFOA are found to absorb this fluorinated compound into the 
circulation (Kennedy et al. 2004). The absorption of the precursor compounds, PAPs, were 
examined only in a few studies; however they illustrated that diPAPs homologues can be 
measured in blood after a single oral dose (D'eon and Mabury 2007; D'eon and Mabury 2011a). 
8:2 monoPAPs has also displayed an ability to absorb across the gastrointestinal tract (D'eon 
and Mabury 2007). After absorption, fluorinated chemicals are typically found at the highest 
concentrations in the liver, kidney and serum (Lau et al. 2007).  
Some polyfluoroalkyl substances have the potential to metabolize into the highly persistent 
PFCAs of which the latter most likely does not undergo further metabolism or conjugation 
(Martin et al. 2005). 8:2 diPAPs was administered in rats and successively monoPAPs, PFOA, 
and other intermediate metabolites were measured, suggesting that diPAPs was 
dephosphorylated in several steps to FTOH, which in turn was metabolized into PFCAs in the 
rat (Figure 5) (D'eon and Mabury 2007). The metabolism of FTOH into PFCAs involves the 
formation of several intermediate metabolites, several of which form conjugates including FTOH 
itself (Fasano et al. 2006; Kudo et al. 2005; Martin et al. 2005).  
2.3.3 Toxicological effects 
In animal studies, exposure to PFCAs of varying chain lengths led to enlarged liver mainly 
through hepatocytic hypertrophy and effects such as hepatocellular vacuolation, degeneration, 
necrosis, and lipid droplet accumulation has also been observed with exposure to some 
fluorochemicals. Tumour induction in the rat liver, pancreas, and testis has been reported with 
chronic PFOA exposure. Furthermore, developmental effects with prenatal PFOA exposure in 
mice include neonatal mortality, growth deficits, as well as developmental delays. Finally, PFOA 
exposure has been associated with immunotoxicity (Lau 2012).   
2.3.4 Endocrine disruptive potential  
Fluorinated chemicals have been reported to exert endocrine disruptive effects by interfering 
with the thyroid hormone system or the sex hormone system (Lau et al. 2007). The latter, which 
is the focus of this thesis, has been shown to be affected by several long-chained PFCAs, 
including PFOA, perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), and 
perfluorododecanoic acid (PFdoDA). However, only limited to no data exists for FTOHs, short-
chained PFCAs, and PAPs.  
Several studies have reported effects on steroid hormones levels following PFOA exposure. In 
vivo studies generally report on an increase in serum 17β-estradiol levels (Biegel et al. 1995; 
Biegel et al. 2001; Cook et al. 1992), but show variable effects on testosterone levels; no 
  
change (Biegel et al. 1995; Biegel et al. 2001) or decreasing trend (Cook et al. 1992) following 
exposure. An increase in testosterone levels in vivo within the testicular interstitium have also 
been reported (Biegel et al. 1995). In vitro, PFOA led to decreased testosterone synthesis in 
isolated Leydig cells (Biegel et al. 1995; Zhao et al. 2010). At the receptor level, PFOA can 
increase ER and inhibit AR mediated transactivation in vitro (Kjeldsen and Bonefeld-Jorgensen 
2013), though the latter was not observed in a previous study (Vinggaard et al. 2008). In 
essence, these data suggest that PFOA have estrogenic potential, however the ability to affect 
testosterone synthesis and AR activity of PFOA remain unclear. 
Similar to PFOA, in vivo exposure to PFNA can lead to increased serum 17β-estradiol levels 
and decreased testosterone levels at 5 mg/kg/day. At lower concentrations, testosterone levels 
were elevated (Feng et al. 2009), however as body weight measurements were not reported, it 
is difficult to exclude general toxicity as accounting for these effects. In vitro studies have found 
similar effects on these hormones (Kraugerud et al. 2011), and also report decreased activity of 
the AR and no change in ER activity (Kjeldsen and Bonefeld-Jorgensen 2013). These data 
indicate that PFNA, at least in vitro, have the potential to exert antiandrogenic effects at the 
levels of androgen synthesis and receptor activity and estrogenic effects through increasing 
17β-estradiol levels. It remains unclear if the similar observed effects in vivo are caused by 
general toxicity or through similar mechanisms.  
PFDA and PFdoDA have been reported to decrease plasma/serum androgen levels (Bookstaff 
et al. 1990; Shi et al. 2009a). These changes were also observed in vitro following PFDA 
exposure and challenge with human chorionic gonadotropin (Boujrad et al. 2000). In addition, 
17β-estradiol levels was either not affected or decreased with exposure to PFdoDA in male and 
female rats respectively, though the decrease in females occurred only when body weight was 
reduced (Shi et al. 2009a; Shi et al. 2009b). PFDA, but not PFdoDA, was reported to decrease 
AR mediated transactivation in vitro, but neither compound affected ER activity (Kjeldsen and 
Bonefeld-Jorgensen 2013). This suggests that these longer-chained PFCAs exhibit 
antiandrogenic potential in vivo and/or in vitro and further, that PFDA and PFdoDA are not 
estrogenic. However, considering the estrogenicity of PFNA and PFOA, this should be 
investigated further.  
In accordance with the observed increased in 17β-estradiol levels for long-chained PFCAs, both 
6:2 and 8:2 FTOH led to similar increases in adult zebrafish (Liu et al. 2009; Liu et al. 2010a). 
6:2 FTOH led to increased testosterone in both sexes (Liu et al. 2009), whereas the effects of 
8:2 FTOH were sex specific, causing increased levels in females and decreased levels in males 
(Liu et al. 2010a). Decreased testosterone levels were also shown in the H295R 
steroidogenesis assay following exposure to 8:2 FTOH (Liu et al. 2010b). In vitro studies also 
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suggest that both compounds are estrogenic by increasing proliferation in the MCF-7 
proliferation assay (Maras et al. 2006). 
Albeit somewhat inconsistent, data on FTOHs and long-chained PFCAs point towards these 
compounds being both estrogenic and antiandrogenic. Therefore, it can be speculated that any 
of these compounds, alone or in combination, can affect sex hormone synthesis and action, 
ultimately impacting on reproductive health. In support of this, foetal as well as neonatal 
exposure to PFOA has led to changes in mammary gland development (White et al. 2011), an 
effect which has previously been reported with exposure to synthetic estrogens (Mandrup et al. 
2012), suggesting that PFOA may lead to this effect through exhibiting estrogenic potential in 
vivo. Therefore based on all these data, any putative endocrine disruptive potential of 
fluorinated chemicals should be investigated further. 
2.4 Strategies to address toxicity of food contact materials 
Part of this PhD project revolved around developing a strategy to address toxicities of chemical 
in FCMs of paper and board as well as identifying causative agents arising from FCM by use of 
bioassay guided analysis and analytical chemical tools. The following chapter will briefly 
introduce some in vitro endpoints which have been used previously for investigating effects of 
paper and board materials. These studies included endpoints such as genotoxicity, cytotoxicity, 
estrogenicity, and effects on the aryl hydrocarbon receptor (AhR) activity (Binderup et al. 2002; 
Lopez-Espinosa et al. 2007; Ozaki et al. 2004; Ozaki et al. 2005; Vinggaard et al. 2000; Weber 
et al. 2006).  
In a project called the BIOSAFEPAPER project endpoints covering cytotoxicity and genotoxicity 
were used. When testing extracts from FCMs of paper and board several led to cytotoxicity, 
whereas only few led to effects on genotoxicity (Weber et al. 2006). However, other studies 
have shown genotoxic potential of several FCM samples (Ozaki et al. 2004; Ozaki et al. 2005). 
Estrogenicity of paper and board has been investigated in at least two studies, where several of 
the samples caused effects (Lopez-Espinosa et al. 2007; Vinggaard et al. 2000). Finally, the 
AhR reporter gene assay showed positive response in all extracts in one study, though the 
samples size was small (Binderup et al. 2002).  
Furthermore, one study have implemented a fractionation step as part of the process, when 
wanting to identify causative agents in FCMs. Ozaki and co-workers tested FCMs of paper and 
board for their potential to cause DNA damage (Ozaki et al. 2004) and found several of these to 
cause effect. By fractionating the extracts and subsequently testing the fractions in vitro, they 
successfully identified two potential causative agents (Ozaki et al. 2005).  
  
The studies above all illustrate the usefulness of applying a bioassay-guided approach to obtain 
knowledge on potential hazards of compounds in FCMs. Further, they show that including 
genotoxicity, cytotoxicity, estrogenic endpoints, the AhR reporter gene assay, as well as a 
fractionation step to assess toxicities of FCMs and identifying causative agents in these, may be 
a promising starting point.  
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3. Experimental design 
Two approaches were applied to test the potential toxicology of compounds present or 
suspected of being used in FCMs in vitro, the bottom-up and the top-down approach. Many of 
the same assays were applied in these approaches and thus a brief introduction to the assays 
in which endocrine activity was assessed is given here. Other assays were also included in the 
Manuscripts covering endpoints such as genotoxicity and oxidative stress. A detailed 
description of the experimental methods is given in Manuscript 1-4. 
The AR reporter gene assay is conducted in the Chinese hamster ovary cell-line transfected 
with the human AR expression vector as well as the mouse mammary tumour virus (MMTV)-
luciferase vector (Vinggaard et al. 1999). Upon activation of the receptor the receptor-ligand 
complex is translocated to the nucleus leading to transcription of luciferase. Successively 
luciferin is added and is converted by luciferase into a product, which can be measured as 
luminescence. The ER reporter gene assay is based on a similar principle. The human ovarian 
adenocarcinoma cell-line is used, which is stably transfected with the reporter gene and 
endogenously express both ERα and ERβ (OECD 2012). In the H295R steroidogenesis assay, 
the human adreno-carcinoma cell-line is used. The cells have characteristics of zonally 
undifferentiated human foetal adrenal cells and contain all the proteins necessary to synthesize 
corticosteroids and sex hormones (OECD 2011). Steroid hormones can be measured in the 
supernatant after assay completion. In this PhD up to 10 steroid hormones were measured, and 
gene expression of several genes coding for central proteins involved in steroidogenesis were 
examined for some compounds. 
These assays cover some of the proposed mechanisms-of-action, which may facilitate 
endocrine disruptive effects, which are illustrated in figure 3. Thus, data obtained from the 
assays provide information on whether the compounds can target several mechanisms 
simultaneously leading to an overall greater endocrine activity. 
3.1 The bottom-up approach 
The bottom-up approach covers the classical toxicological approach in which effects of single 
compounds are tested. BPA, five BPA analogues, and nineteen fluorinated substances were 
investigated in 4-9 different in vitro assays, Table 1. The BPA analogues were chosen based on 
the usage of some of these; however the main objective was to test if slight structural changes 
in the compounds could lead to altered potency, efficacy, and mechanism-of-action compared 
to BPA. The selected fluorinated substances represent active ingredients in some technical 
mixtures (TMs) intended for coating of FCMs (PAPs), intermediate metabolites of PAPs 
(FTOHs), and final metabolites of PAPs (PFCAs). Finally, three TMs intended for use in FCMs 
  
of paper and board were included. The TMs contained fluorochemicals for which the specific 
structures, concentrations and levels of residuals are largely unknown. 
Table 1: Substances tested in vitro in the bottom-up approach. In vitro assays included the androgen 
receptor (AR), estrogen receptor (ER), aryl hydrocarbon receptor (AhR) reporter gene assays and the 
H295R steroidogenesis assay (H295R). Further, the retinoic acid receptor (RAR), the glucocorticoid 
receptor (GR), the nrf2, and the p53 CALUX reporter gene assays were used. For abbreviations of 
compounds refer to the Abbreviation list. Color code: Grey = tested, white = not tested.  
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3.2 The top-down approach 
The top-down approach was devised to assess potential toxicity of chemicals present in FCMs 
of paper and board for which the chemical composition is unknown. The FCM samples are 
presented in Manuscript 4 and represent a broad range of intended applications, storage times, 
and materials. At present only data from the AR, ER, and AhR reporter gene assays are 
included in Manuscript 4, however it is intended that the final strategy will contain several other 
assays including the nrf2 CALUX, p53 CALUX, RAR CALUX, GR CALUX, peroxisome 
proliferator-activated receptor alpha and gamma (PPARα, PPARγ) reporter gene assays as well 
as the Comet assay and the Ames test. 
The strategy consists of several steps, as illustrated in Figure 6, which are described in detail in 
Manuscript 4 and include 1) production of extracts from FCMs of paper and board, 2) testing of 
extracts in vitro, 3) fractionation of selected active extracts, 4) testing of fractions in vitro, 5) 
tentative identification of compounds in active fractions, 6) selection of final list of tentatively 
identified compounds for testing based on read-across, biophores, and commercial availability, 
7) in vitro testing of selected tentatively identified compounds, 8) confirmation of tentatively 
identified compounds and quantification of identified compounds, and 9) calculation of 
equivalence factors (EQs) based on concentrations of identified compounds as well as dose-
response parameters for the identified compounds as well the extract.  
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Figure 6: Step-by-step workflow for the FCM strategy. Numbers indicate, 1) production of 
extracts from FCMs of paper and board, 2) in vitro testing of extracts, 3) fractionation of extracts 
exhibiting in vitro activity, 4) in vitro testing of fractions from active extracts, 5) tentative 
identification of compounds based on in vitro activity of fractions, 6) selection of tentatively 
identified compounds by expert judgment for further in vitro examination, 7) testing of selected 
tentatively identified compounds in vitro, 8) quantification of selected tentatively identified 
compounds causing in vitro activity, 9) calculation of equivalence factors (EQs). Abbreviations: 
ID = identification, FCM = food contact material. 
  
  
4. Results 
A brief summary of major findings presented in Manuscript 1-4 are listed below. 
4.1 Bisphenol A and structural analogues 
Manuscript 2 
Are structural analogues to bisphenol A safe alternatives?  
Rosenmai, A.K., Dybdahl, M., Pedersen, M., van Vugt-Lussenburg, B.M.A., Wedebye, E.B., 
Taxvig, C., and Vinggaard, A.M., 2014. Tox Sci. 139, 35-47. 
The aim of this study was to compare the toxicological effects of BPA to that of its analogues 
BPB, BPE, BPF, BPS, and HPP. Together with BPA, these five analogues were investigated 
across a battery of in vitro assays and QSAR models. The endpoints examined covered 
endocrine disruption such as ER and AR activities as well as effects on steroidogenesis, but 
also endpoints related to metabolism, teratogenicity, genotoxicity, and carcinogenicity.  
The observed effects on AR and ER activity were similar for BPA and the five analogues, and 
the compounds generally exhibited similar potencies. One exception was BPS, which was less 
potent on ER activity compared to the remaining test compounds and showed only a decreasing 
trend on AR activity. Overall, compound exposure in the steroidogenesis assays led to 
decreased androgen levels and increased estrogen and progestagen levels. An exception is 
BPS, which did not affect estrogen levels and showed a marked effect on progestagen levels 
compared to BPA, which did not affect progesterone and led to a decreasing trend on 17α-OH 
progesterone in this assay. Corticosteroid levels differed qualitatively between the test 
compounds.  
 
4.2 Fluorinated chemicals 
Manuscript 1 
Fluorochemicals used in food packaging materials inhibit male sex hormone synthesis 
Rosenmai, A.K., Nielsen, F.K., Pedersen, M., Hadrup, N., Trier, X., Christensen, J.H., and 
Vinggaard, A.M., 2013. Toxicol. Appl. Pharmacol.. 266, 132-142. 
The aim of the investigation was to obtain information on the potential endocrine activities on 
AR and steroidogenesis of six fluorinated compounds. To achieve this, we examined four PAPs, 
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as well as 8:2 FTOH and PFOA in vitro in the AR reporter gene assay and the H295R 
steroidogenesis assay.  
Three of the test compounds, namely 8:2 diPAPs, 8:2 monoPAPs, and 8:2 FTOH, generally led 
to decreases in androgen and progestagen levels, and led to increased levels of at least one of 
the measured estrogens. CYP19 mRNA levels were increased with exposure to 8:2 diPAPs, 8:2 
monoPAPs, and 8:2 FTOH, whereof the two latter also led to decreased Bzrp mRNA levels. 
None of the remaining genes were affected with exposure to any of the six fluorinated 
chemicals. 8:2 triPAPS, 10:2 diPAPs, and PFOA also led to decreases in some of androgens 
measured and caused an increase in at least one of the measured estrogens. No effect was 
observed on AR activity of any of the compounds.  
Manuscript 3 
Fluorinated compounds and technical mixtures for use in food contact materials have estrogenic 
activity in an in vitro screening 
Rosenmai, A.K., Trier, X., Taxvig, C., van Vugt-Lussenburg, B.M.A. and Vinggaard, A.M. 
Manuscript in preparation. 
In this study, we examined sixteen fluorinated chemicals and three fluorine-containing TMs for 
the ability to interfere with the endocrine system in vitro as well as compare the activities on 
different endpoints between the compounds. Endpoints such as genotoxicity and oxidative 
stress were also included in the panel of in vitro assays. The compounds included were four 
PAPs, their intermediate metabolites (FTOH), as well as their final metabolites (PFCAs ranging 
from perfluorobutanoic acid (PFBA) to PFdoDA). Furthermore, we included three fluorine-
containing TMs, TM1-TM3, of unknown composition intended for coating of FCMs of paper and 
board.  
The main effects observed for several of the tested compounds were estrogenic potential either 
through increasing ER activity or increasing estrogen levels. TM2, PFDA, perfluoroundecanoic 
acid (PFunDA), and PFdoDA led to increases in 17β-estradiol levels, whereas TM2, TM3, 8:2 
monoPAPs, 8:2 FTOH 6:2 FTOH, 4:2 FTOH, PFNA, and PFOA increased ER activity. Only 8:2 
triPAPs and 8:2 monoPAPs led to increased AhR activity. The short-chained PFCAs did not 
cause effect in any of the assays, and none of the compounds led to effects on AR activity. 
  
  
4.3 Food contact materials 
Manuscript 4 
A strategy to identify problematic chemicals in food contact materials of paper and board  
Rosenmai, A.K., Bengtström, L., Taxvig, C., Trier, X., Petersen, J.H., Granby, K., and 
Vinggaard, A.M. Manuscript in preparation.  
In this study we wanted to obtain information on the potential hazards of chemicals present in 
FCMs of paper and board by developing a step-by step FCM strategy applying both analytical 
chemistry tools as well as bioassay guided analysis. Only data from the AR, ER, and AhR 
reporter gene assays are included in the Manuscript at present, though the final FCM strategy is 
intended to include 11 assays covering genotoxicity, oxidative stress and many more.   
In the initial screening of the 20 extracts from paper and board, we identified that all extracts led 
to effects in the AhR reporter gene assay, whereas only some led to changes in ER and AR 
activity. Two extracts underwent further investigation by use of the full strategy developed, 
extract S4 and extract S8.  
Extract S8 exhibited ER activity. The extract was fractionated and fractions were tested in the 
ER reporter gene assay. Tentative identification was conducted in active fractions, and BPA, di-
isobutyl phthalate (DiBP), Di-butyl phthalate (DBP), and butyl-benzyl phthalate (BBP) were 
selected for further testing. BPA, DBP, and BBP led to effects individually in the ER reporter 
gene assay and their identity was confirmed in the extract and fractions. Based on quantification 
of these tree compounds in the extracts, we calculated estrogen equivalence factors (EEQs) for 
BPA, DBP, and BBP as well as the extract. The sum of EEQs calculated for identified 
compounds exceeded that of the extract. Extract S4 exhibited AR activity. The step-by-step 
procedure described above was also applied for this extract. Based on the tentative 
identification in fractions abietic acid (AA), dehydroabietic acid (DHAA), 4-oxo-retinoic acid, 
isorhamnetin, and rhamnetin was selected for testing in vitro. All led to decreased AR activity 
when tested individually, except isorhamnetin, however only the identity of DHAA and AA was 
confirmed. The sum of androgen equivalence factors (AEQs) for DHAA and AA exceeded that 
of the extract.   
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5. Discussion 
Food packaging materials constitute a potential source of human exposure to chemicals, as 
compounds may migrate into foods from the packaging. Many compounds are catalogued as 
food contact substances, including some intended for food packaging materials, but many of 
these are likely not sufficiently assessed for toxicological effects to allow for a complete risk 
assessment. This is of concern since it implies that humans are exposed to compounds through 
foods, for which limited data on the toxicology is available.  
In this PhD project, the aim was to investigate if compounds known, or suspected to be used in 
FCM could have the potential to cause adverse effects, with specific focus on endocrine 
activities. Two approaches were applied; the bottom-up and the top-down approach, in which 
BPA analogues, fluorinated chemicals, and extracts from FCMs of paper and board were 
examined.  
5.1 The tested hypotheses 
5.1.1 Bisphenol A analogues 
The aim was to gain knowledge about the toxicology of BPA analogues to ultimately be able to 
allow for the assessment of putative toxicological effects caused by these compounds. I 
hypothesized that the analogues would exhibit similar endocrine mechanisms-of-action as BPA 
in vitro. Overall, I found this to be the case as described in Manuscript 2. Here, a comparable 
qualitative effect on ER and AR activity, as well as effect on androgen and estrogen levels, was 
evident. However, there were also differences in effects of the analogues for some of the 
endpoints investigated, as the qualitative effects on corticoids differed and some compounds led 
to marked effects on progestagens compared to BPA. From Manuscript 2, I established that the 
BPA analogues display effects for most endocrine mechanisms-of-action that are comparable to 
BPA, but for some endocrine endpoints they do not. This similarity in effects suggests that 
neither of the analogues are good alternatives to BPA based on the parameters investigated 
here. 
In many of the applied assays, BPS had a profile that was distinct from BPA. BPS only led to 
decreasing trends on AR activity, exhibited a less potent effect on ER activity, and no effect on 
estrogen levels. However, BPS led to a marked increase in progestagen levels compared to 
BPA. The differences in ER and AR activities between BPS and BPA was expected based on 
previous findings (see chapter 2.2.4), as a polar bridge is suggested to decrease the activity for 
both these endpoints (Kitamura et al. 2005; Paris et al. 2002; Rivas et al. 2002). These data on 
  
estrogenicity and antiandrogenicity indicates that BPS is a good alternative to BPA. However, 
the toxicokinetics of BPS should also be considered, as there are indications that degradation 
might be slower (Danzl et al. 2009; Ike et al. 2006), potentially leading to a longer half-life. 
Furthermore, the potential effects on progestagen levels need to be further examined, as these 
effects could lead to a distinct toxicology of BPS compared to BPA in vivo. 
As evidenced by these experiments, simply substituting a known endocrine disruptive chemical, 
BPA in this case, with structurally similar compounds is not straight forward, as they can have 
both similar and different toxicological effects. BPB, BPE, BPF, and HPP generally led to very 
similar effects compared to BPA on estrogen and androgen levels, as well as activity of ER and 
AR. As BPA in vivo caused effects associated with exposure to estrogenic and antiandrogenic 
compounds (Christiansen et al. 2014; Moral et al. 2008), it may be inferred that the substitutes 
we tested will also exert such effects, which is supported by the reported estrogenic potential of 
BPF and BPS in vivo (Stroheker et al. 2003; Yamasaki et al. 2004). To my knowledge, no 
publicly available in vivo data exists on any potential endocrine disruptive activities of BPB, 
BPE, and HPP. Thus, it can only be speculated whether the estrogenicity and antiandrogenicity 
observed in vitro in this study will lead to similar effects in vivo. 
In my opinion, we need to sincerely consider results from the in vitro measurements, as they 
strongly suggest that BPA analogues have similar mechanisms-of-action as BPA. We need to 
use this knowledge to design further studies to better understand the toxicology of the 
chemicals, with the ultimate goal of assuring that humans are not exposed to harmful 
compounds. 
5.1.2 Fluorinated chemicals 
Since knowledge about endocrine activity of some fluorinated chemicals is presently very 
limited, another aim was to gain further insight into this. I hypothesized that fluorochemicals with 
unknown endocrine disruptive potential would exhibit comparable effects to longer-chained 
PFCAs through similar mechanisms-of-action and performed experiments to test this. The 
results are described and discussed in Manuscript 1 and 3. These studies showed that the 
fluorinated substances targeted different mechanisms within the experimental setup, and thus 
the hypothesis can be rejected. However, some sub-groups of fluorinated compounds 
seemingly exhibit similar effects: PAPs inhibited steroidogenesis leading to decreased androgen 
and/or progestagen levels, FTOH activated the ER, and the long-chained PFCAs increased 
17β-estradiol levels. Furthermore, we observed no discernible effect of short-chained PFCAs, 
which suggest these as good alternatives to long-chained PFCAs based on the parameters 
investigated here. Finally, two of three tested TMs exhibited estrogenic potential, which 
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warrants further studies into characterizing the specific chemical structures of the fluorinated 
compounds present in these TMs. 
Previous studies have mainly focused on the ability of long-chained PFCAs to exhibit sex 
hormone-related endocrine disruptive activities (Biegel et al. 1995; Biegel et al. 2001; Bookstaff 
et al. 1990; Cook et al. 1992; Kjeldsen and Bonefeld-Jorgensen 2013; Kraugerud et al. 2011; 
Shi et al. 2009a), which makes sense as these constitute the final metabolites of many 
fluorinated chemicals (D'eon and Mabury 2007; Fasano et al. 2006; Kudo et al. 2005; Martin et 
al. 2005) and PFOA has a long half-life in humans (Olsen et al. 2007). However, as several of 
the PAPs, TMs, and FTOHs also exhibit endocrine activity and some show markedly different 
profiles to long-chained PFCAs, our data emphasize that the contribution of these substances 
should not be neglected, or at the very least be characterized further. This is particularly 
important since they may cause similar effects in vivo as long-chained PFCAs, or lead to 
different effects due to for instance the antiandrogenic potential of PAPs.  
Though long-chained PFCAs have been reported to affect hormone levels as well as sex 
hormone receptor activity, only few studies have to my knowledge reported on the implications 
of these changes on reproductive parameters sensitive to endocrine disruption. PFdoDA 
exposure led to no changes on age of vaginal opening, age of first estrous cycle, and ovarian 
histology in pre-pubertal female rats (Shi et al. 2009b). However, PFOA exposure in utero or 
neonatally has been shown to cause permanent changes on mammary gland development in 
female offspring, potentially by interfering with ovarian steroids (White et al. 2011). Based on 
these studies, it can be speculated that other fluorinated chemicals affecting 17β-estradiol 
levels, including TM2 and other long-chained PFCAs investigated in this study, might lead to 
changes in mammary gland development in vivo.  
5.1.3 Strategy to assess complex mixtures of unknown composition 
In collaboration with others I developed a strategy to screen FCMs of paper and board for in 
vitro effects and to identify potentially problematic compounds used in such materials from a 
toxicological perspective. I hypothesized that using biodirected analysis in combination with 
analytical chemical tools would be a useful strategy for these purposes. Results are described 
in Manuscript 4.  Overall, the hypothesis was supported, as all the in vitro assays applied were 
responsive to some or all of the extracts. Furthermore, it was also possible to identify five 
agents, DHAA, AA, BPA, BBP, and DBP, which had the ability individually to either affect AR 
activity or ER activity. This is to our knowledge the first report of the antiandrogenic effect of 
DHAA. Based on parameters obtained from testing these individually and quantification of these 
in the extract we calculated EQs, which were greater than that observed for the extract, 
suggesting that the main causative agents have been identified. As BPA was more potent than 
  
both DBP and BBP in the ER reporter gene assay, this compound mainly contributed to the 
effects observed in the extract, despite the lower concentration of BPA compared to BBP and 
DBP. AA mainly contributed to the effect in the AR active extract, as this compound was present 
at high concentrations. 
Our data show that FCMs of paper and board contain compounds that have the potential to 
cause effects in vitro. Of the 20 extracts we produced, it remains unknown what the causative 
agents are in 18 of them, as we did not investigate these further. Nevertheless, it is of concern 
that so many FCMs led to effects at all and the worry is that these 20 samples represent only a 
subset of the FCMs on the market, which can exhibit such activities. This notion is supported by 
several other studies, which have shown that FCMs of paper and board can exhibit both 
estrogenic, genotoxic, cytotoxic potential as well as lead to increased AhR activities (Binderup 
et al. 2002; Lopez-Espinosa et al. 2007; Ozaki et al. 2004; Ozaki et al. 2005; Weber et al. 
2006). Though much data on other parameters related to human exposure and relevance of the 
above activities in humans are still needed, these findings points towards FCMs of paper and 
board as a source of exposure with many potentially problematic compounds. 
Based on our findings as well as previous studies, I recommend testing a much broader 
spectrum of the FCMs of paper and board presently on the market. This could likely give 
information on whether the samples included in this study are representative of the market or 
whether they by chance represent a subset of samples that exhibit a high degree of activity. 
Furthermore, it is recommended that actions should be taken to identify causative agents in 
more FCMs, to determine if these are common components in such materials.  
5.2 Interpretation of in vitro results 
Both the top-down and bottom-up approaches are based on a battery of in vitro assays that all 
consider biochemical effects within isolated systems. Extrapolation from these multifaceted 
systems is not straight forward, and in many cases impossible. In an in vivo environment, 
absorption, distribution, metabolism and elimination may greatly affect the fate of the compound 
within the organism and thus the potential effect, as the compounds might not enter the body, 
might be metabolised to active/inactive compounds, might not be distributed to the relevant 
tissues, and/or might be quickly eliminated from the body. Furthermore, in vivo experiments take 
into account the complex interactions of not only multicellular organs and tissues, but also 
cross-talk between organs, which are of particular importance in endocrine regulation. 
Besides these shortcomings of in vitro methods, there is however studies in which known in 
vitro endocrine disruptive compounds have led to effects in vivo. For example, in vivo exposure 
to ethinyl estradiol, a known ER agonist in vitro (Mattison et al. 2014), led to changes in 
mammary gland development (Mandrup et al. 2012) and in utero exposure to flutamide, a 
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known AR antagonist in vitro (Vinggaard et al. 1999), caused decreased anogenital distance, 
increased nipple retention, cryptorchidism and hypospadias in male offspring (McIntyre et al. 
2001). Furthermore, studies comparing in vitro predictivity of in vivo effects, suggests that in 
vitro results can be used as predictive. As an example of this, Maglich et al. (2014) tested 
compounds with known reproductive toxicity as well as compounds not causing reproductive 
toxicity in the H295R steroidogenesis assay, and found results from this assay as good 
predictors of reproductive toxicity (Maglich et al. 2014). Furthermore, compiling information from 
chemicals tested in 13 in vitro assays related to ER signalling including ER agonism, 
antagonism, binding, and cell growth responses, showed that these collectively could predict in 
vivo effects in the uterotrophic assay (Rotroff et al. 2014); an assay sensitive to estrogenic 
compounds (Stroheker et al. 2003; Yamasaki et al. 2004).  
Collectively, these data illustrate that though many in vivo parameters cannot be accounted for 
in vitro, in vitro assays can be predictive of at least some in vivo effects. As many of the 
investigated compounds led to effects in both the ER and AR reporter gene assay as well as the 
H295R steroidogenesis assay, some of which are suggested from the above to be predictive 
endpoints, these mechanisms could potentially contribute to effects in vivo. 
5.3 Sources and exposure to compounds in food contact materials 
The top-down approach provides information on both the use and effect of compounds in 
FCMs. However, the identification of a problematic compound in one FCM does not necessarily 
equate to it being used generally in such materials and, more importantly, does not necessarily 
mean that humans are exposed. The following chapter will discuss information dealing with 
human exposure to identified compounds, as this can significantly affect the proposed actions 
based on the results obtained from the test strategy.  
5.3.1 Human biomonitoring and sources 
An approach to assess the likely exposure to a compound is to consult previous measurements 
from human cohorts. However, caution should be made regarding ‘non-detected’ compounds as 
it may reflect that they have not been examined, they are quickly eliminated, or are measured in 
the wrong body compartment. On the other hand, if the compound is measurable in humans, it 
suggests that humans are exposed. For example, BPA, identified as the driver behind the ER 
activity of the extract in the FCM strategy (Manuscript 4), has been detected in the general 
population in a large human cohort (Calafat et al. 2008), suggesting human exposure is 
widespread. For BPA, diet is estimated as the main contributor to human exposure (EFSA 
2013). However, biomonitoring data as the above does not in itself reveal the source of 
exposure, except in cases where only very specific applications exists for the compound of 
  
interest. Thus, obtaining information on the sources in general is important before inferring 
FCMs as the origin, since other sources can add to the overall human exposure load. 
Alternatively, information about origin of compounds in FCM of paper and board can be used to 
understand if these are ubiquitously present in these materials, and thus whether it can be 
expected that FCMs in general contribute to human exposure. For instance, are they added 
intentionally, are they non-intentionally added residuals, are they carry-overs from recycled 
materials, or are they natural constituents of paper and board. In the case of AA, identified as 
the driver of AR activity in the extract (Manuscript 4), the compound is a natural constituent of 
resin acids in wood (Roberts 1996; Sjöström and Alen 1998). Thus, if wood rich in resins is 
utilized in the paper, it can be expected that levels of AA will be present in the final paper 
product. AA have been found in extracts from FCMs of paper and board on several accounts 
(Ozaki et al. 2006; Weber et al. 2006) and in foods (Mitani et al. 2007), supporting this notion, 
though the compound is also used during the actual paper making process (Leach and Pierce 
1993; Roberts 1996). Overall, in cases where little data on human levels exist, information as 
the above can be useful, as it illustrates that the compound, in this case AA, can be expected to 
be present in many FCMs of paper and board dependent on the starting material and the 
production process, that it is actually measured in these materials, and that it is present in food 
packed in paper and board. All these findings suggest that human exposure through food 
consumption may occur. 
5.3.2 Migration of compounds from food contact materials 
Another approach to delineate the potential exposure to humans from FCMs of paper and board 
is to obtain information on migration of compounds of interest into food. Migration studies are 
often conducted in food simulants, which is intended to represent different types of foods 
(Arvanitoyannis and Kotsanopoulos 2014). In the top-down approach, the applied extraction 
method is rather crude, involving double-sided ethanol extraction at high temperatures for two 
hours, and thus no consideration to the intended use of the FCMs was taken. The amounts 
extracted will thus most likely overestimate the levels in foods under normal storage conditions 
and in this sense represent a “worst-case scenario”. However, DHAA and AA have shown the 
ability to migrate under milder conditions, including water and 20% ethanol for shorter periods 
and lower temperatures (Ozaki et al. 2006), suggesting that although the extraction method was 
crude, at least some of the compounds present in the extracts would also be present under 
milder conditions, which may be more relevant with respect to human exposure.  
Applying classical food simulants to estimate chemical migration can in some cases 
underestimate the transfer depending on the intended food type for which the FCM is to be 
used. This is the case with some groups of fluorinated chemicals, which will migrate to a higher 
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degree when an emulsifier is present, such as in butter, than they will migrate into classical 
simulants such as ethanol, water, and oil (Begley et al. 2008). However, in the BIOSAFEPAPER 
project in which softer extraction method were applied followed by a filtration step (Weber et al. 
2006), they did tentatively identify several fluorinated chemicals in one extract (Bradley et al. 
2008). Therefore, it is plausible that the compounds would be extracted by our methods if 
present in the FCMs. Nevertheless, these limitations in extraction of fluorinated compounds, 
lend support to them being tested individually, which was done in the bottom-up approach.  
As the applied extraction method used here are crude, in my opinion conducting migration tests 
would be a natural continuum when a causative agent has been identified in FCMs by use of 
our strategy, as it would give insight into the transfer into foods, and thus indirectly human 
exposure.  
  
  
6. Conclusions 
In this project the overall aim was to obtain more knowledge about the toxicology of compounds 
present or suspected of being present in FCMs.  
We investigated two groups of compounds, namely BPA analogues and fluorinated chemicals 
for potential to exhibit endocrine activity in vitro. Overall the tested BPA analogues exhibited 
similar estrogenic and antiandrogenic activities, but caused qualitative different effects on 
corticoids. BPS showed a markedly different profile on the above endpoint, exhibiting less 
potent and efficacious effects or no effect at all; however BPS showed marked effects on 
progestagens compared to BPA. Overall, these finding indicate that structurally similar 
compounds in most cases cause similar effects, at least in vitro. Based on the presented data, it 
is not recommended to substitute BPA with these analogues, before more information is 
available. 
The fluorochemicals exhibited different mechanisms-of-action on the endocrine system, but 
subgroups of fluorinated chemicals exhibit similar effects. Overall, PAPs decreased androgen 
and progestagen levels, FTOHs activated the ER, and long-chained PFCAs increased 17β-
estradiol levels. Furthermore two TMs were estrogenic and none of the short-chained PFCAs 
caused effects in the applied assays. These data emphasise the need to consider effects posed 
by polyfluorinated substances and not just those by the PFCAs, as the PAPs and FTOHs could 
cause similar or different effects than long-chained PFCAs. Furthermore, the data points 
towards examining more TMs available on the market, as two of three tested, were estrogenic 
and finally that short-chained PFCAs as are better alternatives than the long-chained PFCAs 
based on the parameters examined here. 
All the tested FCMs led to effects in at least one of the applied in vitro assays, and further when 
applying the full strategy to two FCMs we successfully identified DHAA and AA as causing 
antiandrogenic effects on the AR activity, and BPA, DBP, and BBP as causing estrogenic 
effects on the ER activity. The FCM strategy using bioassay guided analysis in combination with 
analytical chemical tools thus proved a useful tool to screen for hazards of FCMs and to identify 
potentially problematic compounds in FCMs.  
The aforementioned findings all point towards compounds in FCMs or compounds suspected of 
being used in FCMs as having the potential to exert endocrine activities. However, large data 
gaps related to in vivo and human relevance of these findings remains to be fully elucidated. 
Previous findings however support that in vitro data can be predictive of in vivo effects, and thus 
the data obtained from the present study can be used to prioritize future studies to be 
conducted. Furthermore, data gaps exists with respect to potential human exposure, which 
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could be obtained by understanding the sources of the compounds in FCMs, utilizing human 
biomonitoring data, or to obtain information on the potential of these compounds to migrate into 
foods.  
The data from this PhD project shows that many of the investigated compounds and FCMs 
exhibited in vitro endocrine activities. This is of great concern and the data obtained should be 
used to prioritize further studies on the hazards posed by chemicals in these materials.  
  
7. Future perspectives 
Based on the work performed in this PhD, we have created a platform to characterize potential 
hazards from chemicals in FCMs, which can be used to prioritize further studies. Much work still 
remains with respect to expanding the knowledge on FCMs already investigated, but also with 
respect to understanding the relevance of the results from a human effect and exposure 
perspective. 
In the top-down approach we investigated 20 FCM extracts of which only two were investigated 
in the full step-by-step strategy. Several other extracts led to effects in the AR, ER, and AhR 
reporter gene assays. In future we should examine these extracts by the full strategy to 
elucidate whether the same compounds cause the effect across all extracts or whether other 
compounds could explain the responses. Furthermore, additional FCMs should be tested by the 
strategy to understand if the selected samples are representative of the market.  
In a strategy developed previously, the BIOSAFEPAPER project, 20 FCM extracts were tested 
and several were found cytotoxic, but only one extract genotoxic. The endpoints included in the 
strategy presented here, AR, ER, and AhR activity, were not covered by the BIOSAFEPAPER 
strategy. As we observe effects of many of the extracts, it would be interesting to test the same 
FCMs in both strategies to shed light on whether the differences in findings are caused by the 
effect range covered by the two strategies, the FCMs tested, or other differences such as the 
extraction methods used.  
With respect to the compound classes tested in the bottom-up approach, first and foremost we 
need to characterize the TMs tested in this project to obtain knowledge on the specific chemical 
structures of the fluorinated constituents in the mixture. Further, only three TMs were tested of 
which two showed estrogenic potential, and thus in future studies more TMs should be tested in 
supplement with identification work.  
The 8:2 PAPs tested in this study overall led to antiandrogenic effects. Recently short-chained 
PAPs, which could potentially break down to short-chained PFCAs, have become available on 
the market (Chiron, Norway). Neither of the short-chained PFCAs tested here caused effects in 
the assay applied. Thus, it would be interesting to test the short-chained PAPs, to understand if 
these will lead to similar effects as the short-chained PFCAs or whether they will exhibit similar 
antiandrogenic effects as the long-chained PAPs.  
Finally, five BPA analogues were tested in vitro and the compounds generally led to similar 
qualitative effects as BPA. As a proof of concept, it would be interesting to investigate these five 
analogues in vivo to see if the same is evident in a full organism. If similar toxicological profiles 
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are observed in vivo, such data would illustrate that in vitro data can in some cases be used as 
predictive of in vivo effects.   
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Polyﬂuoroalkyl phosphate surfactants
Polyﬂuoroalkyl phosphate surfactants (PAPS) are widely used in food contact materials (FCMs) of paper and
board and have recently been detected in 57% of investigated materials. Human exposure occurs as PAPS
have been measured in blood; however knowledge is lacking on the toxicology of PAPS. The aim of this
study was to elucidate the effects of six ﬂuorochemicals on sex hormone synthesis and androgen receptor
(AR) activation in vitro. Four PAPS and two metabolites, perﬂuorooctanoic acid (PFOA) and 8:2 ﬂuorotelomer
alcohol (8:2 FTOH) were tested.
Hormone proﬁles, including eight steroid hormones, generally showed that 8:2 diPAPS, 8:2 monoPAPS and
8:2 FTOH led to decreases in androgens (testosterone, dehydroepiandrosterone, and androstenedione) in
the H295R steroidogenesis assay. Decreases were observed for progesterone and 17-OH-progesterone as
well. These observations indicated that a step prior to progestagen and androgen synthesis had been affected.
Gene expression analysis of StAR, Bzrp, CYP11A, CYP17, CYP21 and CYP19 mRNA showed a decrease in Bzrp
mRNA levels for 8:2 monoPAPS and 8:2 FTOH indicating interference with cholesterol transport to the inner
mitochondria. Cortisol, estrone and 17β-estradiol levels were in several cases increased with exposure. In ac-
cordance with these data CYP19 gene expression increased with 8:2 diPAPS, 8:2 monoPAPS and 8:2 FTOH ex-
posures indicating that this is a contributing factor to the decreased androgen and the increased estrogen
levels.
Overall, these results demonstrate that ﬂuorochemicals present in food packaging materials and their metab-
olites can affect steroidogenesis through decreased Bzrp and increased CYP19 gene expression leading to
lower androgen and higher estrogen levels.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Fluorochemicals are a group of manmade compounds that pos-
sess the unique ability to repel water and oil simultaneously (Kissa,
2001). This makes them ideal for multiple purposes including in
coatings for paper and board (Begley et al., 2008). In a recent study
61% of selected food contact materials (FCMs) made of paper and
board were found to contain ﬂuorochemicals and of these 57%
contained polyﬂuoroalkyl phosphate surfactants (PAPS) (Trier,
2011) (Fig. 1). The technical mixtures of paper coatings contain
dialkylated (diPAPS), monoalkylated (monoPAPS) and trialkylated
(triPAPS) homologues (Trier et al., 2011). Among these diPAPS has
been reported to migrate from FCMs into foods (Begley et al.,
2008). Despite these ﬁndings there are no speciﬁc EU legislation for
the use of PAPS in paper and board FCMs (Trier et al., 2011).
Reports of diPAPS in human sera collected in the United States
suggested that not only are these chemicals used, but humans are ex-
posed and can absorb these across the gastrointestinal tract. The
reported total concentration of diPAPS homologues (4:2, 6:2, 8:2
and 10:2 diPAPS) was 4.5 μg/L (D'eon et al., 2009). Metabolism of
PAPS can lead to the formation of highly persistent perﬂuorinated
carboxylic acids (PFCAs) (Fig. 1), such as perﬂuorooctanoic acid
(PFOA), which has a half-life in humans of 3.8 years (Olsen et al.,
2007). In male rats PAPS metabolize into PFCAs possibly through
the intermediate ﬂuorotelomer alcohol (FTOH) (D'eon and Mabury,
2007, 2011). FTOH oxidize into PFCAs in isolated rat hepatocytes
(Martin et al., 2005). Several body compartments have been found
to contain PFCAs, including human blood/serum (Houde et al.,
2006), umbilical cord blood (Kim et al., 2011; Monroy et al., 2008)
and breast milk (So et al., 2006). PFOA has been measured at mean
serum/plasma/whole blood concentrations ranging from 3 to 213 nM
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in the general population worldwide (EFSA, 2008). This indicates that
not only are the general population exposed to PFCAs, but also that fe-
tuses and infants may be exposed through placental passing and/or
breast feeding. Based on the above studies it seems likely that PAPS
also in humans is a precursor of PFCAs and as PAPS is present in
human blood, it is relevant to establish if PAPS in itself have the poten-
tial to cause adverse effects in humans.
To our knowledge no data exists on the toxicology of PAPS,
whereas PFOA and perﬂuorooctane sulfonic acid (PFOS) have been
widely reviewed (Andersen et al., 2008; Kennedy et al., 2004; Lau
et al., 2007; Steenland et al., 2010). Studies conducted in male rats
have shown that exposure to PFCAs of varying chain lengths, which
are all potentially ﬁnal metabolites of PAPS, could decrease testoster-
one levels in vivo (Feng et al., 2009; Shi et al., 2007, 2009). Further-
more decreased gene expression of key enzymes and transporters
involved in steroidogenesis was observed as a result of perﬂuoro-
dodecanoic acid (PFdoDA) exposure in male rats (Shi et al., 2007,
2009). For PFOA a study showed a decrease in testosterone levels
in isolated rat Leydig cells with exposure (Zhao et al., 2010). Finally
8:2 FTOH, a metabolite of PAPS, also showed the capacity to decrease
testosterone levels in the human adrenal cortico-carcinoma cell line
(Liu et al., 2010). The above mentioned studies suggest that PFCAs
and 8:2 FTOH have testosterone-inhibiting potential, and that the
mechanism of action is interference with sex hormone synthesis. In
accordance with these data an epidemiological study investigated
associations between high PFOA and PFOS exposure, semen variables
and hormone levels. A statistically signiﬁcant association was found
between high levels of PFOA and PFOS exposure and a decreased
number of normal sperms as the only parameter (Joensen et al.,
2009). As PAPS resemble PFOA and 8:2 FTOH by containing ﬂuori-
nated chains and being surfactant molecules, it is therefore re-
levant to investigate if PAPS also have endocrine disrupting
potential.
The aim of this study was to examine the potential of four PAPS
(8:2 monoPAPS, 8:2 diPAPS, 10:2 diPAPS and 8:2 triPAPS) and meta-
bolic products of these, PFOA and 8:2 FTOH, to interfere with ste-
roidogenesis and androgen receptor activation using two in vitro
assays, the H295R steroidogenesis assay and the androgen receptor
(AR) reporter gene assay, respectively. The levels of eight steroid
hormones and gene expression levels of six proteins involved in
the steroidogenic pathway were end-points in the H295R steroido-
genesis assay.
Materials and methods
Chemicals
Test chemicals 8:2 triPAPS (65.1%), 10:2 diPAPS (94.6%), 8:2
diPAPS (97.4%), and 8:2 monoPAPS (88.7%) were synthesized by
Chiran (Trondheim, Norway). 8:2 FTOH (97%) was purchased from
Fluorochem Ltd. (Derbyshire, UK) and PFOA (95%) was purchased
from VWR (Herlev, Denmark). The notations 8:2 and 10:2 refer to
the chain length of the ﬂuorinated chains and the CH2 group within
the molecule e.g. the notation 10:2 diPAPS reﬂects that the two
chains contain ten carbon atoms that are fully ﬂuorinated and
two carbon atoms to which hydrogen atoms are attached (Fig. 1).
Stock solutions of 20 mM were prepared in DMSO (Sigma-Aldrich,
Copenhagen, Denmark).
The calibration standard solution for high pressure liquid
chromatography–tandem mass spectrometry (HPLC–MS/MS) analysis
contained dihydrotestosterone, dehydroepiandrosterone (DHEA),
progesterone, estrone, testosterone and 17β-estradiol, all purchased
from Sigma-Aldrich, (Copenhagen, Denmark), as well as 17-OH-
progesterone, cortisol and androstenedione purchased from Steraloids
(Rhode Island, USA), Riedel-de Haën (Seelze, Germany) and Cerilliant
(Round Rock, USA), respectively. Internal standard solution containing
testosterone-d2, 17β-estradiol-d3 andmethyltestosterone-d3were pur-
chased from RIKILT (Wageningen, Nederlands).
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Fig. 1.Metabolic pathway of polyﬂuoroalkyl phosphate surfactants (PAPS) in rat, mice
and isolated rat hepatocytes into ﬂuorotelomer alcohol (FTOH) and perﬂuorinated car-
boxylic acids (PFCAs) (D'eon and Mabury, 2007, 2011; Fasano et al., 2006; Kudo et al.,
2005; Martin et al., 2005). RF1, RF2 and RF3 represent fully ﬂuorinated carbon chains of
varying lengths.
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R1881 which is used in the AR reporter gene assay was purchased
from PerkinElmer (Skovlunde, Denmark).
H295R steroidogenesis assay
The H295R human adrenal cortico-carcinoma cell line was ob-
tained from the American Type Culture Collection (LGC standards,
Boras, Sweden). Cells were cultured in DMEM/F12+glutamine me-
dium with HEPES buffer (Invitrogen, Taastrup, Denmark) containing
1% Insulin–Transferrin–Sodium selenite plus premix (VWR, Herlev,
Denmark) and 2.5% Nu-Serum (BD Bioscience, Brøndby, Denmark)
at 37 °C in a 5% CO2 atmosphere. 3*105 cells/well were seeded in
24-well plates (VWR, Herlev, Denmark) and cultured for 24 h. Sub-
sequently, cells were exposed to 1.6, 3.1, 6.3, 12.5, 25.0, and
50.0 μM of test chemicals for 48 h. Each exposure concentration
was tested in triplicates within each experiment. DMSO concentra-
tions were 0.25% in all exposure groups—a non-cytotoxic concentra-
tion (see Supplementary materials 1). After 48 h exposure the
supernatant was sampled for hormone analysis.
To test whether cell viability was compromised as a result of
chemical exposure 500 μL media and 50 μL MTT stock solution
(Sigma-Aldrich, Copenhagen, Denmark) of 5 mg/mL were added to
wells and incubated for 1–2 h. The medium was removed and
500 μL isopropanol was added. Absorption was measured at
570 nm using a spectrophotometer (Victor2, 1420 Multilabel Coun-
ter, PerkinElmer). Concentration–response relationships for cell
viability testing were performed in all experiments except for those
involving gene expression analysis and hormone analysis by HPLC–
MS/MS. If cell viability decreased by more than 20% in any exposure
group compared to control viability, these hormone data were
removed from the data set according to the OECD test guideline
procedure (OECD, 2011).
Hormone analysis by immunoassay
Three H295R steroidogenesis assay experiments were conducted
for hormone measurements by immunoassay.
Hormones were extracted from cell supernatants using a C18 solid
phase extraction (SPE) cartridge (200 mg, 3 mL) (Biotage, Uppsala,
Sweden) as previously described (Vinggaard et al., 2002). Time-resolved
ﬂuoroimmunoassays were purchased from PerkinElmer (Skovlunde,
Denmark) and were used for quantiﬁcation of 17β-estradiol, testos-
terone, and progesterone. The experimental procedure was per-
formed according to the protocol supplied by the manufacturer. A
sample from each well was tested in duplicate in the immunoassay
and the mean of these measurements was used for further calcula-
tion. Data points obtained from each well were normalized against
the mean of the controls from the same cell plate, and data from
the three experiments were pooled.
Test compounds were tested for autoﬂuorescence and underwent
a chemical-immunoassay interference test in the 17β-estradiol assay
as HPLC–MS/MS measurements of this hormone were below the
limit of quantiﬁcation and thus comparison of the HPLC–MS/MS
and immunoassay results for this hormone was not possible. No
chemical interference in the immunoassay was observed.
Hormone analysis by high pressure liquid chromatography–tandem
mass spectrometry (HPLC–MS/MS)
Hormone measurements by HPLC–MS/MS were conducted for
one H295R steroidogenesis experiment including exposure concen-
trations of 3.1, 12.5 and 50.0 μM for each test compound.
Hormones were extracted according to a method published
previously (Mortensen and Pedersen, 2007). Supernatant was ex-
tracted using a C18 endcapped SPE cartridge (500 mg, 3 mL) (Merck,
Darmstadt, Germany) after addition of an internal standard solution of
testosterone-d2, 17β-estradiol-d3 andmethyltestosterone-d3. Impurities
were removed with demineralized water followed by elution of steroid
hormones from the cartridge with MeOH. The extract was then evapo-
rated to dryness using nitrogen, and resuspended in 40% solution of
MeOH in demineralized water.
Nine hormones, progesterone, 17-OH-progesterone, dehydroepi-
androsterone, testosterone, androstenedione, dihydrotestosterone,
cortisol, estrone and 17β-estradiol, were separated, detected, and
quantiﬁed using the HPLC–MS/MS method described elsewhere
(Mortensen and Pedersen, 2007). Minor modiﬁcations were made
to accommodate a smaller sample size and to include more hor-
mones. The LC system (Agilent 1100) was equipped with an Atlantis
C18 column (2.1×150 mm, 3 μm) (Waters Corp., Milford, MA, USA)
maintained at 40 °C. The sample injection volume was 50 μL.
17β-estradiol and estrone were measured in ESI− mode using 65%
MeOH and 0.01% ammonia for mobile phase (0.15 mL/min, isocratic
ﬂow rate). The remaining steroid hormones were measured in ESI+
mode using 65% MeOH and 0.1% acetic acid for mobile phase
(0.2 mL/min, isocratic ﬂow rate). The mass spectrometer was a
Quattro Ultima triple quadropole instrument (Waters Corp., Milford,
MA, USA). Calibration standards were run before and after sample
analysis at levels of 0.25, 1.25, 2.5, 5.0, and 10.0 ng/mL.
The absolute recoveries of the hormones in the cell extracts were
estimated to be 70–87%, based on the absolute recoveries of the
three internal standards in 90 experiments. Thus the sensitivity of
the method is comparable to the analysis in blood (Mortensen and
Pedersen, 2007).
The limit of quantiﬁcation (LOQ) of the cell extracts was estimat-
ed as 6 times signal-to-noise at a low concentration level, and was
b0.1 ng/mL for all hormones except for DHEA which was b0.8 ng/mL.
The dihydrotestosterone and 17β-estradiol levels in extracts were
bLOQ and will thus not be further discussed.
Each obtained data point was normalized against the mean of
plate control.
mRNA isolation and cDNA synthesis
The H295R steroidogenesis assay was conducted as described
above with the exception that 0.6*105cells/well were seeded in
96-well plates. Gene expression analysis was conducted for three
H295R steroidogenesis experiments including exposure concentra-
tions of 3.1, 12.5 and 50.0 μM.
After supernatant removal, mRNA isolation from cells and con-
version of mRNA to cDNA were done by using the TaqMan® Fast
Cells-to-CT™ Kit (Applied Biosystems, Nærum, Denmark) according
to product protocol. During mRNA isolation DNase was added to the
lysis solution (1:100) to remove genomic DNA. cDNA was synthe-
sized by reverse transcription on a thermal cycler (PTC-200, MJ Re-
search). mRNA isolate and cDNA were stored at−20 °C.
Table 1
Names, abbreviations and catalogue numbers on Taqman gene expression assay.
Protein/enzyme name Abbreviation Catalogue number
Steroidogenic acute regulatory protein StAR Hs00264912_m1
Benzodiazepine receptor Bzrp Hs00559362_m1
Cholesterol side-chain cleavage enzyme CYP11A Hs00167984_m1
17α-hydroxylase/17,20 lyase/17,20 desmolase CYP17A1 Hs01124136_m1
21-hydroxylase CYP21A2 Hs00365734_g1
Aromatase CYP19A1 Hs00903413_m1
β-actin Hs99999903_m1
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Quantitative real-time polymerase chain reaction (qRT-PCR)
cDNAwas analyzed on a 7900 HT Fast Real-time PCR system using
TaqMan® Gene Expression Assays (Applied Biosystems, Nærum,
Denmark) containing primers and probes for genes coding for six
proteins involved in steroidogenesis (Table 1). β-actin was used as
housekeeping gene. 384-well plates (Applied Biosystems, Nærum
Denmark) were used for qRT-PCR analysis. In each well TaqMan®
Gene Expression Assay (0.5 μL), TaqMan® Gene Expression Master
Mix (5.0 μL), nuclease free water (2.5 μL) and cDNA template
(2.0 μL) were added. All genes were analyzed on a single plate in du-
plicates. The thermal cycling program was initiated with 95 °C for
20 s followed by 45 cycles of 95 °C for 1 s and 60 °C for 20 s.
Ct values were determined for each target. Relative quantiﬁcation of
mRNAwas calculated by ﬁrst normalizing each data point to the house-
keeping gene. No consistent signiﬁcant effect on the housekeeping gene
was observed. Successively datawas normalized to the average of the
non-exposed group (ΔΔCt=(Ct(target gene)−Ct(housekeeping gene))−
Ct(average control)) within each of the three experiments. Finally
fold change values (2−ΔΔCt) were calculated, the three experi-
ments were pooled and these data were plotted.
Androgen receptor reporter gene assay
Two experiments in triplicates for each exposure concentration
were conducted. The assay was performed as previously described
by Vinggaard et al. (2002). The Chinese hamster ovary (CHO) cell
line was obtained from the American Type Culture Collection (LGC
standards, Boras, Sweden). Cells were transfected with pSVAR0
and MMTV-LUC for testing of agonistic and antagonistic effects on
the activation of the AR, and with pSVAR13, encoding for a mutated
AR, and MMTV-LUC for testing of cell viability. All plasmids were
generous gifts from Dr. Albert Brinkmann (Erasmus University,
Rotterdam). A known androgen receptor agonist, R1881 was added
to all wells on the antagonism plates, at a constant concentration
of 0.1 nM. Test chemicals were added leading to ﬁnal exposure con-
centrations of 0.2, 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25.0, and 50.0 μM on
agonism, antagonism and toxicity plates. Luciferase activity was
measured on a luminometer (BioOrbit, Galaxy) by the addition of lu-
ciferin. Within an experiment each data point was normalized
against the mean of control from the same cell plate and successively
the data from the two experiments were pooled.
Statistical analysis
One-way analysis of variance (ANOVA) was performed on hor-
mone, gene expression, AR reporter gene and cell viability data
with a successive Dunnett's post-test to examine differences be-
tween exposed groups and controls. The criterion for statistical sig-
niﬁcance was pb0.05, pb0.01, and pb0.001 leading to the marking
*, **, and ***, respectively. ΔΔCt values were used for statistical anal-
ysis of gene expression data (Zeuthen et al., 2010). Data was assessed
for normal distribution and homogeneity of variance.
All statistical analysis was conducted in GraphPad Prism 5. All in-
formation obtained from the data was taken into account. Thus im-
munoassay and gene expression data represent three experiments
in triplicates, HPLC–MS/MS data represent triplicates within one ex-
periment and AR reporter gene assay represents two experiments in
triplicates.
Results
The H295R steroidogenesis assay was conducted to gain informa-
tion on the ability of the test compounds to affect the synthesis of
sex hormones. Measurements of steroid hormones, including proges-
terone, 17-OH-progesterone, dehydroepiandrosterone, testosterone,
androstenedione, dihydrotestosterone, cortisol, estrone and 17β-
estradiol, and expression of central genes involved in steroidogenesis
allow assessment of the potential of the compounds to exert such ef-
fects as well as obtaining information on the mechanism of an effect.
Figs. 2–4 show an overview of the steroid hormone proﬁles after
exposure to increasing concentrations of 8:2 diPAPS, 8:2monoPAPS
and 8:2 FTOH, respectively, with concentration–effect relation-
ships for each measured hormone and bar windows illustrating
effects on gene expression of proteins involved in steroidogenesis.
An overview of the qualitative effects, lowest observable effect con-
centrations (LOECs), and the tentative maximum efﬁcacy (Emax) values
for all hormones after 8:2 triPAPS, 10:2 diPAPS, 8:2 diPAPS, 8:2
monoPAPS, 8:2 FTOH, and PFOA exposure is shown in Table 2. For
further reference to LOEC values it should be noted that signiﬁcant
effects observed at one low concentration, which was not replicated
at higher concentrations, have not been considered as representative
LOECs. Such data is reported in Table 2, but indicated with the mark-
ing b. Data for 8:2 triPAPS, 10:2 diPAPS, and PFOA will only be de-
scribed brieﬂy.
Effects on hormones
8:2 diPAPS exposure led to a statistically signiﬁcant decrease in
the androgens, testosterone, androstenedione, and DHEA with
LOECs of 25.0, 12.5, and 50.0 μM, respectively (Fig. 2 and Table 2).
Furthermore a decrease in the progestagens, progesterone and
17-OH-progesterone was observed after exposure to 8:2 diPAPS
with LOECs of 3.1 and 12.5 μM, respectively. Estrone increased
signiﬁcantly as a result of exposure to 8:2 diPAPS at the highest
test concentration of 50.0 μM, whereas a non-signiﬁcant increasing
trend was observed for 17β-estradiol (Fig. 2). Finally, cortisol levels
also increased signiﬁcantly with a LOEC of 50.0 μM (Fig. 2).
Like for 8:2 diPAPS, exposure to 8:2 monoPAPS resulted in de-
creases in the level of all measured androgens and progestagens.
8:2 monoPAPS also caused an increase in estrone whereas the
17β-estradiol level was unaffected (Fig. 3 and Table 2). Where corti-
sol level was increased with exposure to 8:2 diPAPS this remained
unaffected after 8:2 monoPAPS exposure. The LOECs for 8:2
monoPAPS on testosterone, androstenedione and DHEA were
25.0, 12.5, and 12.5 μM, respectively. Progesterone and 17-OH-
progesterone LOECs were 50.0 and 3.1 μM, respectively. Finally, es-
trone had a LOEC of 50.0 μM. Generally the potencies and tentative
efﬁcacies of 8:2 monoPAPS were greater than that of 8:2 diPAPS
for the affected hormones, except for progesterone for which a
greater potency and efﬁcacy was found after 8:2 diPAPS exposure
(Table 2).
The effect of 8:2 FTOH on the measured hormones was similar to
that of 8:2 diPAPS and 8:2 monoPAPS, showing decreased androgen
and progestagen levels (Fig. 4 and Table 2). LOECs for testosterone,
androstenedione, progesterone and 17-OH-progesterone were
3.1 μM. As for 8:2 monoPAPS the cortisol level was unaffected.
17β-estradiol increased signiﬁcantlywith a LOEC of 12.5 μM, and for es-
trone all exposure groups were increased compared to the control. 8:2
FTOH showed greater potency for progesterone, 17-OH-progesterone,
androstenedione and testosterone than 8:2 diPAPS and 8:2 monoPAPS
(Table 2).
8:2 triPAPS exposure (Table 2) did not lead to changes in levels of
DHEA, androstenedione, 17β-estradiol and cortisol. A decrease was
observed in some exposure groups in progestagens, but these data
did not seem to be concentration-dependent. An increase in estrone
and a decrease in testosterone levels were observed with LOECs of
12.5 and 50.0 μM, respectively. Exposure to PFOA caused no change
in androgens, progestagens, and cortisol, whereas 17β-estradiol de-
creased signiﬁcantly at low concentrations and increased signiﬁ-
cantly at higher concentrations and estrone increased with a LOEC
of 12.5 μM (Table 2). 10:2 diPAPS led to signiﬁcant decreases in
135A.K. Rosenmai et al. / Toxicology and Applied Pharmacology 266 (2013) 132–142
progesterone and 17-OH-progesterone with LOECs of 50.0 μM and
3.1 μM, respectively. DHEA and androstenedione levels also de-
creased with LOECs of 3.1 and 12.5 μM, respectively; however the
level of testosterone, cortisol and 17β-estradiol was not affected by
exposure. Estrone level increased signiﬁcantly at an exposure con-
centration of 50 μM of 10:2 diPAPS (Table 2).
Quality control of the hormone measurements was done by
comparingHPLC–MS/MS and immunoassaymeasurements, conducting
Fig. 2. Steroid hormone proﬁle caused by 8:2 diPAPS. Concentrations are given in μM and response in fold change. Concentration–effect relationships for progesterone, testosterone
and 17β-estradiol are based on immunoassay data from three independent experiments of three replicates in each experiment. Each data point was normalized to the mean of the
experiment controls and subsequently the three experiments were pooled. The concentration–effect relationships for the remaining hormones are based on HPLC–MS/MS data
from one experiment performed in triplicates. The bars represent proteins involved in steroidogenesis of which StAR, Bzrp, CYP11A, CYP17, CYP21, and CYP19 gene expression
levels were measured in three experiments in triplicates. Arrow up (↑) indicates an increase in the relative level of mRNA, arrow down (↓) represents a decrease in the relative level
ofmRNA and n.s. indicates that no statistically signiﬁcant changewas observed.Markings of *, **, and *** represent a statistically signiﬁcant level of pb0.05, b0.01 and b0.001, respectively.
136 A.K. Rosenmai et al. / Toxicology and Applied Pharmacology 266 (2013) 132–142
chemical-immunoassay interference test and securing that cell viability
was not compromised. Comparing progesterone and testosterone hor-
mone data obtained from the HPLC–MS/MS and immunoassay methods,
these generally showed similar concentration–effect relationships as a re-
sult of exposure to the six ﬂuorochemicals. It was not possible to com-
pare 17β-estradiol data between the two methods, as the levels were
Fig. 3. Steroid hormone proﬁle caused by 8:2 monoPAPS. Concentrations are given in μM and response in fold change. Concentration–effect relationships for progesterone, testos-
terone and 17β-estradiol are based on immunoassay data from three independent experiments of three replicates in each experiment. Each data point was normalized to the mean
of the experiment controls and subsequently the three experiments were pooled. The concentration–effect relationships for the remaining hormones are based on HPLC–MS/MS
data from one experiment performed in triplicates. The bars represent proteins involved in steroidogenesis of which StAR, Bzrp, CYP11A, CYP17, CYP21, and CYP19 gene expression
levels were measured in three experiments in triplicates. Arrow up (↑) indicates an increase in the relative level of mRNA, arrow down (↓) represents a decrease in the relative level
ofmRNA and n.s. indicates that no statistically signiﬁcant changewas observed.Markings of *, **, and *** represent a statistically signiﬁcant level of pb0.05, b0.01 and b0.001, respectively.
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below the limit of quantiﬁcation when measured by HPLC–MS/MS. No
consistent concentration-dependent effect on cell viability was observed
for the six tested ﬂuorochemicals in cells used for immunoassay
hormone analysis (see Supplementary materials 1) and thus it was
assumed that compromised cell viability was generally not an issue
for any of the data obtained in the H295R steroidogenesis assay.
Fig. 4. Steroid hormone proﬁle caused by 8:2 FTOH. Concentrations are given in μM and response in fold change. Concentration–effect relationships for progesterone, testosterone
and 17β-estradiol are based on immunoassay data from three independent experiments of three replicates in each experiment. Each data point was normalized to the mean of the
experiment controls and subsequently the three experiments were pooled. The concentration–effect relationships for the remaining hormones are based on HPLC–MS/MS data
from one experiment performed in triplicates. The bars represent proteins involved in steroidogenesis of which StAR, Bzrp, CYP11A, CYP17, CYP21, and CYP19 gene expression
levels were measured in three experiments in triplicates. Arrow up (↑) indicates an increase in the relative level of mRNA, arrow down (↓) represents a decrease in the relative level
ofmRNA and n.s. indicates that no statistically signiﬁcant changewas observed.Markings of *, **, and *** represent a statistically signiﬁcant level of pb0.05, b0.01 and b0.001, respectively.
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Table 2
The effect of six ﬂuorochemicals on steroidogenesis in the H295R steroidogenesis assay. The qualitative effect (QE) (↓ or ↑), the lowest observable effect concentration (LOEC) and
the tentative efﬁcacy (Emax) given in % change are shown. Immunoassay values are based on three experiments performed in triplicates and the HPLC–MS/MS values are based on
one experiment performed in triplicates. All values have a signiﬁcance level of pb0.05.
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Progesteronea QE ↓ ↓ ↓ ↓ ↓ n.s.
LOEC (µM) 12. 5b 50 3.1 50 3.1 n.s.
Emax (%) 26 ± 10 22 ± 16 60 ± 14 42 ± 10 45 ± 18 n.s.
17-OH-Progesteronec QE ↓ ↓ ↓ ↓ ↓ n.s.
LOEC (µM) 12.5b 3.1 12.5 3.1 3.1 n.s.
Emax (%) 14 ± 6 28 ± 3 50 ± 10 67 ± 3 55 ± 6 n.s.
Cortisolc QE n.s. ↓ ↑ n.s. n.s. n.s.
LOEC (µM) n.s. 3.1b 50 n.s n.s . n.s.
Emax (%) n.s. 25 ± 15 38 ± 13 n.s. n.s. n.s.
DHEAc QE n.s. ↓ ↓ ↓ ↓ n.s.
LOEC (µM) n.s. 3.1 50 12.5 12.5b n.s.
Emax (%) n.s. 29  ± 3 56 ± 8 72 ± 3 39 ± 9 n.s.
Androstenedionec QE n.s. ↓ ↓ ↓ ↓ ↓
LOEC (µM) n.s. 12.5 12.5 12.5 3.1 12.5b
Emax (%) n.s. 17 ± 3 45 ± 6 65 ± 3 54 ± 4 19 ± 9
Testosteronea QE ↓ n.s. ↓ ↓ ↓ n.s.
LOEC (µM) 50 n.s. 25 25 3.1 n.s.
Emax (%) 34 ± 21 n.s. 63 ± 10 56 ± 20 53 ± 16 n.s.
Estronec QE ↑ ↑ ↑ ↑ ↑ ↑
LOEC (µM) 12.5 50 50 50 12.5b 12.5
Emax (%) 34 ± 8 30 ± 11 121 ± 9 137 ± 82 146 ± 24 75 ± 9
17β-estradiola QE n.s. n.s. n.s. n.s. ↑ ↓/↑
LOEC (µM) n.s. n.s. n.s. n.s. 12.5 1.6/50
Emax (%) n.s. n.s. n.s. n.s. 41 ± 19 24 ± 19/17 ± 22 
n.s. = not statistically signiﬁcant.
The light red shade indicates a decrease in the respective hormone level; the light green shade indicates an increase in hormone level; the gray shade indicates that both a decrease
and an increase in hormone level were observed.
aImmunoassay data.
bThe LOEC is based on a single signiﬁcant ﬁnding which is not reﬂected in higher concentrations.
cHPLC–MS/MS data.
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Effects on gene expression
8:2 diPAPS, 8:2 monoPAPS and 8:2 FTOH led to increased expres-
sion of CYP19 mRNA with LOECs of 50.0, 50.0 and 3.1 μM, respectively
(Fig. 5). Both 8:2 monoPAPS and 8:2 FTOH led to decreased levels of
Bzrp mRNA with LOECs of 12.5 μM.
Neither StAR, CYP11A, CYP17, nor CYP21 showed signiﬁcant
changes as a result of exposure to 8:2 diPAPS, 8:2 monoPAPS and
8:2 FTOH. Likewise none of the examined target genes showed
changes in gene expression after exposure to 8:2 triPAPS, 10:2
diPAPS and PFOA (data not shown).
Effects on AR transcriptional activation
All six ﬂuorochemicals were tested for their ability to agonize or
antagonize the activation of the AR by using a reporter gene assay.
The test chemicals showed no agonistic or antagonistic effect in the
applied assay, at test concentrations ≤50 μM (see Supplementary
materials 2).
Discussion
Three of the tested chemicals, namely 8:2 diPAPS, 8:2 monoPAPS,
and 8:2 FTOH, showed signiﬁcant effects on androgen levels in the
H295R steroidogenesis assay in a concentration-dependent manner.
Testosterone and androstenedione decreased with exposure to all
three chemicals, and DHEA decreased after exposure to 8:2 diPAPS
and 8:2 monoPAPS (Figs. 2–4). Neither 8:2 diPAPS, 8:2 monoPAPS
nor 8:2 FTOH appeared to be AR agonists or antagonists, and thus
among the two endpoints, inhibition of androgen production
through interference with steroidogenesis appeared to be the main
target.
8:2 triPAPS, 10:2 diPAPS and PFOA showed a less marked effect
on androgens in the H295R steroidogenesis assay, and none of
these test compounds caused agonistic or antagonistic effects in
the AR reporter gene assay. Results for 8:2 triPAPS and 10:2 diPAPS
will not be discussed further. It should be mentioned however that
results obtained with exposure to 8:2 triPAPS may be a result of ex-
posure to a mixture of chemicals as the purity of the 8:2 triPAPS
product only was 65.1%. Impurities in the 8:2 triPAPS product are
mainly 8:2 diPAPS and 8:2 monoPAPS (personal communication,
Chiron, Norway) and thus the cells in the 8:2 triPAPS experiment
are exposed to a mixture of these three compounds. It is believed
that the observed changes in hormones, estrone and testosterone
(Table 2) with exposure to 8:2 triPAPS are a result of 8:2 diPAPS
and 8:2 monoPAPS exposure.
To understand the mechanism underlying the decreases in andro-
gens in the steroidogenic pathway caused by 8:2 diPAPS, 8:2
monoPAPS and 8:2 FTOH, the hormone proﬁles were examined in de-
tail (Figs. 2–4). An inhibition was also observed for progesterone and
17-OH-progesterone with exposure to these compounds, indicating a
target located prior to both progestagen and androgen synthesis. A
disturbance at any level prior to these in steroidogenesis could poten-
tially lead to the observed decreases in both of these steroid hormone
classes. Gene expression data was obtained for three genes involved
prior to androgen and progestagen formation in steroidogenesis.
StAR and Bzrp which facilitate the transport of cholesterol to the
inner mitochondrial membrane and constitute the rate-limiting step
in steroidogenesis, and CYP11A which cleaves the side chain of cho-
lesterol after its arrival to the inner mitochondria, and constitute
the enzymatically rate-limiting step. Among these three genes, Bzrp
gene expression was inhibited following exposure to 8:2 monoPAPS
and 8:2 FTOH indicating a down-regulation of this gene, leading to a
decreased transport of cholesterol into the inner mitochondria. An-
other mechanism that could contribute to the observed decreases in
androgens is through pushing of the equilibrium from androgens to
estrogens leading to increased formation of 17β-estradiol and es-
trone. The levels of estrogens generally increased after exposure to
8:2 diPAPS, 8:2 monoPAPS and 8:2 FTOH (Table 2), despite the de-
crease in substrates, androstenedione and testosterone. This suggests
that the equilibrium between the two groups of sex hormones was af-
fected. This was supported by an observed increase in CYP19 gene ex-
pression levels following 8:2 diPAPS, 8:2 monoPAPS and 8:2 FTOH
exposure which potentially can lead to the observed decreases in an-
drogens and increases in estrogens.
Besides the above suggested mechanisms of action the decreased
androgen levels could be caused by interferences with translation of
mRNA into proteins and activity of important proteins in steroido-
genesis. As the test compounds are surface active they may also af-
fect the ﬂuidity of cell membranes as described previously for PFOS
(Hu et al., 2003; Xie et al., 2010), though our results do not seem to
support this hypothesis, but rather suggests that the mechanism is
speciﬁc, as described above.
Liu et al. (2010) have previously studied the effects of 8:2 FTOH in
the H295R steroidogenesis assay at an exposure period of 24 h. De-
spite the differences in exposure time, 24 h versus 48 h, many of
the measured hormones showed similar trends in the two studies,
including a decrease in 17-OH-progesterone, androstenedione and
testosterone. However Liu et al. (2010) also found a decrease in cor-
tisol levels and no change in progesterone levels. They hypothesized
that 8:2 FTOH caused a general down-regulation of steroidogenesis
through decreased cAMP levels (Liu et al., 2010). In the present
study cortisol levels stayed unaffected and progesterone levels de-
creased with 8:2 FTOH exposure. The absence of a cortisol decrease
and the increase in 17β-estradiol indicate that a site speciﬁc mecha-
nism of action is likely to occur in the present study, which is
Fig. 5. Gene expression levels following 8:2 diPAPS, 8:2 monoPAPS, and 8:2 FTOH exposure are shown as fold change values (2−ΔΔCt) of mRNA for steroidogenic acute regulatory
protein (StAR), benzodiazepine receptor (Bzrp), cholesterol side-chain cleavage enzyme (CYP11), 17α-hydroxylase/17,20 lyase/17,20 desmolase enzyme (CYP17), CYP21 and aro-
matase (CYP19). Concentration–effect relationships are based on data from three experiments in triplicates. All data are corrected for housekeeping gene β-actin, each data point
was normalized against the mean of experiment controls and the three experiments were pooled. Markings of *, **, and *** represent a statistically signiﬁcant level of pb0.05, b0.01
and b0.001, respectively.
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supported by gene expression data for Bzrp and CYP19. Differences
in hormone proﬁles in the two studies may be a result of different in-
cubation periods.
PFOA showed a signiﬁcant increase in estrogen levels at higher
concentrations in the H295R steroidogenesis assay. However, no ef-
fect was observed on androgen levels in the H295R steroidogenesis
assay and in the AR reporter gene assay. Previously PFOA has been
tested for AR antagonism in vitro (Vinggaard et al., 2008) showing re-
sults in accordance with those in the present study. The hormone
data are in agreement with previous in vivo studies where no con-
vincing downward change in testosterone and an increase in
17β-estradiol serum levels were found with exposure to PFOA
(Biegel et al., 2001; Cook et al., 1992). In contrast, studies conducted
on isolated rat Leydig cells have shown that PFOA has the potential
to decrease testosterone levels in vitro (Zhao et al., 2010). The fact
that PFOA showed no effect on AR activation or androgen levels in
the present in vitro studies does not exclude however, that PFOA
could interfere with the androgen pathway in vivo for instance by dis-
turbance of metabolism of steroid hormones. This has been suggested
previously, as expression of genes associated with steroid metabolism
was induced in fetal mouse liver after exposure to PFOA (Rosen et al.,
2007). The discrepancy between in vitro effects on testosterone synthe-
sis in the present study and the study by Zhao et al. (2010) could be
explained by species differences, human versus rat, or by qualitative dif-
ferences in the steroidogenic pathway in the adrenal and testis. Overall
the present study does not supply additional evidence of PFOA interfer-
ingwith androgen synthesis, but our study supports the hypothesis that
PFOA can cause increased estrogen levels.
The technical mixtures used for coating of food packaging
materials mainly contain diPAPS homologues, but also triPAPS and
monoPAPS (Trier et al., 2011). These can undergo dephosphorylation
and oxidation into FTOH and PFCA homologues in rats (D'eon and
Mabury, 2007, 2011). The present study included an assessment of
individual metabolites in a shared metabolic pathway. The OECD
guideline states that the metabolic capacity of H295R cells is currently
unknown, but that it is probably limited (OECD, 2011). Moreover,
Liu et al. (2010) found no conjugates of the perﬂuorinated acids or
the acids themselves indicating that no biotransformation of 8:2
FTOH into PFCAs occurred (Liu et al., 2010). When comparing the
effect on the hormone levels of 8:2 FTOH and PFOA in the present
study, the lack of uniformity between the two proﬁles indicates
that a full biotransformation of 8:2 FTOH into PFOA has not occurred,
as qualitatively similar effects otherwise would have been expected
for the two compounds. It can thus be assumed that the data
obtained for 8:2 FTOH is a result of exposure to 8:2 FTOH itself and
not the metabolite PFOA. The potential of H295R cells to dephos-
phorylate PAPS into FTOH can indirectly be elucidated through com-
parison of hormone proﬁles. As described previously it is believed
that the effects on testosterone and estrone with 8:2 triPAPS expo-
sure are a result of impurities. The lack of qualitative uniformity be-
tween hormone proﬁles of 8:2 triPAPS compared to 8:2 diPAPS, 8:2
monoPAPS and 8:2 FTOH indicates that no or minor metabolism of
8:2 triPAPS has occurred. The apparent lack of metabolism of PAPS
and FTOH in H295R cells suggests that the individual metabolites
exert an effect in this system.
As pointed out the technical mixture used for FCMs consists of
PAPS of various degrees of alkylation, but also varying lengths of the
ﬂuorinated chain. In the present study compounds with a ﬂuorinated
chain length of eight or ten carbon atoms were included, however
contributions from shorter chained or longer chained PAPS should
be examined in future studies. Furthermore, longer chained PAPS
would be metabolized in vivo into longer chained PFCAs, which may
contribute to the overall effect on the androgen pathway as described
previously (Feng et al., 2009; Shi et al., 2007, 2009).
Human serum levels of diPAPS homologues with chain lengths
4:2, 6:2, 8:2 and 10:2 were measured to be 4.5 μg/L (D'eon et al.,
2009). This approximately equals to 5 nM if all homologues con-
tribute equally. LOEC for 8:2 diPAPS on testosterone was 25.0 μM,
which is far above the blood level. However, the short exposure period
of 48 h applied in the present study does not reﬂect a life-long human
exposure. In addition, the contribution of diPAPS homologues in
combination with metabolic products of these (monoPAPS and
FTOH), as well as the general cocktail of chemicals that humans are
exposed to, may together cause sex hormone disturbances in vivo
and adverse effects on human health.
In summary 8:2 diPAPS, 8:2 monoPAPS, and 8:2 FTOH all gave rise
to decreases in levels of all measured androgens in the steroidogenic
pathway. The mechanism underlying this effect is suggested to be
speciﬁc and to have two targets, inhibition of Bzrp and induction of
CYP19 gene expression, thereby giving rise to the characteristic hor-
mone proﬁles for these three chemicals. This study is a ﬁrst contribu-
tion in gaining knowledge on the toxicology of PAPS. There is a need
for further toxicological studies to be conducted on these chemicals,
as very little is known within this ﬁeld, the chemicals are widely
used, humans are exposed and no speciﬁc EU legislation to control
the use of PAPS in FCMs exists.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.taap.2012.10.022.
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Background: Bisphenol A (BPA) is a chemical with widespread
human exposure suspected of causing low-dose effects. Thus, a
need for developing alternatives to BPA exists. Structural ana-
logues of BPA have already been detected in foods and humans.
Due to the structural analogy of the alternatives, there is a risk of
effects similar to BPA.
Objectives:The aimwas to elucidate and compare the hazards of
bisphenol B (BPB), bisphenol E (BPE), bisphenol F (BPF), bisphe-
nol S (BPS) and 4-cumylphenol (HPP) to BPA.
Methods: In vitro studies on steroidogenesis, receptor activity,
and biomarkers of effect, as well asQuantitative Structure-Activity
Relationship (QSAR) modeling.
Results: All test compounds caused the same qualitative effects
on estrogen receptor and androgen receptor activities, and most of
the alternatives exhibited potencies within the same range as BPA.
Hormone profiles for the compounds indicated a specific mecha-
nism of action on steroidogenesis which generally lead to decreased
androgen, and increased estrogen and progestagen levels. Differ-
ential effects on corticosteroid synthesis were observed suggest-
ing a compound-specific mechanism. Overall, BPS was less estro-
genic and antiandrogenic than BPA, but BPS showed the largest
efficacy on 17-hydroxyprogesterone (17-OH progesterone). Fi-
nally, there were indications of DNA damage, carcinogenicity, ox-
idative stress, effects on metabolism, and skin sensitization of one
or more of the test compounds.
Conclusions: Interference with the endocrine system was the
predominant effect of the test compounds. A substitution of BPA
with these structural analogues should be carried out with caution.
Key words: bisphenol A; BPA analogues; in vitro; QSAR;
steroidogenesis.
Bisphenol A (BPA) is a chemical used in many applications
including production of polymer products such as polycarbon-
ate plastics and epoxy resins which are used in various food con-
tact materials (EFSA, 2006). BPA can furthermore be used as an
additive (Geens et al., 2011), e.g., in thermal papers for receipts
(Liao and Kannan, 2011; Mendum et al., 2011) and have been
found in recycled paper (Geens et al., 2011; Vinggaard et al.,
2000).
Total BPA levels (conjugated + free) have been measured in
more than 90% of urine samples from the U.S. population (n =
2517; Calafat et al., 2008) and the population of seven Asian
countries (n = 296; Zhang et al., 2011b) between 2003–2004
and 2006–2010, respectively, suggesting that the vast majority
of the population is exposed. Furthermore, conjugated and/or
unconjugated BPA has been detected in human amniotic fluid
(Edlow et al., 2012; Yamada et al., 2002), umbilical cord blood
(Chou et al., 2011; Lee et al., 2008), and placenta (Cao et al.,
2012; Jimenez-Diaz et al., 2010) suggesting that the fetus is ex-
posed. Diet is estimated the main source of human exposure fol-
lowed by thermal paper (EFSA, 2013).
BPA has been widely investigated with respect to its tox-
icological hazard and has shown low-dose effects including
disturbed mammary gland development (Moral et al., 2008),
changes in normal behavioral development (Xu et al., 2010),
and changes in obesity associated parameters (Miyawaki et al.,
2007) in rodents. BPA is well known for its estrogenic activ-
ity (Gould et al., 1998; Grignard et al., 2012; Kitamura et al.,
2005; Krishnan et al., 1993; Paris et al., 2002), but other mecha-
nisms of action have also been reported such as human pregnane
X receptor (PXR) agonism (Sui et al., 2012), effects on steroid
hormone synthesis (Zhang et al., 2011a), and androgen receptor
(AR) antagonism (Kitamura et al., 2005; Lee et al., 2003a; Paris
et al., 2002; Vinggaard et al., 2008), all of which contribute to
the overall potential of BPA to interfere with hormone systems.
In 2010, the Canadian Government prohibited the import,
sale, and advertisement of polycarbonate baby bottles contain-
ing BPA (Government of Canada, 2010), and in 2011, the Eu-
ropean Union prohibited the use of BPA in the manufacture of
polycarbonate feeding bottles for infants (The European Com-
mission, 2011). Thus, an incentive for developing alternative
substances exists. Structural analogues such as bisphenol S
(BPS) have already been found in canned soft drinks, canned
foods (Gallart-Ayala et al., 2011; Vinas et al., 2010), and ther-
mal receipt papers (Becerra and Odermatt, 2012; Liao et al.,
2012b). Bisphenol B (BPB) has been found in canned tomatoes
(Grumetto et al., 2008), canned soft drinks, and canned beers
C© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology.
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(Cunha et al., 2011). In addition, BPS (free and conjugated) has
been detected in 81% of urine samples from the general popu-
lation collected from USA and seven Asian countries (n= 315;
Liao et al., 2012a), and BPB has been found in 28% of blood
sera from Italian endometriotic women (n = 58; Cobellis et al.,
2009).
Generally limited information on the hazards of these BPA
analogues is available. However, as a consequence of the struc-
tural similarity of these alternatives to BPA, there is a risk
that they could lead to similar adverse effects. Thus, an ur-
gent need for investigating the hazards of the alternatives to
BPA exists. In the present study, the overall aim was to com-
pare the hazard of BPB, bisphenol E (BPE), bisphenol F (BPF),
BPS, and 4-cumylphenol (HPP) to BPA by characterizing their
toxicological profiles in silico and in vitro. The toxicological
profiling included acute and local effects, endocrine disrup-
tion, teratogenicity, genotoxicity, carcinogenicity, and effects
on metabolism.
METHODS
In Silico Profiling
Two QSAR modeling tools, MultiCASE (version 2.4.1.4)
and Leadscope (version 3.04-10) were applied. The individual
QSAR models are described in Supplementary materials 1 and
in Dybdahl et al. (2012), Jensen et al. (2008, 2011), Jonsdottir
et al. (2012), and Vinggaard et al. (2008). Experimental data for
compounds included in the training set of QSAR models for a
given endpoint are indicated in Table 1.
MultiCASE is a statistical model system that aims to dis-
cover fragment combinations, called biophores/biophobes for
active/inactive molecules, relevant for an observed effect. Fur-
ther MultiCASE identifies modulators, such as physiochemical
properties, which may affect the probability of a fragment be-
ing a biophore/biophobe. Warnings are given in predictions if a
fragment is not represented in the training set, or if a contradic-
torymodulator is present in a prediction.Warnings were consid-
ered an indication that the molecule was outside the model ap-
plicability domain. MultiCASE predictions are reported as pos-
itive or negative.
Leadscope uses a library of 27,000 structural features typi-
cally found in small drug molecules and eight calculated molec-
ular descriptors for QSAR modeling. The best correlated fea-
tures are selected when building a predictive model. In this
study, a compound is in domain if there is≥30% structural sim-
ilarity with a training set compound and if the compound con-
tains at least one structural feature from the model. Predictions
are provided as probabilities (p) for the presence of a given ef-
fect. In this study, p ≥ 0.7 is considered a positive prediction
and p ≤ 0.3 a negative prediction.
FIG. 1. Chemical structures and CAS numbers for BPA, BPB, BPE, BPF,
BPS, and HPP.
In Vitro Profiling
Test chemicals. BPA, BPB, BPE, BPF, BPS, and HPP
stock solutions of 40mM were prepared in dimethyl sulfox-
ide (DMSO). BPA, BPF, BPS, and HPP were purchased from
Sigma-Aldrich (Copenhagen, Denmark) and BPB and BPE
were purchased from VWR (Herlev, Denmark). For chemical
structures and CAS numbers, see Figure 1.
H295R steroidogenesis assay. The H295R steroidogenesis
assay (H295R assay) was performed to assess test compound
potential to affect steroid hormone synthesis. The assay was
conducted as described previously (Rosenmai et al., 2013) using
human adrenal cortico-carcinoma cells (ATCC, LGC standards,
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Boras, Sweden). Prochloraz (Ehrenstorfer, Augsburg, Ger-
many) and forskolin (Sigma-Aldrich, Brøndby, Denmark) were
included as a negative and positive control, respectively. Test
compounds were added in seven 2-fold dilutions in triplicates
ranging from 0.8 to 50Mwith a constant vehicle concentration
in all wells. Cell viability was assessed in the 3-(4,5-Dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) as-
say (Mosmann, 1983) as described previously (Rosenmai et al.,
2013). For information on criteria for cytotoxicity and exclusion
of data due to cytotoxicity for all assays see Supplementary ma-
terials 2.
Hormones were extracted from cell supernatants by solid
phase extraction (SPE) as previously described (Mortensen and
Pedersen, 2007; Vinggaard et al., 2002). Time-resolved flu-
oroimmunoassays (PerkinElmer, Skovlunde, Denmark) were
used for quantification of 17-estradiol, testosterone, and
progesterone in two to three H295R steroidogenesis experi-
ments. Additionally 10 hormones were analyzed by high pres-
sure liquid chromatography-tandemmass spectrometry (HPLC-
MS/MS)including progesterone, 17-OH progesterone, dehy-
droepiandrosterone (DHEA), androstenedione, testosterone, di-
hydrotestosterone, corticosterone, cortisol, 17-estradiol, and
estrone in one experiment. Hormones were separated, identi-
fied, and quantified as previously described (Mortensen and
Pedersen, 2007) with a few modifications (Rosenmai et al.,
2013). The limit of quantification (LOQ) was estimated as de-
scribed in Rosenmai et al. (2013), and was 1000 pg/ml for
DHEA, 500 pg/ml for dihydrotestosterone, 100 pg/ml for an-
drostenedione and 17-estradiol, and 50 pg/ml for the remain-
ing hormones measured. Both methods were used to quantify
testosterone and progesterone, and the results were generally
in accordance. DHEA and corticosterone levels at 50M HPP
exposure as well as all dihydrotestosterone and 17-estradiol
measurements by HPLC-MS/MS were below LOQ.
Estrogen receptor (ER) reporter gene assay. Activation of
ERs by test compounds were tested in a stably transfected hu-
man ovarian adenocarcinoma cell line (BG1Luc4E2) which was
provided by Michael Denison (University of California, USA).
Experiments were generally conducted according to the Organ-
isation for Economic Co-operation and Development (OECD)
test guideline (OECD, 2012). Approximately 72 h before ex-
periment set up, cells were transferred to estrogen-stripped
medium. Successively cells were seeded (4 × 104 cells/well)
∼48 h before exposure. After ∼22 h exposure, luciferase ac-
tivity was measured. Positive controls, 17-estradiol (Sigma-
Aldrich), and methoxychlor (ICN biomedicals, Aurora, Ohio,
USA) were included in experiments. Two experiments of three
to four replicates were conducted with seven 10-fold dilutions
of test compounds ranging from 0.0001 to 100M. The DMSO
concentration was 0.25% in all treatment groups and 0.2% in
controls. Cell viability was scored by visual evaluation.
Androgen receptor (AR) reporter gene assay. The potential
of the chemicals to interfere with the activation of the AR was
tested in an AR reporter gene assay as described by Vinggaard
et al. (2002). Chinese hamster ovary (CHO) cells were pur-
chased from American Type Culture Collection (ATCC, LGC
standards, Boras, Sweden) and plasmids for receptors and re-
porter gene were gifts from Albert Brinkmann (Erasmus Uni-
versity, Rotterdam, The Netherlands). A positive and negative
control, R1881 (PerkinElmer) and hydroxyflutamide (OHF)
(Toronto Research Chemicals, Toronto, Canada), respectively,
was included in experiments. R1881 was added at a concentra-
tion of 0.1nM on antagonism plates. Three experiments in trip-
licates were conducted with eight 2-fold dilutions of test com-
pound between 0.4 and 100M. Vehicle concentrations were
constant in all wells.
Aryl hydrocarbon receptor (AhR) reporter gene assay. AhR
activation leads to transcription of metabolizing enzymes
(Ma, 2008). Stably transfected rat hepatoma (H4IIE-CALUX)
cells provided by Dr Michael Denison (University of Cali-
fornia, USA) were used. The assay was conducted as pre-
viously described (Laier et al., 2003) with a few modifica-
tions. Cells were incubated for ∼22 h in minimum essen-
tial medium (MEM)  [1% foetal bovine serum (FBS), 1%
penicillin/streptomycin/fungizone (PSF)], chemical exposure
was performed for 24 h, and successively luminescence was
measured. Cell viability was tested as previously (Laier et al.,
2003), but cells were seeded at a concentration of 1.1 × 104
cells/well. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) was
used as a positive control. Two experiments in triplicates were
conducted with nine 2-fold dilutions of test compounds ranging
from 0.4 to 100M with a constant vehicle concentration in all
wells.
Nrf2, retinoic acid receptor (RAR), and p53 reporter gene
assays. The Nrf2, p53, and RAR are involved in responses to
oxidative stress (Motohashi and Yamamoto, 2004), responses
to DNA damage (Horn and Vousden, 2007), and play a cen-
tral role during embryonic development (Mark et al., 2009), re-
spectively. The BDS-CALUX reporter gene assays, developed
and carried out by BioDetection Systems b.v. (Amsterdam, The
Netherlands), are based on the human U2OS osteosarcoma cell
line which is stably transfected with a reporter gene and a re-
ceptor, RAR assay (Van Vugt-Lussenburg et al., unpublished
data) or solely a reporter gene, p53-CALUX (Van der Linden
et al., 2014) and Nrf2-CALUX (Van Vugt-Lussenburg et al.,
unpublished data).
The U2OS-CALUX cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) (Invitrogen, Breda, Nether-
lands) with 7.5% fetal calf serum (Invitrogen), 1× nonessen-
tial amino acids (Invitrogen) and 10 U/ml penicillin and 10
g/ml streptomycin (Invitrogen). The assays were conducted
in DMEM without phenol-red (Invitrogen) supplemented with
5% dextran coated charcoal (DCC) stripped fetal calf serum,
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and amino acids and antibiotics as above. Positive controls,
actinomycin D, all-trans-retinoic acid, and curcumin (Sigma-
Aldrich, Zwijndrecht, Netherlands) for the p53, RAR, and Nrf2
assays, respectively were included in experiments. Two inde-
pendent experiments of three to six replicates were conducted
with eight 2-fold dilutions of test compounds in concentrations
ranging from 0.8 to 100M with a constant vehicle concentra-
tion in all wells. 3 × 103 cells/well were seeded in 384-well
plates and incubated for 24 h. After incubation, cells were ex-
posed to test compounds for 24 h. Successively the luciferase
signal was measured on a luminometer (Berthold Centro, Bad
Wildbad, Germany).
Data Handling and Statistical Analysis
In vitro data were normalized to the mean of the control from
the same cell plate within each experiment. Normalized residu-
als to means were assessed for normal distribution (D’Agostino
& Pearsons omnibus test) and variance homogenicity (one-
way ANOVA). All variances were homogenous. A one-way
ANOVA (Dunnett’s post hoc test) was conducted if all data for
a specific endpoint were normally distributed. In other cases a
Kruskal-Wallis test (Dunn’s post hoc test) was used to assess
differences between means. If the test showed significant dif-
ferences between means and the same qualitative dose-response
relationship in the majority of the experiments, the independent
experiments and the pooled means of the experiments was fit-
ted to a sigmoidal dose-response fit. Constraints in the curve
fits were set at 1 for controls and at the maximum/minimum
response for the upper/lower limit of the model for the specific
compound (Hadrup et al., 2013). The exposure concentration
leading to 50% of the maximum response (EC50) and the ten-
tative maximum efficacy (Emax) values, which describe the ob-
served maximum change in response compared with control,
were predicted based on curve fits from the independent exper-
iments. Means of these or single values are presented on tabular
form dependent on the number of experiments. All data analysis
was conducted in GraphPad Prism 5.
RESULTS
A broad toxicological characterization of BPA, BPB, BPE,
BPF, BPS, and HPP was conducted using seven in vitro assays
as well as predictions performed in an array of QSAR models.
In Table 1, predictions based on QSAR modeling are shown. In
Tables 2 and 3, predicted Emax and EC50 values are shown for
in vitro experiments.
Endocrine Interference and Teratogenicity
Steroidogenesis was affected by all test compounds in the hu-
man adrenal cortico-carcinoma cells (Fig. 3, Table 3).
Overall, progestagen levels increased with exposure to BPB,
BPE, BPF, BPS, and HPP; however, BPA and BPB did not in-
crease progesterone levels significantly in the majority of the
experiments. BPF and BPS led to the greatest Emax values on
progesterone and 17-OH progesterone levels, respectively.
Testosterone, androstenedione, and DHEA levels generally
decreased with exposure to the test compounds. However,
DHEA did not change with HPP exposure and increased in
level with BPB exposure. BPA and BPE showed the most po-
tent effect on androgens levels compared with the remaining test
compounds. The EC50 and Emax values for decreased androgens
ranged from 0.3 to 28.0M and 44 to 89%, respectively (Table
3).
Generally 17-estradiol and estrone levels were increased
by test compounds though BPS did not cause an effect. BPB
and HPP increased estrone levels significantly with efficacies
of 1592 and 845%, respectively. EC50 values for both estrogens
differed by less than a factor of∼3 between the test compounds.
BPA, BPB, BPS, and HPP decreased cortisol levels withEmax
values in the same range, 72–78%, and EC50 values ranging by
a factor ∼3.5. BPF led to increased cortisol levels. BPB, BPS,
and HPP led to decreased corticosterone levels; whereas BPE
and BPF led to increased levels (Table 3). BPA exposure did
not affect corticosterone levels.
ER activity was increased by all six compounds (Fig. 2). BPB
and HPP were equally potent to BPA (EC50 ∼ 0.1M) (Table
2). BPE, BPF, and BPSwere less potent; however, the EC50 val-
ues were all within a factor of ∼15 to BPA. BPS was the least
potent of the six compounds. Emax values ranged from 156 to
386%. In the QSAR models for estrogenic effects, all six com-
pounds, except BPB, have been experimentally tested positive
for ER binding and activation and were part of the training sets.
BPB was predicted positive for ER binding and out of domain
for ER activation.
All test compounds decreased the activity of the AR (Fig. 2).
BPS only led to a decreasing trend and was not modeled. BPA,
BPB, andBPF had similar EC50 values, whereas BPE had higher
and HPP lower potency (Table 2). The EC50 values differed by
less than a factor of ∼2.7 and Emax values ranged from 72 to
92%. Of the tested compounds, only BPE led to an agonistic re-
sponse in the AR assay with an EC50 of 16.0M (SD= 2.0) and
Emax of 169% (SD= 37; data not shown). The QSARmodel for
AR antagonism includedBPA andBPF in the training set, which
has previously shown AR antagonism experimentally. BPB and
BPE were predicted positive for antiandrogenicity, while BPS
and HPP were predicted negative. The most relevant biophores
in the QSARmodel require either substitutions on both benzene
rings or one substituted benzene ring combined with an unsub-
stituted carbon atom in the methylene bridge, which could ex-
plain the difference in QSAR prediction and in vitro result for
HPP.
Finally, the test compounds were predicted negative in a
QSAR model for human teratogenicity (Table 1). This is in ac-
cordance with experimental data on RAR activation showing
that all test compounds, except BPF, had no effect on this end-
point (data not shown).
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FIG. 2. ER agonism, AR antagonism, p53 agonism, and Nrf2 agonism data for BPA (dark blue), BPB (green), BPE (light blue), BPF (orange), BPS (pink),
and HPP (black) shown as fold change compared with control (±SD) as a function of the logarithm to the concentration (log(M)). Curve fits and data points are
based on means of replicates from independent experiments.
Oxidative Stress, DNA Damage, and Cancer
BPF and HPP led to reporter gene activation in the Nrf2-
CALUX assay (Fig. 2, Table 2), whereas the remaining com-
pounds did not lead to changes in response.
BPA and BPB caused reporter gene activation in the p53-
CALUX assay (Fig. 2, Table 2). BPE showed an increasing
trend; however, this was not modeled as it was not significant
in both experiments. In the QSARmodels, BPA had been tested
negative for several genotoxicity endpoints and was part of the
training sets for these models. BPA was either predicted nega-
tive or was out of domain of the genotoxicity models which did
not include BPA in the training set. The remaining compounds
gave either negative predictions for genotoxicity or were out of
domain of the models.
BPA has been tested experimentally and was part of the train-
ing sets for the QSAR models for rodent cancer (AF1–AF4)
(Table 1). BPA was positive for cancer in male rats, marginally
positive in male mice, and negative for female rats and mice.
BPB and BPF were predicted positive in male mice and female
mice, respectively. However, the prediction for BPB was based
on only five chemicals containing the biophore of which two
where tested marginally positive including BPA. The overall
Research Collaboration Agreement (RCA) QSAR cancer call
were negative for all compounds, except BPB which was out
of domain. An estimate of the carcinogenic potency in rodents
(TD50) indicated very low potency (>1000 mg/kg/day) for all
compounds (data not shown).
Metabolism
BPA, BPE, and BPF activated the AhR in vitro showing po-
tencies ranging from 48.8 to 54.8M. BPA led to a lower effi-
cacy than BPE and BPF. BPB, BPS, and HPP had no effect on
AhR activity (Table 2).
All compounds were predicted positive in at least
one of the applied models for cytochrome P450 (CYP)
substrate/inhibition (Table 1). Only robust predictions (p≥ 0.7
or p ≤ 0.3) are mentioned in the following. HPP and BPB were
predicted CYP2D6 substrate and inhibitor, respectively. All
compounds except BPS were predicted CYP3A4 substrates,
and BPS and HPP were predicted CYP2C9 substrates. All
compounds except BPB were predicted negative for CYP2C9
inhibition and BPS was furthermore predicted negative for
CYP2D6 inhibition. Robust predictions for PXR binding was
only obtained for BPB and HPP which were predicted positive.
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FIG. 3. Hormone profiles for BPA (dark blue), BPB (green), BPE (light blue), BPF (orange), BPS (pink), and HPP (black) from the H295R steroidogenesis
assay. Data shown as fold change compared with control (±SD) as a function of the logarithm to the concentration (log(M)). Curve fits and data points are based
on means of replicates from independent experiments for 17-estradiol analyzed by immunoassay and one experiment in triplicates for the remaining hormones
analyzed by HPLC-MS/MS. Basal production of progesterone, 17-OH progesterone, corticosterone, cortisol, DHEA, androstenedione, testosterone, and estrone
were 494 ± 136, 5732 ± 1009, 185 ± 46, 3202 ± 931, 10,122 ± 4932, 45,347 ± 13,088, 1686 ± 298, and 247 ± 154 pg/ml, respectively, given as means of
controls ± SD from six cell plates (n = 18) measured by HPLC-MS/MS.
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TABLE 1
QSAR Predictions for Test Co
Notes. Color code: red, positive; green, negative; white, out of domain. (*) Included in the training set of the model and the experimental result is indicated.
aLeadscope model, p ≥ 0.7 and p ≤ 0.3 is a positive and negative prediction, respectively.
bIn vitro.
cIn vivo.
Sensitization and Skin Irritation
All six compounds were either predicted or tested positive
for skin sensitization. All compounds gave negative predictions
for respiratory sensitization. Training set compounds, BPA and
BPS were tested negative for skin irritation, and BPB, BPF, and
HPP were predicted negative.
DISCUSSION
Endocrine Interference
BPA and the five analogues showed a clear effect on AR
and ER activity as well as on steroid hormone synthesis in the
present study, suggesting that these compounds may interfere
with the endocrine system through several modes of action. In
general, we found similar qualitative effects of the test com-
pounds on endocrine activity.
Estrogenic effects of the test compounds were observed both
for ER activation and for estrogen synthesis. In the ER reporter
gene assay BPA showed a similar potency as BPB and HPP.
BPE, BPF, and BPS were slightly less potent than BPA. BPS
showed both low potency and efficacy. Furthermore, BPS was
the only compound not leading to an effect on estrogen levels
in the H295R assay, suggesting BPS as the overall least estro-
genic compound. BPB and HPP showed a higher efficacy on es-
trone levels than the remaining compounds indicating a greater
overall estrogenic potential of these compounds compared with
BPA.
Antiandrogenic effects were observed for the six test com-
pounds on AR activity and androgen synthesis. BPS only
showed a decreasing trend at higher concentrations on AR ac-
tivity, indicating a less antiandrogenic potential of BPS com-
pared with the remaining test compounds. Androgen levels in
the H295R assay were generally decreased by all test com-
pounds with BPA and BPE being the most potent.
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TABLE 2
Tentative Maxi Efficacy (Emax) and Values for Concentrations Causing 50% of the Maximum Response (EC50) for Test Compounds in
Reporter Gene Assays
Notes. Emax and EC50 values (bold) based on means of predicted values from dose-response curve fits for independent experiments. Standard deviations (SD)
are shown if more than one experiment was modeled and 95% confidence intervals (CI) if one experiment was modeled. Color code: green, activation; red,
deactivation; white, no significant change. VW: very wide; —: the constraints of the model were reached and thus no confidence interval could be predicted.
aValue based on one experiment, as other significant experiment could not be fitted to the nonlinear regression model applied.
The estrogenic and antiandrogenic potential of BPA and the
remaining test compounds have been reported previously (Ca-
baton et al., 2009; Chen et al., 2002; Grignard et al., 2012;
Kitamura et al., 2005; Kuruto-Niwa et al., 2005; Rivas et al.,
2002; Xu et al., 2005). Exposure to estrogenic and antiandro-
genic chemicals have been associated with breast cancer devel-
opment (Yue et al., 2013) and effects on the male reproduc-
tive system (Sharpe and Skakkebaek, 2008; Skakkebaek et al.,
2001), respectively. Potent effects were observed on ER activ-
ity (EC50 = 0.08–1.17M), AR activity (EC50 = 1.9–5.1M)
and steroid hormone levels (EC50 = 0.3–28.0M) in the present
study, which are in the range of high-end urine concentrations
of BPA (conjugated and free) in Danish children of ∼100nM
(Frederiksen et al., 2013). As the test compounds all exhibited
estrogenic and antiandrogenic potential they may contribute to
these types of effects.
The effects on progestagen levels differed between BPA and
the remaining test compounds as BPA had little effect on these
hormones whereas the remaining compounds generally led to
increased progestagen levels. BPS as well as BPF led to the
greatest changes in efficacy on 17-OH progesterone and pro-
gesterone levels, respectively. Administration of a synthetic
progestagen in utero has been associated with virilization of fe-
male mice and feminization in male mice (Willingham et al.,
2006). Thus, these data indicate that the five analogues, espe-
cially BPS and BPF, may have effects which are not prominent
for BPA on this endpoint.
Finally, the effect on the corticosteroids differed between the
six compounds. Generally BPE and BPF led to increased corti-
costeroid levels, whereas the remaining test compounds led to
decreased levels, suggesting a compound-specific mechanism
of effect which could be caused by dissimilar upstream or down-
stream effects. The increased corticosteroid levels observed for
BPE and BPF may be of concern as such increases in utero
have been associated with development of effects involved in
the metabolic syndrome, as well as changes in behavior later in
life (Drake et al., 2007), and thus these compounds may be of
specific concern for these endpoints.
In summary, the six test compounds generally led to increased
progestagen and estrogen levels, and decreased androgen levels
in the H295R assay (Fig. 3, Table 3). This suggests that the ob-
served effects were caused by specific interactions, and were
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TABLE 3
Te Maximum Efficacy (Emax) and Values for Concentrations Causing 50% of the Maximum Response (EC50) for Test Compounds in
the H295R Steroidogenesis Assay
Notes. Emax and EC50 values (bold) based on means of predicted values from dose-response curve fits for independent experiments. Standard deviations (SD)
are shown if more than one experiment was modeled and 95% confidence intervals (CI) if one experiment was modeled. Color code: green, activation; red,
deactivation; white, no significant change. VW: very wide; —: the constraints of the model was reached and thus no confidence interval could be predicted.
aNormalized to means of controls from all cell plates within experiment.
not a result of a general down- or upregulation of steroidogen-
esis. The specific interactions within steroidogenesis have pre-
viously been investigated for BPA in the H295R assay (Zhang
et al., 2011a). BPA exposure was suggested to cause an increase
in progesterone and decrease in androgen levels through inhibi-
tion of the CYP17 lyase reaction and to increase estrogen lev-
els through inhibition of metabolism of estrogens (Zhang et al.,
2011a). Overall, the present study is in accordance with these
findings (Table 3), suggesting that one or both of the specific
interactions of BPA suggested by Zhang et al. (2011a) may be
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evident for the test compounds. Differences in hormone profiles
for BPA between the two studies may reflect temporal or com-
pensatory effects as a result of differential exposure times, 24 h
versus 48 h.
Oxidative Stress, DNA Damage, and Cancer
BPA and BPB increased p53 activity and BPE caused an in-
creasing trend indicating potential to cause DNA damage. BPF
and HPP led to increased Nrf2 activity indicating potential for
oxidative stress (Table 2). Furthermore, BPB and BPF had pos-
itive predictions in one of the QSAR models for cancer (Table
1) in which BPA was tested experimentally positive.
In previous studies BPA has been reported to have genotoxic
potential (Atkinson and Roy, 1995; Iso et al., 2006; Tsutsui
et al., 1998), but other studies have reported negative findings
for genotoxicity (Ibuki et al., 2008; Lee et al., 2003b). Further-
more, BPF has shown genotoxic potential in the HepG2 cells
using the Comet assay (Cabaton et al., 2009) and when assess-
ing the ability to cause histone H2AX phosphorylation (Aude-
bert et al., 2011), but BPF showed no effect in the micronucleus
assay (Cabaton et al., 2009). These contradicting data for BPA
and BPF from previous studies are in accordance with the data
from the present study. To our knowledge, no data exists on
the potential of the remaining test compounds to cause DNA
damage or cancer. The in vitro assays were conducted without a
metabolizing system and thus bioactivated metabolites are not
assessed in this study. The authors suggest that further investiga-
tions of these compounds into their genotoxic and carcinogenic
potential as well as potential to cause oxidative stress should be
performed.
Metabolism
Interactions with several CYP enzymes as well as two recep-
tors, AhR and PXR, associated with metabolism were investi-
gated either in silico or in vitro. In the AhR reporter gene assay
effects were observed at high concentrations for BPA, BPE, and
BPF. All compounds were predicted positive in at least one of
the QSARmodels for CYP substrate recognition and inhibition,
and BPB and HPP were predicted PXR binders (Table 1).
All the test compounds have previously been reported to in-
duce activation of the human PXR receptor in vitro (Sui et al.,
2012). Thus, these data indicate that at least BPB and HPP may
lead to PXR activation though binding directly to the receptor.
PXR as well as AhR activation induce expression of enzymes
involved not only in the metabolism of xenobiotics but also of
endogenous hormones (Arlotto et al., 1991; Ma, 2008; You,
2004). PXR activation has been associated with decreased an-
drogen levels (Zhang et al., 2010) and increased corticosterone
and aldosterone levels (Zhai et al., 2007). Thus, activation of
these receptors by the test compounds may add to the overall
endocrine potential by increasing or decreasing the removal of
endogenous hormones in vivo causing disruption of homeosta-
sis.
Metabolism of the bisphenol analogues have to our knowl-
edge not been investigated in vivo previously. However, several
BPA analogues were studied in river water (Ike et al., 2006),
pond sediments (Ike et al., 2006), and seawater (Danzl et al.,
2009) showing that the degradation varied with BPS having the
least efficient degradation compared with the remaining ana-
logues tested. Furthermore, ToxCast data for BPA, BPB, BPS,
and HPP have been released by the U.S. Environmental Protec-
tion Agency (EPA) for effects on various CYP enzymes (U.S.
EPA, 2014). Comparing these data with the QSAR predictions
in the present study there were some deviations in CYP en-
zyme inhibition and activation data. The deviations may be due
to reasons related to the basis and/or the performance of the
models/assays. The CYP QSAR predictions are based on hu-
man clinical data and various human in vitro endpoints (Jons-
dottir et al., 2012), whereas the ToxCast data origin from in vitro
experiments in human cell lines. Furthermore, the criteria for
classification as active/inactive for ToxCast as well as QSAR
data may explain differential outcomes.
The differences in the QSAR profiles for the test compounds
indicate that the metabolism of the tested compounds differs.
However, further studies have to be conducted with respect to
metabolism of the BPA analogues to obtain firm knowledge re-
garding this issue.
CONCLUSIONS
In the present study, the most marked effects were on en-
docrine interference. Potent effects were observed on ER ac-
tivity, AR activity, and steroid hormone levels, suggesting that
the compounds may act by several modes of action within the
endocrine system. When comparing the compounds, BPS had
the lowest estrogenic and antiandrogenic activity, but had high
efficacy on progestagen levels. The remaining BPA analogues
had toxicological profiles that were generally similar to BPA.
Finally, several of the compounds were flagged for genotoxic-
ity, carcinogenicity, effects on metabolism and oxidative stress.
Considering these findings, substituting BPA with any of the
tested analogues should be carried out with caution.
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In a few cases we observed increased response in the cell viability test with exposure to 
test compounds. We are conducting additional cell viability measurements to shed light on 
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We obtained inconclusive results on 17β-estradiol levels with 6:2 FTOH exposure and 
testosterone levels with TM3 exposure in the H295R steroidogenesis assay. Additional 
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Abstract 22 
Food packaging of paper and board often contain numerous chemicals with potential to contaminate 23 
food and thus can represent a route for human chemical exposure. Fluorinated compounds are used 24 
in technical mixtures (TMs) intended for food packaging due to their repellency properties, but the 25 
fluorinated constituent of TMs are often not known. Polyfluorinated alkyl phosphate ester 26 
surfactants (PAPs) are known constituents that can metabolize into perfluoroalkyl carboxylic acids 27 
(PFCAs) and fluorotelomer alcohols (FTOHs). Humans are exposed to fluorinated compounds, 28 
which are readily detectable in serum, but also in umbilical cord blood, suggesting foetal exposure. 29 
Foetal exposure to endocrine disrupting chemicals may adversely affect normal development, 30 
placing focus on fluorinated compounds as some have potential to interfere with hormone systems.  31 
In this study, we aimed at gaining further knowledge on the endocrine activity of fluorinated 32 
compounds including short chained PFCAs and three TMs, for which little toxicological knowledge 33 
is publically available. We also analysed several PAPs, FTOHs, and longer chained PFCAs by 34 
applying a broad panel of in vitro assays such as ER, AR, and AhR reporter gene assays and H295R 35 
steroidogenesis assay.  36 
Overall, the main effects were estrogenic. We found that some PAPs, FTOHs, and TMs were 37 
estrogenic either through activation of the estrogen receptor and/or increasing 17β-estradiol levels 38 
in vitro. Conversely, short chained PFCAs did not cause any discernible effects. As PAPs of longer 39 
chains showed endocrine activity, future studies should include short chained PAPs and a further 40 
investigation of the tested TMs is advised. 41 
Keywords 42 
Fluorinated compounds, polyfluorinated alkyl phosphate ester surfactants, perfluoroalkyl carboxylic 43 
acids, fluorotelomer alcohols, estrogenicity, endocrine activity, steroidogenesis  44 
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Introduction 45 
In modern society the road from food production to consumption can be long and complex. It 46 
involves multiple steps, many of which have the potential to contaminate the food source with 47 
unwanted substances. Food packaging materials are potential sources of such contamination 48 
(Borchers et al. 2010). For example, food packaging of paper and board can contain a complex 49 
mixture of chemicals, some of which stem from the material itself and others originating from 50 
added printing inks, adhesives, and coatings. If these chemicals migrate to the food source, there is 51 
a potential risk for human exposure and downstream health effects.  52 
Among the chemicals used in food packaging materials of paper and board are fluorinated 53 
compounds, which are typically added to technical mixtures (TMs) because of their ability to repel 54 
water and oils (Kissa 2001). Polyfluorinated alkyl phosphate ester surfactants (PAPs) have been 55 
used in such TMs (Trier et al. 2011), but TMs containing other fluorinated compounds are also 56 
available on the market. The specific chemicals structures of the fluorinated constituents of some of 57 
these TMs are unknown, which pose particular challenges with respect to assessing toxicity and 58 
exposure. 59 
PAPs can metabolize into the final metabolites perfluoroalkyl carboxylic acids (PFCAs), including 60 
perfluorooctanoic acid (PFOA), likely through the intermediate metabolites, fluorotelomer alcohols 61 
(FTOHs) (Figure 1) (D'eon and Mabury 2007; D'eon and Mabury 2011). Together with PAPs, 62 
FTOHs and PFCAs may also be present in TMs as residuals (Prevedouros et al. 2006), and thus 63 
potentially constituting a direct and indirect source of exposure. Indeed, both PAPs and the final 64 
metabolites have been detected in human sera/plasma (Calafat et al. 2007; D'eon et al. 2009; Houde 65 
et al. 2006; Olsen et al. 2012) and breast milk (Kubwabo et al. 2013; So et al. 2006), with PFCAs 66 
also detected in umbilical cord blood (Kim et al. 2011; Monroy et al. 2008). Thus, humans may be 67 
exposed to fluorinated chemicals in foetal, neonatal, as well as adult life. This is of general concern 68 
considering the long serum half-life of PFOA in humans (Olsen et al. 2007), and of particular 69 
concern in relation to foetal exposure, as endocrine disrupting chemicals may contribute to 70 
disrupted development culminating in compromised health at birth or later in life (Skakkebaek et al. 71 
2001). 72 
The reported effects of PFOA exposure are many, including increased incidence of liver, pancreatic, 73 
and testicular tumours, as well as liver toxicity in animal studies (Lau 2012). Fluorinated 74 
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compounds can also interfere with the endocrine system, including increased serum/plasma 17β-75 
estradiol levels following exposure to some PFCAs and FTOHs (Biegel et al. 1995; Biegel et al. 76 
2001; Cook et al. 1992; Feng et al. 2009; Liu et al. 2009; Liu et al. 2010a) and decreased 77 
testosterone levels following exposure to some PFCAs in vivo (Bookstaff et al. 1990; Cook et al. 78 
1992; Shi et al. 2010). Finally, exposure to PAPs can result in increased estrogen and decreased 79 
androgen levels in vitro (Rosenmai et al. 2013). Notably, these studies typically analysed longer 80 
chained fluorinated compounds, and the potential for endocrine disruption of the shorter chained 81 
PFCAs and fluorinated constituents of some TMs remain largely unknown. 82 
In this study, we sought to gain further insight into the potential of fluorinated compounds to 83 
interfere with the endocrine system. We chose a broad screening approach, as available data on 84 
toxicity is very limited with regard to shorter chained PFCAs and fluorinated constituents in some 85 
TMs. We analysed the effects of three TMs, PFCA of chain lengths 4-12, three FTOHs and four 86 
PAPs, which also enabled comparison between toxicological profiles of substances. Through 87 
various in vitro assays, we find effects on several endpoints, including estrogen receptor (ER) and 88 
aryl hydrocarbon receptor (AhR) activity, as well as estrogen levels. Overall, the FTOHs, PAPs and 89 
TMs showed some endocrine activity, whereas the shorter chained PFCAs did not cause any 90 
discernible effects. Finally, we also analysed the potential of the fluorinated compounds and TMs to 91 
affect receptors and biomarkers involved in oxidative stress (Motohashi and Yamamoto 2004), 92 
genotoxicity (Horn and Vousden 2007), and embryonic development (Mark et al. 2009), but 93 
observed no effects. 94 
Materials and Methods 95 
Test compounds and technical mixtures 96 
All compounds used in the study are listed in Table 1 together with their respective CAS numbers 97 
and reported purity. In addition, three commercially available fluorine-based technical mixtures 98 
(TM) for use in food contact materials were tested and are denoted TM1, TM2, and TM3, 99 
corresponding to Solvera PT5045 (fluoropolyether ammonium phosphate salt, Solvey Solexis, 100 
Italy), Capstone (fluorinated acrylic cationic copolymer, Du Pont de Nemeurs, The Netherlands), 101 
and Cartafluor CFI (fluorinated acrylic cationic copolymer, Clariant presently owned by Archroma, 102 
Austria), respectively. 103 
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Stock solutions were prepared by dissolving PFdoDA and TM3 in ethanol, TM1 and TM2 in H2O, 104 
and all other compounds in dimethyl sulfoxide (DMSO). Concentrations of stock solutions were 20 105 
mM for PAPs and 40 mM for all remaining compounds. TMs were of unknown concentration. 106 
Stated intervals of compounds for example PFBA-PFHpA, denotes an interval of chain lengths, in 107 
this case, the compounds PFBA, PFPA, PFHxA, and PFHpA. 108 
Steroidogenesis assay 109 
The steroidogenesis assay was performed using the NCI-H295R human adrenal cortico-carcinoma 110 
cell line (ATCC, LGC standards, Boras, Sweden) as described previously (Rosenmai et al. 2013). 111 
Positive controls were included in all experiments to assure assay performance (see (Rosenmai et al. 112 
2014) for control specifications). Extraction and quantification of progesterone, testosterone, and 113 
17β-estradiol (Time-resolved fluoroimmunoassays, PerkinElmer, Skovlunde, Denmark), as well as 114 
cell viability assessment was performed as previously described (Rosenmai et al. 2013; Vinggaard 115 
et al. 2002). Compounds causing increased 17β-estradiol levels were tested for immunoassay 116 
interference and showed no interference (data not shown).  117 
TMs, 6:2 FTOH, 4:2 FTOH, PFBA-PFHpA, and PFNA-PFdoDA were tested in triplicate reactions 118 
in 2-5 experiments. Test compounds were tested at a maximum concentration of 50 µM and TMs 119 
were tested in a maximum concentration of 0.25% of original material across seven two-fold 120 
dilutions. Vehicle concentrations were constant within each cell plate. Testosterone and 17β-121 
estradiol levels were quantified for PFBA-PFHpA, 6:2 FTOH, and 4:2 FTOH, whereas all 122 
hormones were quantified for PFNA-PFdoDA and the TMs. 123 
Reporter gene assays 124 
The estrogen receptor (ER), androgen receptor (AR), and aryl hydrocarbon receptor (AhR) reporter 125 
gene assays were conducted as previously described (Laier et al. 2003; Rosenmai et al. 2014; 126 
Vinggaard et al. 2002) with a few exceptions. The retinoic acid receptor (RAR), nuclear factor 127 
(erythroid-derived 2)-like 2 (nrf2), p53, and  glucocorticoid receptor (GR) CALUX reporter gene 128 
assays were constructed by and performed at BioDetection Systems essentially as described 129 
previously (Piersma et al. 2013; Rosenmai et al. 2014). 130 
The stably transfected human ovarian adenocarcinoma cell line, BG1Luc4E2 (ER) (gift from Dr. 131 
Michael Denison, University of California, USA), Chinese hamster ovary cells (AR) (ATCC, LGC 132 
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standards, Boras, Sweden), stably transfected rat hepatoma cells, H4IIE-CALUX (AhR) (gift from 133 
Dr. Michael Denison, University of California, USA), and stably transfected human U2OS 134 
osteosarcoma cell line (RAR CALUX, nrf2 CALUX, p53 CALUX, GR CALUX (BioDetection 135 
Systems, The  Netherlands)) were used. All assays and experiments were conducted with positive 136 
controls to assure assay performance. The positive control was dexamethasone in the GR CALUX 137 
reporter gene assay and specification for controls in the remaining reporter gene assays are given in 138 
Rosenmai et al. (2014). The AR reporter gene assay was conducted in antagonist mode and thus 139 
cells were co-exposed with 0.066 nM or 0.1 nM R1881. Plasmids for receptors and reporter gene 140 
for transfection in the AR reporter gene assay were kind gifts from Albert Brinkmann (Erasmus 141 
University, Rotterdam, The Netherlands). In the ER reporter gene assay, cell viability was assessed 142 
by the previously described visual evaluation (Rosenmai et al. 2014) or by addition of resazurin at 143 
3.3 µg/mL in wells, incubation for three hours, and fluorescence measurement.  144 
All test compounds and TMs were tested in the ER and AhR reporter gene assays. TMs, 6:2 FTOH, 145 
4:2 FTOH, and all PFCAs excluding PFOA were tested in the AR reporter gene assay and PFOA-146 
PFdoDA were tested in the nrf2 CALUX, p53 CALUX, RAR CALUX, and GR CALUX reporter 147 
gene assays.  148 
All assays were performed in 2-5 experiments in 2-6 replicate reactions across 7-10 concentrations. 149 
The dilution factor was two in all reporter gene assays for all test compounds and TMs, with the 150 
exception of a dilution factor of ten for test compounds in the ER reporter gene assay. The 151 
maximum tested concentration for TM1 and TM2 was 0.25% of original material and 100 µM for 152 
all PFCAs and FTOHs. A 1 mg/µL EtOH solution of TM3 was prepared, which was diluted by a 153 
factor 400 for the tested maximum concentration in the applied assays. The maximum tested 154 
concentration for PAPs was 100 µM in the ER reporter gene assay and 50 µM in the AR reporter 155 
gene assays. The maximum tested concentration for the diPAPs was 25 µM and for tri- and 156 
monoPAPs it was 50 µM in the AhR reporter gene assay. Vehicle concentrations were constant in 157 
all wells within each experiment in the AR, AhR, RAR CALUX, GR CALUX, nrf2 CALUX, and 158 
p53 CALUX reporter gene assays. In the ER reporter gene assays the vehicle concentration was 159 
0.2-0.25% in all wells, except for PAPs for which vehicle was 0.5% but only at the maximum tested 160 
concentration. 161 
Data processing and statistical analysis 162 
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All statistical analysis was conducted on individual experiments. Within each experiment replicates 163 
were normalized to the mean of the controls. Residuals to mean within each exposure group were 164 
tested for whether means of these were significantly different by conducting a one-way ANOVA. 165 
Further, residuals to mean within each exposure group were pooled and tested for normal 166 
distribution by use of the D’agostino Pearson’s Omnibus test. If pooled residuals were normally 167 
distributed, a one-way ANOVA (post-test Dunnett) was performed. A Kruskal Wallis (post-test 168 
Dunn) was performed on normalized data if pooled residuals were not normally distributed.  169 
If the post-test led to a significant dose-dependent effect in the majority of experiments in either the 170 
p53 CALUX, nrf2 CALUX, GR CALUX, RAR CALUX, AhR, AR, and ER reporter gene assays, 171 
this was perceived as the dominant effect. If cytotoxicity was observed, the data was removed from 172 
the dataset and if a significant increase was observed in cell viability this was reported in Table 2 if 173 
this effect could not be ignored as a chance finding. In the steroidogenesis assay, effects were 174 
reported if the majority of experiments showed significant changes in the post-test in response to 175 
increasing exposure concentration, if these effects did not occur at concentrations leading to 176 
statistically significant cytotoxicity.  177 
The qualitative effects are reported in Table 2 and one representative experiment is shown for some 178 
endpoints in which statistically significant effects were observed in the majority of experiments in 179 
Figure 2, 3, and 4. All data processing and statistical analyses were performed in GraphPad Prism 5. 180 
Results 181 
Effects on steroidogenesis 182 
TM2 exposure led to a significant increase in 17β-estradiol levels (Table 2, Figure 2), but no effects 183 
were observed on testosterone and progesterone. Perfluoroalkyl carboxylic acids of chain lengths 184 
10-12 (PFDA-PFdoDA), all led to increased 17β-estradiol levels. This increase was accompanied 185 
by an increased response in one or all experiments of the cell viability assays. PFDA-PFdoDA did 186 
not affect progesterone and testosterone levels with increasing exposure and PFBA-PFHpA, PFNA, 187 
TM1, and 4:2 FTOH did not affect any of the hormones measured. 6:2 FTOH did not lead to 188 
changes in testosterone levels and the effect on 17β-estradiol was inconclusive as noted in Table 2, 189 
as two independent experiments showed significantly increased 17β-estradiol levels, but only one 190 
experiments followed a classical dose-response relationship. TM3 caused no significant change in 191 
progesterone and 17β-estradiol levels, but led to a decreasing trend in testosterone levels in both 192 
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experiments. This decrease was only significant in one experiment and thus results on testosterone 193 
were deemed inconclusive in Table 2. 194 
ER activity 195 
TM2, TM3, 4:2 FTOH, 6:2 FTOH, 8:2 FTOH, and 8:2 monoPAPs led to increased activity in the 196 
ER reporter gene assay (Table 2, Figure 3). For PFOA and PFNA an increased response was seen in 197 
the ER reporter gene assay, which was accompanied by an increased response in the cell viability 198 
assay in some cases (Table 2). TM1, 8:2 triPAPs, 8:2 diPAPs, 10:2 diPAPs, PFBA-PFHpA and 199 
PFDA-PFdoDA exposure did not affect ER activity. 200 
AR antagonism 201 
A decreased response was observed with exposure to some test compounds and TMs in the AR 202 
reporter gene assay, but in all cases lowered response was accompanied by cytotoxicity, and the 203 
effect was attributed to compromised cell viability; stated as ‘no effect’ in Table 2. 204 
AhR activity 205 
8:2 triPAPs and 8:2 monoPAPs caused an increased AhR activity (Table 2, Figure 4). None of the 206 
remaining compounds led to changes in activity of the receptor. 207 
GR CALUX, nrf2 CALUX, p53 CALUX and RAR CALUX reporter gene assays 208 
PFOA-PFdoDA did not lead to increased activity of the GR and RAR and did not lead to increased 209 
levels of nrf2 and p53 in the reporter gene assays (data not shown). 210 
Discussion 211 
We have analysed the endocrine activity of a selection of fluorinated compounds including; i) 212 
compounds used in food packaging materials (PAPs), ii) compounds occurring as metabolic product 213 
of the functional coating ingredient or occurring as impurities in some TMs (FTOH and PFCAs), 214 
and iii) three different commercially available TMs containing fluorinated compounds of unknown 215 
chemical composition. An overview of major results for PAPs, FTOHs, and PFCAs are shown in 216 
Figure 1. We tested for a variety of endocrine activities, including estrogenicity and 217 
antiandrogenicity. Overall, the most prominent effect was estrogenicity, either by causing increased 218 
17β-estradiol levels or increased ER activity.  219 
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Estrogenicity of perfluorinated alkyl carboxylic acids and fluorotelomer alcohols 220 
Previous studies have shown that PFOA and PFNA exposure can cause increased serum 17β-221 
estradiol levels in vivo (Biegel et al. 1995; Biegel et al. 2001; Cook et al. 1992; Feng et al. 2009) 222 
and in vitro (Kraugerud et al. 2011; Rosenmai et al. 2013). We observed increased 17β-estradiol 223 
levels following PFDA-PFdoDA exposure, but PFNA did not cause an effect. PFOA and PFNA 224 
stimulated ER transactivation in our ER reporter gene assay, whereas PFDA-PFdoDA did not cause 225 
any effects. PFOA-PFdoDA were tested previously for ER mediated transactivation of a reporter 226 
protein in vitro, in which only PFOA caused an effect (Kjeldsen and Bonefeld-Jorgensen 2013). 227 
Thus, both studies suggest that PFOA can affect ER activity in vitro, whereas PFDA-PFdoDA 228 
cannot. Notably, we observed divergent results for PFNA compared to that reported previously in 229 
vitro on both ER activity and effects on 17β-estradiol levels. Although we have no clear explanation 230 
for this, the use of different cell-lines or exposure regimes can be a parameter that has influenced 231 
the output. Finally, an increase in response in the cell viability assay was observed occasionally in 232 
both the ER reporter gene assay and the steroidogenesis assay, which may indicate stimulation of 233 
cell proliferation or increased mitochondrial activity. Therefore, it is difficult to judge whether the 234 
increased 17β-estradiol levels and ER activity are caused by direct interference with the endpoint of 235 
interest, increased cells numbers or interference with mitochondria. Regardless, either modality 236 
could be relevant in vivo, as the net result may be increased 17β-estradiol in the serum or increased 237 
ER activity.   238 
6:2 and 8:2 FTOH has shown estrogenic potential in the breast cancer cell line MCF-7 (Maras et al. 239 
2006), which is in accordance with increased ER activity with 4:2, 6:2, and 8:2 FTOH exposure in 240 
our study. These compounds further increased plasma 17β-estradiol levels in vivo (Liu et al. 2009; 241 
Liu et al. 2010a) and in vitro for 8:2 FTOH (Rosenmai et al. 2013). However, 6:2 FTOH exposure 242 
led to inconclusive results regarding 17β-estradiol levels, thus previous findings could not be 243 
confirmed. Collectively however, the presented data together with previously published results 244 
strongly suggests that most of the tested fluorinated compounds exert estrogenic effects. 245 
Antiandrogenicity of perfluorinated alkyl carboxylic acids and fluorotelomer alcohols 246 
Fluorinated compounds can exert antiandrogenic effects in vivo by decreasing serum/plasma 247 
testosterone levels following exposure to PFOA (Cook et al. 1992), PFDA (Bookstaff et al. 1990), 248 
and PFdoDA (Shi et al. 2009). We observed no decrease in testosterone in vitro, suggesting that the 249 
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in vivo effects are not caused by a direct interference with the intracellular steroidogenic pathway. 250 
The in vivo studies report on decreased body weight, where Bookstaff et al. (1990) and Shi et al. 251 
(2009) can establish effects on testosterone levels either at concentrations below that leading to 252 
decreased body weight or by comparing to pair-fed controls, whereas Cook et al. (1992) observe a 253 
significant decreasing trend, which cannot be established when compared to controls. The latter 254 
study implies general toxicity with lowered testosterone as a function thereof, rather than directly 255 
by antiandrogenic action of the compounds (Cook et al. 1992). As opposed to a previous study 256 
(Kjeldsen and Bonefeld-Jorgensen 2013), we observed no AR antagonism upon PFOA-PFDA 257 
exposure despite the experimental conditions being very similar. We speculate that this can be due 258 
to differences in the agonists applied on the antagonist plates, the cell concentrations, and/or the 259 
amount transfected of reporter vector and receptor plasmids.  260 
It has been shown that 6:2 FTOH and 8:2 FTOH exposure in vivo increases testosterone levels in 261 
females, whereas in males an increase is observed with 6:2 FTOH, whereas 8:2 FTOH cause a 262 
decrease in testosterone (Liu et al. 2009; Liu et al. 2010a). The male findings are in line with other 263 
results published with 8:2 FTOH exposure (Liu et al. 2010b; Rosenmai et al. 2013). However, we 264 
detected no effect on testosterone levels by 6:2 FTOH in the present study. Collectively, the 265 
presented data as well as data from previous studies on antiandrogenicity of the tested fluorinated 266 
compounds are not completely in line and thus the mechanism behind an antiandrogenic effect 267 
remains unclear. 268 
Comparison of endocrine activity of PAPs, FTOH, and PFCAs 269 
As mentioned, PAPs can metabolize in vivo into the final metabolites PFCAs, possibly through the 270 
intermediate metabolite FTOH (D'eon and Mabury 2007; D'eon and Mabury 2011). Thus, our study 271 
allowed comparison of effects across groups of compounds and assays to gain further insight into 272 
mechanism-of-action and overall endocrine activity.   273 
The mechanism of action causing altered hormone levels in the steroidogenesis assay is clearly 274 
different between PAPs (shown previously in (Rosenmai et al. 2013)), FTOHs, and PFCAs (Table 275 
2). Overall, PAPs lead to decreased androgen and progestagen levels, whereas 4:2 FTOH, 6:2 276 
FTOH, and all the tested PFCAs do not. It is likely that the effect of PAPs is caused by a direct 277 
effect on steroidogenesis, as indicated by altered mRNA expression of key steroidogenic genes by 278 
some PAPs (Rosenmai et al. 2013). Although mRNA levels were not measured in this study, the 279 
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hormone data for PFDA-PFdoDA indicate a different mechanism, possibly involving interference 280 
with CYP19 or 17β-estradiol clearance, both of which could lead to the observed increased estrogen 281 
levels. 282 
8:2 monoPAPs, FTOHs, PFOA, and PFNA harbour the potential to increase ER activity in the ER 283 
reporter gene assay (Table 2). This highlights three points: 1) as none of the tri- or di-alkylated 284 
PAPs caused any effect, it indicates that the degree of alkylation may play a role in ER activity. 2) 285 
8:2 monoPAPs may contribute significantly to estrogenicity as parent compound (8:2 monoPAPs), 286 
intermediate metabolite (8:2 FTOH), and final metabolite (PFOA and PFNA), all led to ER activity. 287 
3) short chained FTOH may be an important contributor to effects exerted by short chained 288 
fluorinated compounds, as 6:2 FTOH and 4:2 FTOH led to activity, whereas none of the short 289 
chained PFCAs did. These points are only valid if test compounds did not metabolize within the 290 
cells, as the effects then could be caused by metabolites and not the test compound per se. However, 291 
as the tri- and di-alkylated PAPs did not cause any effects, it is unlikely that PAPs dealkylated into 292 
FTOH in the cells. Likewise, since the shorter chained PFCAs did not activate the ER, but their 293 
upstream metabolites 4:2 and 6:2 FTOH did, it is also unlikely that the FTOHs metabolized into 294 
PFCAs.  295 
The AhR plays a role in regulation of several enzymes involved in metabolism of xenobiotics (Ma 296 
2008). As 8:2 triPAPs and 8:2 monoPAPs activated the AhR, this may add to the overall endocrine 297 
activity of these compounds, as it could affect the clearance rate of compounds exerting effects. 298 
From this and a previous study (Rosenmai et al. 2013), it becomes clear that the mechanism and 299 
pathway of endocrine effects of the PAPs, FTOH, and PFCAs is different. Overall, PAPs induce 300 
effects across several endpoints, and are thus more potent than the FTOHs and PFCAs. However, 301 
these metabolites also cause effects, which may lead to greater endocrine disruptive potential of 302 
PAPs, as metabolism will not deactivate the compound, but rather form other active compounds. 303 
Estrogenicity of technical mixtures – what is next? 304 
The three TMs that we tested are all commercially available and intended for coating of food 305 
packaging of paper and board. However, information on the specific fluorinated chemical structures 306 
of the TMs, fluorinated impurities, or other chemicals for that matter, is not publically available or 307 
is very difficult to find. The characterization of impurities of the TMs is in progress (Trier & 308 
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Eschauzier, Manuscript in preparation). These data gaps limit our ability to conclude on the active 309 
compounds causing the effects, but it does not exclude the fluorinated constituents as being 310 
causative agents. 311 
Both TM2 and TM3 showed estrogenic potential by affecting 17β-estradiol levels and/or ER 312 
activity. As no effect was observed on testosterone or progesterone levels, it is unlikely that the 313 
dominating fluorinated constituents in the mixtures exhibit similar activities as PAPs. On the other 314 
hand, it is possible that impurities such as FTOHs and PFCAs are present in the TMs and thus 315 
contribute to the effects, as these also affected ER activity and 17β-estradiol levels. As we have 316 
limited knowledge about the concentrations of such impurities, it is only possible to speculate on 317 
such contributions. Regardless, the fact that the TMs show estrogenic potential warrants further 318 
investigations into composition of the mixture. It would also be informative to study the ability of 319 
the specific fluorinated compounds to migrate into foods to obtain further information regarding 320 
exposure risk. 321 
Is short-chained chemistry a better alternative? 322 
To our knowledge little is known about the endocrine activity of shorter-chained fluorinated 323 
compounds. As the industry is shifting towards such compounds (Scheringer et al. 2014), which 324 
potentially metabolize into short-chained PFCAs, we also included PFBA-PFHpA in our study.  325 
In view of hazard potentials, we would deem PFCAs with chain lengths of 4-7 (PFBA-PFHpA) 326 
better alternatives than the remaining test compounds, as they caused no effects in any of the 327 
applied assays. However, we need to acknowledge that the compounds were tested in vitro, which 328 
has certain limitations. Furthermore, as the tested PAPs had a greater endocrine activity overall than 329 
the PFCAs, we need to include shorter-chained PAPs in future investigations to assess, if these also 330 
have greater potential than their final metabolites. 331 
Genotoxicity and oxidative stress 332 
PFOA has previously been reported to increase the incidence of several types of tumours in animal 333 
models (Lau 2012). Thus, we included two tests, nrf2 CALUX and p53 CALUX reporter gene 334 
assays, to assess the ability to cause oxidative stress and genotoxicity, respectively. As we observed 335 
no effects with test compound and TM exposure, this study provides no further evidence for the 336 
potential of genotoxic effects or oxidative stress.  337 
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Summary 338 
We have shown that fluorinated compounds can be estrogenic and that parent compounds seem to 339 
be more potent than their metabolites. The compounds likely act through different mechanisms of 340 
action and target several pathways, which may add to the overall potential for endocrine activity. In 341 
some cases the TMs showed estrogenicity, whereas the short chained PFCAs did not, which to our 342 
knowledge is the first report of endocrine activities or lack thereof for these compounds and TMs. 343 
We suggest initiating further studies within this area, starting foremost with characterizing the 344 
composition of the TMs. It would likewise be prudent to investigate the endocrine activity of 345 
shorter-chained PAPs to obtain further knowledge on whether short-chained chemistry is a better 346 
alternative to long-chained fluorinated compounds. 347 
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Tables 461 
Table 1: Names, abbreviations, CAS numbers and purity of test compounds. 462 
Abbreviation Name CAS Purity 
4:2 FTOH 4:2 fluorotelomer alcohol 2043-47-2 97 % 
6:2 FTOH 6:2 fluorotelomer alcohol 647-42-7 97 % 
8:2 FTOH 8:2 fluorotelomer alcohol 678-39-7 97 % 
PFBA Perfluorobutanoic acid 375-22-4 98 % 
PFPA Perfluoropentanoic acid 375-85-9 97 % 
PFHxA Perfluorohexanoic acid 307-24-4 97 % 
PFHpA Perfluoroheptanoic acid 375-85-9 99 % 
PFOA Perfluorooctanoic acid 335-67-1 
3825-26-1 
96 % 
98 % 
PFNA Perfluorononanoic acid 375-95-1 97 % 
PFDA Perfluorodecanoic acid 335-76-2 98 % 
PFunDA Perfluoroundecanoic acid 2058-94-8 95 % 
PFdoDA Perfluorododecanoic acid 307-55-1 97 % 
8:2 monoPAPs 8:2 polyfluoroalkyl phosphate ester surfactants 57678-03-2 99.5 % 
8:2 diPAPs 8:2/8:2 polyfluoroalkyl phosphate ester surfactants 678-41-1 98.3 % 
10:2 diPAPs 10:2/10:2 polyfluoroalkyl phosphate ester surfactants 1895-26-7 94.6 % 
8:2 triPAPs 8:2/8:2/8:2 polyfluoroalkyl phosphate ester surfactants NA 99.5 % 
NA: Not available  463 
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Table 2: Qualitative effects of fluorinated compounds and technical mixtures (TMs) on 464 
progesterone (P), testosterone (T), and 17β-estradiol levels in the steroidogenesis assay (H295R) as 465 
well as effects on human estrogen receptor (hER), human androgen receptor (hAR), and aryl 466 
hydrocarbon receptor (AhR) activity. Results are based on statistically significant exposure-related 467 
effects observed in the majority of independent experiments within each assay. Increased responses 468 
are indicated with an upward arrow (↑, green), decreased responses are indicated with a 469 
downward arrow (↓, red), and no effect is indicated with the marking (-). 470 
  H295R hER hAR AhR 
  P T E2        
TM1 - - - - - - 
TM2 - - ↑ ↑ - - 
TM3 - a - ↑ - - 
8:2 triPAPs ↓ ↓ - - - ↑ 
10:2 diPAPs ↓ - - - - - 
8:2 diPAPs ↓ ↓ - - - - 
8:2 monoPAPs ↓ ↓ - ↑ - ↑ 
8:2 FTOH ↓ ↓ ↑ ↑ - - 
6:2 FTOH   - a ↑ - - 
4:2 FTOH   - - ↑ - - 
PFdoDA - - ↑b - - - 
PFunDA - - ↑b - - - 
PFDA - - ↑c - - - 
PFNA - - - ↑c - - 
PFOA - - ↓↑d ↑c - - 
PFHpA   - - - - - 
PFHxA   - - - - - 
PFPA   - - - - - 
PFBA   - - - - - 
Grey areas: not tested/measured 471 
Striped areas: results from Rosenmai et al. (2013) 472 
(a) inconclusive 473 
(b) increased response in cell viability plate observed in concentrations giving response in all 474 
experiments leading to significant effects 475 
(c) increased response in cell viability plate observed in concentrations giving response in one 476 
experiments of those leading to significant effects 477 
 (d) a U-shaped concentration-response curve was reported with a decrease in E2 levels at lower 478 
exposure concentrations and an increase at higher exposure concentrations  479 
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Figures  480 
 481 
Figure 1: Metabolic pathway of PAPs into the intermediate metabolites FTOH and the final 482 
metabolite PFCAs (D’eon et al., 2007, 2011). The main effects for the groups of fluorinated 483 
compounds are shown in the grey boxes based on results from this study and Rosenmai et al. 484 
(2013). Number of compounds leading to effects is indicated in brackets. RF1 = F(CF2)nCH2CH2. 485 
RF2 = F(CF2)n. In this study: diPAPs (n = 8 or 10), monoPAPs and triPAPs (n = 8), FTOHs (n = 4, 486 
6, or 8), PFCAs (n = 3-11). 487 
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Figure 2: Increased 17β-estradiol levels following exposure to TM2 based on data from the 489 
steroidogenesis assay. Fold change (±SD) as a function of percent (%) original material provided. 490 
Data is based on one representative experiment. 491 
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Figure 3: Increased estrogen receptor activity following exposure to TM2, TM3, 8:2 monoPAPs, 493 
and FTOHs based on data from the ER reporter gene assay. Fold change (±SD) as a function of 494 
percent (%) original material provided for TMs and exposure concentration (µM) for FTOHs and 495 
monoPAPs. Data is based on one representative experiment. 496 
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Figure 4: Increased aryl hydrocarbon receptor activity following exposure to 8:2 monoPAPs and 498 
8:2 triPAPs in the AhR reporter gene assay. Fold change (±SD) as a function of exposure 499 
concentration (µM). Data is based on one representative experiment. 500 
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Abstract 21 
Food contact materials (FCMs) constitute a source of human exposure to chemicals. Lists of 22 
compounds intended for use in these materials exist, but limited knowledge is available on the 23 
potential toxicological effects of many of the compounds allowing for appropriate risk assessment. 24 
In this study, we aimed at developing a strategy which allows for screening of FCMs and 25 
identification of potentially problematic compounds in these materials by means of applying 26 
analytical chemistry tools as well as bioassay guided analysis in combination. 27 
A step-by-step approach was developed in which extracts from FCMs were tested in vitro, active 28 
extracts underwent fractionation, fractions were tested in vitro, and tentative identification of 29 
compounds was conducted in active fractions. Selected tentatively identified compounds were 30 
tested individually in vitro and quantified in the extracts. The battery of in vitro assays covered 31 
endpoints related to endocrine disruption, oxidative stress, cytotoxiticy and genotoxicity. 32 
All 20 extracts led to effects on aryl hydrocarbon receptor activity, whereas only a subset of extracts 33 
led to effects on estrogen receptor (ER) and androgen receptor (AR) activity. Two extracts were 34 
selected for further investigation by use of the step-by-step strategy, one extract from a pizza box 35 
and one from a sandwich wrapper. By doing so, we successfully identified di-butyl phthalate, butyl-36 
benzyl phthalate, and bisphenol A (BPA) as causing ER activity in the pizza box of which BPA 37 
mainly caused the effect. In the sandwich wrapper extract, which caused AR antagonism, we 38 
identified two causative agents, dehydroabietic acid (DHAA) and abietic acid, of which the latter 39 
was present at high concentrations and thus mainly caused the effect in the extract. This is to our 40 
knowledge the first reporting of the antiandrogenicity of DHAA. 41 
Collectively these data suggest that applying the strategy is a useful tool to assess potential hazards 42 
posed by chemicals in FCMs of paper and board, as well as identifying causative agents. 43 
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Introduction 46 
Assuring food safety is a challenge in modern society as the potential sources of food contamination 47 
are many, one of which is compounds migrating from food contact materials (FCMs) (Borchers et 48 
al. 2010). We already know of several compounds, which are used in FCMs and which have the 49 
potential to cause adverse effects, such as bisphenol A (BPA) and phthalates. BPA is used in 50 
applications such as polycarbonate plastic bottles, as a monomer used for epoxy resin coatings in 51 
cans for foods and drink (EFSA 2006), and have been found in recycled paper (Geens et al. 2011; 52 
Vinggaard et al. 2000), whereas phthalates are used in applications such as PVC tubing, food-53 
packaging films, and have been measured in paper and board (Cao 2010). BPA and phthalates are 54 
known endocrine disruptors, and have shown adverse effects in vivo (Christiansen et al. 2014; 55 
Foster 2006; Miyawaki et al. 2007). 56 
Besides these known compounds there are multiple other compounds used in FCMs. A compiled 57 
list of indirect additives including up to 3000 compounds, some of which are intended for FCMs, 58 
have recently been compared to available toxicity data (Neltner et al. 2013). This comparison 59 
revealed that the majority of the indirect additives are not sufficiently examined for toxicological 60 
effects (Neltner et al. 2013). Though no specific EU regulation exists on the use of chemicals in 61 
FCMs of paper and board, there is a framework directive, which states that compounds used in 62 
FCMs should not migrate into foods in amounts, which can adversely affect human health (The 63 
European Commission 2004). Based on the aforementioned data, it becomes apparent that a 64 
strategy is needed to obtain information on potential effects of compounds present in FCMs. 65 
The vast numbers of compounds, for which little is known on adverse effects pose challenges as 66 
testing all the compounds would be extremely time consuming. Thus, several previous studies have 67 
investigated effects of mixtures of compounds originating from FCMs of paper and board by 68 
applying a bioassay guided analysis approach. In these studies extracts from FCMs of paper and 69 
board were tested in vitro assessing endpoint such as genotoxicity, cell toxicity, and endocrine 70 
disruption (Binderup et al. 2002; Lopez-Espinosa et al. 2007; Ozaki et al. 2004; Ozaki et al. 2005; 71 
Vinggaard et al. 2000; Weber et al. 2006). On several occasions compounds were identified by use 72 
of these strategies, which could explain the observed effects either fully or partly. These strategies 73 
can be applied to enable a future prioritization of studies to be conducted on the identified 74 
compounds. 75 
In this study, we wanted to develop a test strategy to obtain information on the potential effects of 76 
compounds present in FCMs of paper and board by applying both analytical chemistry tools and 77 
bioassay guided analysis. A broad battery of in vitro assays was used to examine effects of 78 
compounds present in the materials including endpoints associated with endocrine disruption, 79 
oxidative stress, cytotoxiticy and genotoxicity. Additional data obtained by the Comet assay and 80 
Ames test will be published elsewhere, but is part of the overall strategy. Extracts from 20 FCMs 81 
were tested in these assays and two of the extracts underwent further investigation by in vitro 82 
testing of fractions of the extracts. Finally the compounds that most likely were responsible for the 83 
in vitro effects in question were identified.  84 
  
Materials and Methods 85 
The step-by-step procedure in the FCM strategy is shown in Figure 1. The strategy involved several 86 
steps including, 1) preparation of extracts from FCMs of paper and board, 2) testing of extracts in 87 
vitro, 3) fractionation of selected active extract, 4) testing of fractions in the assay in which the 88 
extract led to effect, 5) tentative identification of compounds in active fractions, 6) evaluation to 89 
narrow down the list of tentatively identified compounds, 7) in vitro testing of final list of 90 
tentatively identified compounds, 8) verification of presence of substances in the extract as well as 91 
quantification of active identified compounds, and 9) evaluation of contribution to effect in extract 92 
of identified compounds by calculating equivalence factors (EQs). 93 
Test compounds and chemicals 94 
Ethanol (99.9 %) used for the extraction and re-dissolving of evaporated extracts was purchased 95 
from Merck (Darmstadt, Germany). Methanol (99.9 %) used for mobile phases for HPLC 96 
fractionation was purchased from Rathburn (Walkerburn, Scotland). All aqueous solutions were 97 
prepared using ultrapure water obtained from a Millipore Milli-Q Gradient A10 system (Millipore, 98 
Bedford, MA, USA). HPLC MS grade formic acid and a water solution of 25 % ammonium 99 
hydroxide were obtained from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade acetonitrile was 100 
obtained from Merck (Darmstadt, Germany). Standards for the LC-qTOF method; bisphenol A 101 
(BPA), methylparaben, perfluorooctanoic acid (PFOA), bisphenol A diglycidyl ether (BADGE) as 102 
well as deuterated BPA (d16-BPA) used for the quantitative determination of bisphenol A were 103 
obtained from Sigma-Aldrich. Di-butyl phthalate (DBP), deuterated di-butyl phthalate (d4-DBP), 104 
butyl-benzyl phthalate (BBP), and di-isobutyl phthalate (DiBP) were used for quantitative 105 
determination in fractions and extracts. Abietic acid (AA), dehydroabietic acid (DHAA), 106 
isorhamnetin and rhamnetin (Sigma-Aldrich) as well as 4-oxo-retinoic acid (Santa Cruz 107 
Biotechnology, TX, USA) were used for quantification in extracts and fractions thereof.  108 
Stock solutions for testing in vitro of DBP, BBP, DiBP, BPA, AA, DHAA, isorhamnetin, 109 
rhamnetin, and 4-oxo-retinoic acid were prepared in DMSO at 40-50 mM.  110 
Paper and board samples 111 
In total 20 different paper and board samples were applied in the test strategy. See Table 1 for paper 112 
and board characteristics. 113 
Production of extracts and fractions 114 
The paper and board extracts and fractions were produced as described previously (Bengtstrom et 115 
al. 2014). Selected FCM extracts exhibiting in vitro activity in the initial screening phase were 116 
fractionated (indicated in Table 1 with the marking *) by liquid chromatography (LC). New extracts 117 
were produced before fractionation, which was performed in two separate rounds, one under 118 
alkaline and one under acidic conditions. 119 
Tentative identification of compounds in fractions of extracts by HRMS 120 
  
The extracts and corresponding fractions exhibiting in vitro activity were analysed by high 121 
resolution mass spectrometry (HRMS) techniques (time-of-flight mass spectrometry coupled to 122 
either gas or liquid chromatography (GC-qTOF or LC-qTOF, Agilent Technologies, Santa Clara, 123 
CA, USA)). The methods for the tentative identification process are presented in full detail in 124 
Bengtström et al. (Manuscript in preparation). In brief, the highly concentrated extracts and 125 
fractions were diluted 1:100 v/v prior to analysis. Cut-offs for peaks were based on the threshold of 126 
toxicological concern for substances with suspected genotoxic effects (Cramer Class III) (EFSA 127 
Scientific Committee 2012), corresponding to 25 ng/dm2, for both tentative identification methods. 128 
Peaks with areas below this threshold were not further investigated. 129 
 130 
In GC-qTOF, the extracts and fractions were ionized by electron ionization (EI) at 70 eV. Only 131 
peaks above the area corresponding to one tenth d4-DBP were analysed by the GC-qTOF to 132 
compensate for differences in detector response. Analysis was performed in the Agilent 133 
MassHunter Qualitative software with the NIST library v.1.1.  134 
 135 
Data obtained by the LC-qTOF analysis was analysed by using MassHunter Qualitative software as 136 
well as ProGenesis QI software (Nonlinear Dynamics Limited, UK). Only peaks with area above 137 
one per cent of that corresponding to BADGE for positive mode and PFOA for negative mode were 138 
considered. Differences in detector response and ion suppression were compensated for by this cut-139 
off. Compounds were tentatively identified by using a customized library containing approximately 140 
2300 matrix specific entries (Bengtström et al., Manuscript in preparation) as well as the 141 
ChemSpider and PubMed database. 142 
Quantitative determination of phthalates by GC-qTOF 143 
Phthalates were quantified by the accredited method described previously (Petersen and Jensen 144 
2010). All quantified phthalates showed good linearity (R2 > 0.98, not weighted, not forced through 145 
0). The phthalate standards used for an external calibration curve were run using the same 146 
parameters and settings as described in Bengtström et al. (Manuscript in preparation). Extracts were 147 
diluted 1:1000 v/v with ethanol prior to analysis. The data was analysed by the Agilent MassHunter 148 
Quantitative software.   149 
Quantitative determination by LC-MS/MS 150 
All extracts were diluted 1:1000 v/v with ethanol before analysis. Quantification of BPA was based 151 
on an accredited LC tandem mass spectrometry (LC-MS/MS) method, described in Table 2. The 152 
eight-point calibration curve (0, 7.5, 15, 30, 75, 150, 225 and 300 ng mL-1) consisted of BPA 153 
standard in methanol and water (75:25, v/v). Internal standard, d16-BPA at 150 ng mL-1, was added 154 
to both calibration standards and extracts. The mass transition reactions used for BPA quantification 155 
were m/z 227.2 > 212.1 as quantifier, m/z 227.2 > 133.1 as qualifier and m/z 241.2 > 223.1 for d16-156 
BPA.  157 
A seven point calibration curve (0, 10, 20, 50, 100, 200 and 500 ng mL-1) with a standard mixture in 158 
ethanol of AA, DHAA, 4-oxo-retinoic acid, isorhamnetin, rhamnetin recognized as the most likely 159 
  
to cause AR activity was analysed according to Table 2. Masses used for quantification of AA were 160 
m/z 301.5 > 301.5 and for DHAA m/z 299.5 > 299.5. The mass transition reactions used for 4-oxo-161 
retinoic acid quantification were m/z 313.2 > 254.2 as quantifier, m/z 313.2 > 163.1 as qualifier. For 162 
isorhamnetin m/z 315 > 300 and m/z 315 > 151 was used as quantifier and qualifier respectively; 163 
and for rhamnetin m/z 315 > 300 and m/z 315 > 165 was used as quantifier and qualifier.   164 
The calibration curves for all methods were obtained by plotting the peak area versus 165 
concentrations. All compounds quantified showed good linearity (R2 > 0.98, not weighted, not 166 
forced through 0) in their respective method and investigated range. Data from both quantifications 167 
were analysed by the Waters QuanLynx (v 4.1) software. 168 
Reporter gene assays for testing of extracts, fractions, and tentatively identified compounds 169 
Nine reporter gene assays were applied to test the extracts from FCMs. These assays included the 170 
androgen receptor (AR), estrogen receptor (ER), aryl hydrocarbon receptor (AhR), and peroxisome 171 
proliferator-activated receptors (PPARα/γ) reporter gene assays. Furthermore, the glucocorticoid 172 
receptor (GR), retinoic acid receptor (RAR), nuclear factor (erythroid-derived 2)-like 2 (nrf2), and 173 
p53 CALUX reporter gene assays were applied. The experimental procedures and materials used 174 
for these assays have been described previously (Piersma et al. 2013; Rosenmai et al. 2014; Taxvig 175 
et al. 2012; Vinggaard et al. 2002). The AR reporter gene assay was conducted in both agonist and 176 
antagonist mode (0.1 nM R1881 added) on extracts. Extracts were tested in a maximum 177 
concentration of 0.25-1 % of extract provided in 2-3.3 fold dilutions. The vehicle concentrations 178 
were constant except in the nrf2, p53, RAR and GR CALUX reporter gene assays, in which the 179 
vehicle was diluted accordingly. The experiments were repeated 1-3 times. Data from the nrf2, p53, 180 
RAR, and GR CALUX as well as PPARα/γ reporter gene assays are currently not included in this 181 
paper, but will be included before submission of the manuscript. Data from the Comet assay and 182 
Ames test obtained from testing the extracts will be published elsewhere.  183 
All fractions of extract S4 and S8 were tested in the AR and ER reporter gene assay, respectively, in 184 
one concentration of 0.25 % of fraction provided. 1-2 experiments were conducted in 2-4 replicates. 185 
Tentatively identified compounds were tested in the ER and AR reporter gene assays. Compounds 186 
included DHAA, AA, rhamnetin, isorhamnetin, and 4-oxo-retinoic acid in the AR reporter gene 187 
assay and BPA, DiBP, BBP, and DBP in the ER reporter gene assay. 188 
All in vitro experiments were conducted with a positive control, which was 17β-estradiol in the ER 189 
reporter gene assay and R1881 or hydroxyflutamide (OHF) in the AR reporter gene assay in the 190 
agonism or antagonism mode, respectively. 191 
In vitro data processing and calculation of equivalence factors 192 
For extracts and tentatively identified compounds statistical analysis was conducted on individual 193 
experiments in which data was normalized to vehicle controls. Residuals to means within each 194 
exposure group was tested for whether means of these were statistically different (ANOVA) and 195 
successively pooled and tested for normal distribution (D’agostino Pearson’s Omnibus test). Data 196 
  
for which pooled residuals were normally distributed were analysed by a one-way ANOVA (post-197 
test Dunnett) and all other data were analysed by the Kruskal Wallis test (post-test Dunn). Exposure 198 
groups, in which cell toxicity was observed, were removed before statistical analysis was 199 
conducted. Data obtained from testing fractions underwent no further data processing. 200 
The overall criteria for reporting in vitro effects for extracts and selected tentatively identified 201 
compounds were that means between exposure groups should exhibit statistically significant 202 
differences, the effects should be dose-dependent, and should be reflected in the majority of 203 
conducted experiments.  204 
In AR antagonism mode the tentative lowest observable effect concentrations (LOECs) were 205 
reported as the concentration at which a ≥ 25% decrease was observed. In agonist mode tentative 206 
LOECs were reported if ≥ 50% increase was observed. The greatest response at non-cytotoxic 207 
concentrations in the ER, AR, and AhR reporter gene assays were reported as the tentative 208 
maximum efficacy (Emax). 209 
Dose-response data for selected extracts, selected tentatively identified compounds in fractions, and 210 
positive controls in the respective assay were fitted to a four parameter sigmoidal curve fit in which 211 
the limits were fixed at 1 and the tentative Emax. Based on these curve fits Hill slopes and EC50 212 
values were obtained, which were used for determination of estrogen equivalence factors (EEQs) 213 
and androgen equivalence factors (AEQs) for both extracts (EQmeas) and for identified compounds 214 
in fractions (EQcalc). The following equations were used to calculate EQs, 215 
(1) 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = 𝑏𝑟𝑏𝑏𝑟𝑏 ∗ 𝑡𝑡𝑡−𝑏𝑡𝑡𝑡𝑡𝑏
1+10(log(𝐸𝐸50)−𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)∗ℎ𝑐𝑖𝑖𝑖𝑖𝑐𝑖𝑐 216 
 217 
(2) 𝑐𝑟𝑟𝑐𝑟𝑟𝑏𝑟𝑐𝑏𝑐𝑟𝑟 = 𝑙𝑟𝑙(𝐸𝐸50) − 𝑙𝑡𝑙� 𝑐𝑐𝑖−𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑐𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑐−𝑏𝑐𝑐𝑐𝑐𝑏�ℎ𝑖𝑙𝑙𝑖𝑙𝑡𝑡𝑖  218 
Here top and bottom represent the highest and lowest y-values, respectively, and Hill slope and 219 
EC50 values are estimated from the curve fit. 220 
The tentatively identified compounds were quantified in the extract and based on the parameters 221 
obtained from the individual dose-response curves, the predicted response was calculated by using 222 
equation (1). The concentration of the identified compound inserted were those leading to the 223 
tentative Emax in the extract. Successively this calculated response was inserted in equation (2), in 224 
which all parameters inserted were based on the positive control; leading to the identified 225 
compounds being converted into EQs of the positive control. The EQs for individual compounds 226 
were summed to obtain the EQcalc. For the extract the EQmeas was calculated by inserting the 227 
tentative Emax for the extract into equation (2) with all the parameters in the equation being based on 228 
the positive control.  229 
Results 230 
In vitro effects of extracts 231 
  
An overview of data obtained for the extracts in the AR, ER, and AhR reporter gene assay are given 232 
in Table 3 with the determined tentative LOECs (dm2/mL) and tentative efficacies (Emax) (%). 233 
Concentration-response relationships for extracts S4 and S8 that were further investigated for 234 
determination of causative agents are shown in Figure 2. 235 
Several of the extracts led to AR agonism (S2, S3, S4, S11, S16, and S18) and antagonism (S2, S3, 236 
S4, S5, S13, and S18). Notably, extract S4, which was further examined by fractionation and 237 
identification of causative agents both led to agonism and antagonism in the AR reporter gene 238 
assay. This dual modality on AR activity was also observed for extract S2, S3, and S18. S4 was 239 
selected for further examination as it showed a tentative Emax of 52 % in the antagonist mode with a 240 
tentative LOEC of 2.3*10-2 (dm2/mL). Twelve extracts did not affect AR activity. 241 
Nine of the extracts led to increased ER activity with tentative Emax values ranging from 63-245% 242 
increase compared to the control and tentative LOECs ranging from 1.3*10-3-5.9*10-2 (dm2/mL). 243 
Extract S8 was chosen for further investigation as it showed high potency and materials were 244 
available for fractionation. 11 extracts did not increase ER activity. Indications of cytotoxicity were 245 
observed in some cases at higher extract concentrations. 246 
All extracts caused increased AhR activity in the reporter gene assay of which S8 and S14 exhibited 247 
marked potency and efficacy in the range of 2.3-4.8 dm2/mL and more than 1000 % increase in 248 
response. Extract S2-S4 were among the less active samples leading to approximately 100 % 249 
increase in response and tentative LOECs of around 2.1*10-1-6.3*10-2 dm2/mL. 250 
In vitro effects of fractions 251 
Data from the ER and AR reporter gene assays for the fractions, both alkaline and acidic, are shown 252 
in Figure 2. The fractions selected to undergo further identifications were those giving the greatest 253 
change in response in the respective assay. Fraction 8 of extract S4 showed a marked decrease in 254 
response in both the acidic and alkaline mode and was chosen for further identification. Acidic 255 
fraction 9 and 10 also led to a decreasing trend compared to the remaining fractions, but were not 256 
further tested. Fractions of extract S8 led to a marked increase in acidic fraction 7 and alkaline 257 
fraction 6, and these were chosen for further investigation. Several other acidic fractions led to 258 
increased responses, but were not further tested. 259 
Tentative identification of compounds in selected fractions  260 
A comprehensive list of all peaks and compounds tentatively identified for fractions with activity in 261 
the ER or AR reporter gene assays is submitted as Supplementary Materials. The selection of 262 
compounds for further investigation in vitro was based on an expert judgment including information 263 
on previously reported effects, read-across, and commercial availability of tentatively identified 264 
compounds. 265 
In extract S8, BPA, DBP, and DiBP tentatively identified in both the acidic and alkaline fraction 266 
with ER activity, were selected for further investigation. Moreover, BBP found in the acidic 267 
fraction with ER activity, was also selected for additional testing. For the fractions of extract S4 268 
  
causing AR activity, tentatively identified compounds, namely DHAA, AA, isorhamnetin, 269 
rhamnetin, and 4-oxo-retinoic acid were selected for further in vitro testing.  270 
In vitro testing of tentatively identified compounds 271 
Of the four selected compounds tested for ER activity, BPA, BBP, and DBP led to increased 272 
activity, whereas DiBP did not lead to any effect. Among the five selected compounds tested for 273 
AR antagonism, four caused marked effects, namely isorhamnetin, 4-oxo-retinoic acid, AA, and 274 
DHAA. Marked cytotoxicity accompanied the decreased response for rhamnetin and thus we could 275 
not establish whether this compound had antagonistic effects on AR activity. Results for tentatively 276 
identified compounds affecting the ER and AR activity are shown in Figure 2. 277 
Quantification of identified compounds 278 
Confirmation of tentatively identified compounds was conducted in both fractions and extracts, 279 
whereas the quantification of these was only done in the extracts. In order to confirm the identity 280 
and to quantify the compounds, standards of the selected tentatively identified compounds were 281 
analysed by either GC-qTOF or LC-MS/MS. Relative retention times and fragmentation patterns 282 
for both BPA and the phthalate standards, analysed by GC-qTOF, confirmed the initial 283 
identification as correct, according to criteria set previously (The European Commission 2002), 284 
whereas only two of five tentatively identified compounds in the AR active extract and fractions of 285 
this, DHAA and AA, had matching relative retention times between standards and fraction (> 0.2 286 
min) when analysed by LC-MS/MS. Moreover, DHAA and AA were the only compounds out of 287 
the five tested that had an entry in the customized database. Concentrations for quantified 288 
compounds causing effects are given in Table 4.   289 
Calculated and measured equivalence factors 290 
The EEQs calculated based on identified compounds were higher than that measured, EEQcalc = 291 
1.42*10-5 µM versus EEQmeas = 2.23*10-6 µM.  The same was evident for AEQs based on identified 292 
compounds in the AR reporter gene assay, AEQcalc = 1.49*10-1 µM versus AEQmeas = 8.84*10-2 293 
µM. The calculated and measured EQs are shown in Table 4. 294 
Discussion 295 
In this study, we aimed at developing a strategy to identify potentially problematic compounds in 296 
FCMs of paper and board by applying a step-by-step approach, as illustrated in Figure 1. 20 FCMs 297 
were investigated of which several caused effects in the in vitro assays, Table 3. The full strategy 298 
was applied on two extracts, the sandwich wrapper consisting of virgin pulp (extract S4) and the 299 
pizza box consisting of recycled material (extract S8), which were active in the AR and ER reporter 300 
gene assays, respectively. Applying the work-flow to these extracts illustrated that the strategy 301 
could be used to identify causative agents present in the extracts, as we successfully identified 302 
DHAA, AA, BPA, DBP, and BBP, which could more than explain the responses of the extracts.  303 
The food contact material strategy 304 
  
In vitro effects of extracts 305 
The extracts tested in the three in vitro assays showed activity to a varying degree depending on the 306 
assay. All extracts led to effects in the AhR reporter gene assay, whereas in the ER and AR reporter 307 
gene assays effects were only observed for some extracts.  308 
Several of the paper and board extracts induced ER activity, which is in accordance with findings of 309 
estrogenicity of kitchen rolls reported previously (Vinggaard et al. 2000). Kitchen rolls made from 310 
recycled materials in particular led to effects, which was suggested primarily to be caused by the 311 
occurrence of BPA in these materials (Vinggaard et al. 2000). In the present study eight of 14 312 
extracts fully or partly based on recycled materials caused effects and one extract out of six made of 313 
virgin paper caused effect. The results suggest that estrogenic potential is prevalent in recycled 314 
compared to virgin paper, though recycled paper in itself is not a clear marker of estrogenicity, as 315 
six recycled FCMs did not lead to effects.  316 
The AhR activity was induced by all the extracts tested suggesting that common compounds are 317 
present in the extracts leading to effects, or that many different compounds present in FCMs have 318 
the ability to activate the receptor. Four extracts were previously examined for ability to activate the 319 
AhR, which all led to effects to varying degrees (Binderup et al. 2002), supporting the findings of 320 
the current study. Binderup et al. (2002) suggested mono-ortho PCBs as contributing to the effects 321 
to a minor degree. However, other well-known AhR activators were not examined, such as dioxins, 322 
non ortho-PCBs and PAHs (Binderup et al. 2002). We are in the process of investigating the 323 
extracts further to shed light on potential reasons for the activities observed (Bengtström et al., 324 
Manuscript in preparation).  325 
Identification of causative agents 326 
The list of tentatively identified compounds in active fractions underwent an expert evaluation. This 327 
evaluation was based on previously reported effects, known biophores for the effect in question, 328 
read-across, and commercial availability of compounds, leading to a final candidate list. This 329 
process was successful as most of the final candidate compounds led to effects in the assays and 330 
were present in the extract. Of the nine tentatively identified compounds on the final list, seven 331 
caused effects in the respective assay, namely DBP, BBP, BPA, DHAA, AA, isorhamnetin, and 4-332 
oxo-retinoic acid, of which five were also identified and quantified in the extracts.  333 
The tentative identification was conducted by use of high resolution mass spectrometry (HRMS), 334 
qTOF, which is necessary when examining a complex matrix as paper and board. HRMS has high 335 
sensitivity when scanning broad mass ranges as well as high mass resolution. The advantages of 336 
this is two-fold: 1) broad ranges of compounds can be identified, which is essential, as we wanted 337 
as many compounds as possible to be identified and 2) high mass resolution allows for accurate 338 
identification, causing a higher degree of certainty in the tentative identification, ultimately leading 339 
to a reduced list of candidate compounds. 340 
  
We further applied two chromatographic separation methods, GC and LC. This enabled analysis of 341 
a broader spectrum of compounds, compared to using only one of the methods, as GC-MS separates 342 
small, non-polar and thermostable volatiles, whereas LC-MS separates larger, more polar, thermo-343 
labile compounds. The four compounds selected for further investigation from fractions active in 344 
ER were tentatively identified by GC-qTOF, whereas the five compounds selected for further 345 
investigation from AR active fractions were tentatively identified by LC-qTOF. These data 346 
illustrate that by using these two methods in combination, we obtain more knowledge on 347 
compounds present in the extracts, as none of the AR active compounds were identified by GC-348 
qTOF. 349 
Utilizing GC-qTOF in combination with EI ionization allowed for tentative identification by use of 350 
a vast commercially available mass spectral library. In contrast, no such library is available for 351 
identification using LC-qTOF, which is a major disadvantage, and thus we build a customized 352 
database for this purpose (Bengtström et al., Manuscript in preparation). Only DHAA and AA had 353 
matches in the customized database, whereas the other AR active compounds did not, and further 354 
these were not confirmed in the extract when compared to standards.  This illustrates that using a 355 
customized database enhances the likelihood for correct identification, as DHAA and AA was 356 
found in both the database and in the extracts, which is in-line with that previously reported (Kind 357 
and Fiehn 2007). 358 
Equivalence factors 359 
In the AR reporter gene assay, four of the five tentatively identified compounds in the sandwich 360 
wrapper made from virgin pulp (extract S4), namely DHAA, AA, isorhamnetin, and 4-oxo-retinoic 361 
acid, all inhibited AR activity, whereas no AR antagonism at non-cytotoxic concentrations of 362 
rhamnetin could be detected. Only the identities of DHAA and AA were confirmed in the extract. 363 
The AEQcalc values for these two compounds were higher than the AEQmeas of the extract, 364 
suggesting that AA and DHAA can explain the response observed.  365 
In the ER reporter gene assay the sum of the calculated EEQs for identified compounds were higher 366 
than the EEQ measured for the pizza box (extract S8), suggesting that we have identified the 367 
causative agents. The somewhat higher EEQcalc compared to the EEQmeas could be caused by other 368 
compounds being present in the extract, which inhibit the ability of BPA, DBP, and BBP to activate 369 
the ER. Furthermore, an assumption for the calculated EEQ is that dose-addition occurs in the 370 
extract, however if this is not the case, this could add to the observed differences in EEQs. Finally, 371 
the lesser EEQ measured in the extract could also be caused by cytotoxicity. Overall, we were 372 
successful in identifying well-known EDs in the extract of the pizza box (extract S8) made from 373 
recycled fibres.  374 
Identified causative agents 375 
BPA is used in thermal paper (Liao and Kannan 2011; Mendum et al. 2011) and has previously 376 
been reported in recycled paper (Vinggaard et al. 2000), which may explain the observed presence 377 
of this compound in the pizza box (extract S8) in our study. Furthermore, phthalates are used in 378 
  
inks, lacquers, and adhesives, and are considered general environmental contaminants and therefore 379 
occur in recycled paper and board (Fasano et al. 2012; Pocas et al. 2010; Suciu et al. 2013), possibly 380 
explaining the presence of BBP and DBP in this study. Besides being used intentionally or non-381 
intentionally in paper and board, human exposure through the diet to BPA and DBP is believed to 382 
be a major source (EFSA 2013; Wormuth et al. 2006) and the compounds or their metabolic 383 
products are routinely measured in human urine (Calafat et al. 2008; CDC 2014), suggesting 384 
widespread exposure.  385 
The ability of BPA, DBP, and BBP to exhibit estrogenicity in vitro has been reported previously 386 
(Ghisari and Bonefeld-Jorgensen 2009; Gould et al. 1998; Grignard et al. 2012; Kitamura et al. 387 
2005; Krishnan et al. 1993; Mankidy et al. 2013; Paris et al. 2002; Shen et al. 2009; Zhang et al. 388 
2011) and thus these data are in-line with the activities observed here in the ER reporter gene assay. 389 
In our study the potency of BPA is greater than BBP and DBP and thus despite the higher 390 
concentrations of DBP in the extract, it is BPA that drives the effect, which is illustrated by the 391 
higher EEQ for BPA, than that of the phthalates.  392 
Besides the in vitro estrogenicity of BPA, this compound has led to low-dose effects in vivo such as 393 
disturbed mammary gland development (Moral et al. 2008), behavioural changes (Xu et al. 2010), 394 
as well as decreased anogenital distance (Christiansen et al. 2014). Whereas phthalates have led to 395 
effects such as hypospadias, cryptorchidism, changes in nipple retention, and reduced anogenital 396 
distance (Foster 2006). Based on these findings it is of concern that these compounds are present in 397 
FCMs of paper and board. 398 
DHAA and AA are resin acids present in different types of resins, and thus the compounds may 399 
very well be present in paper and board materials, as they are naturally occurring constituents of 400 
wood (Roberts 1996; Sjöström and Alen 1998). During the pulping process, DHAA and AA can be 401 
removed, but they can also be present in the final paper product (Roberts 1996). Besides the natural 402 
occurrence in wood, these compounds are also used in the paper making process (Leach and Pierce 403 
1993; Roberts 1996). In the BIOSAFEPAPER project and a study by Ozaki et al. (2006), DHAA 404 
and AA were identified in several of the FCMs investigated (Ozaki et al. 2006; Weber et al. 2006). 405 
In the latter study the compounds were detected in 15 out of 20 FCMs of paper and board and were 406 
shown capable of migrating into food simulants (Ozaki et al. 2006). Furthermore, DHAA and AA 407 
were detected in foods packed in FCM of paper (Mitani et al. 2007), suggesting that human 408 
exposure may occur through food consumption. 409 
In the AR reporter gene assay DHAA and AA have similar dose-response relationships, Figure 2, 410 
however as AA is present in higher amounts, this compound drives the effect in the extract. To our 411 
knowledge, these results are the first to show antiandrogenicity of DHAA. AA however has been 412 
reported to exhibit antiandrogenic potential on AR activity in two in vitro assays (Rostkowski et al. 413 
2011) in accordance with our findings.  Furthermore, AA has shown the ability to inhibit 5α-414 
reductase activity (Roh et al. 2010), which is responsible for converting testosterone into its more 415 
potent form, dihydrotestosterone. This mechanism-of-action is different from that examined in the 416 
present study, AR activity, however these two mechanisms might lead to a greater overall 417 
  
antiandrogenic potential of AA. Various endocrine disrupting effects have further been reported in 418 
studies on fish (Christianson-Heiska et al. 2008; Orrego et al. 2010). Overall, these studies imply 419 
that DHAA and AA have the potential to interfere with hormone systems, which could be a concern 420 
if human exposure occurs. 421 
In the present study, we have illustrated that bioassay guided analysis is a valuable tool for 422 
examining FCMs of paper and board for presence of potentially problematic compounds. In the 423 
strategy several in vitro assays were included in which several of the extracts caused effects. This 424 
highlights that the ‘contamination level’ of FCMs may be high and that we need to focus more on 425 
this potential source of human exposure to chemicals. However, it is noteworthy that rejecting 426 
FCMs as potentially problematic based on in vitro assays solely is not straight-forward, and we 427 
need more experience in interpreting the in vitro outcome before recommendations can be given. 428 
By applying the strategy, we successfully identified three compounds with estrogenic potential as 429 
well as two compounds with antiandrogenic potential, which were present in the selected FCMs of 430 
paper and board. We recommend further studies to be conducted applying this strategy on FCMs of 431 
paper and board in order to improve and refine the strategy further. Large numbers of FCMs still 432 
remain to be tested in this set-up and many more could contain potentially problematic compounds.  433 
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 584 
Figure 1: Step-by-step workflow for the FCM strategy. Numbers indicate, 1) production of extracts from FCMs of paper and board, 585 
2) in vitro testing of extracts, 3) fractionation of extracts exhibiting in vitro activity, 4) in vitro testing of fraction from active extracts, 586 
5) tentative identification of compounds based on in vitro activity of fractions, 6) selection of tentatively identified compounds by 587 
expert judgment for further in vitro examination, 7) testing of selected tentatively identified compounds in vitro, 8) quantification of 588 
selected tentatively identified compounds causing in vitro activity, 9) calculation of equivalence factors (EQs). Abbreviations: ID = 589 
identification, FCM = food contact material. 590 
  
Table 1: Sample overview of the tested FCMs of paper and board with indication of usage or intended use, material type, suppliers, pulp type, whether the materials were printed and the 591 
mass volumes. 592 
Extract no. Usage Material Supplier Pulp type Printing Grammage (g/m2) 
S2 Plain paper Paper Paper industry Virgin pulp No 45 
S3 Baking paper Paper Retail Virgin pulp No 45 
S4 Sandwich wrapper
* Paper Retail Virgin pulp No 40 
S5 Baking paper Paper Retail Virgin pulp No 40 
S6 Baking mold Paper Retail Virgin pulp Yes 40 
S7 Flour baga Paper Retail Virgin pulp Yes 80 
S8 Pizza box
* Corrugated fibreboard Retail Recycled  Yes 550 
S9 Susceptor for microwave popcorn Paperboard Printing industry Virgin and recycled Yes 190 
S10 Sausage tray Paperboard Printing industry Virgin and recycled Yes 270 
S11 Microwave pizza tray Paperboard Printing industry Virgin and recycled Yes 475 
S12 Frozen fish box Paperboard Printing industry Virgin and recycled Yes 400 
S13 Cake tray Paperboard Printing industry Virgin and recycled Yes 420 
S14 Tomato punnet Paperboard Printing industry Virgin and recycled Yes 400 
S16 TEPP Chinese Zineth  Paperboard Printing industry Recycled  Yes 310 
S17 Microwave popcorn bag Paper Printing industry Recycled  Yes 90 
S18 TEPP Chinese Spark Paperboard Printing industry Recycled  Yes 330 
S19 Paperboard with UV print Paperboard Printing industry Recycled  Yes 280 
S20 Paperboard with water soluble print Paperboard Printing industry Recycled  Yes 230 
S21 Paperboard with offset print Paperboard Printing industry Recycled  Yes 280 
S22 Cereal boxa Paperboard Retail Recycled  Yes 380 
aContained food at purchase. *Samples for further fractionation.593 
  
Table 2: Methods used for quantification of a) bisphenol A and b) for compounds found in AR active fractions. 
 a)      b)    
LC conditions 
     
LC conditions 
   Instrument Waters Acquity UPLC System (Waters, 
Milford, USA)  
 
Instrument Agilent 1200 Series HPLC (Agilent 
Technologies, CA, US)  
Column Kinetex C18 (2.6 µm, 2.1x100 mm) 
(Waters) 
  
Column Gemini C18 (3µm 2 x 200 mm) (Phenomenex, 
CA, USA) 
Column temperature 40°C  
   
Column temperature 40°C 
  Injection volume 3 µL  
   
Injection volume 3 µL 
  Mobile phase A: water   
   
Mobile phase 
A: water  + 0.01 formic acid 
  B: methanol   
   
 B: methanol  
  Flow rate 0.3 mL min-1  
   
Flow rate 0.2  mL min-1 
  Gradient Time (min) %A %B 
  
Gradient Time (min) %A %B 
 0 80 20 
  
 0 10 90 
 1 55 45 
  
Total run time 10 min 
   4.5 20 80 
  
 
    5.5 2 98 
  
MS conditions 
    13 2 98 
  
Instrument Micromass Quattro Ultima (Waters, 
Milford, USA) in MRM mode 
Post time 2 min  
   
Ionization mode ESI- 
  Total run time 15  
   
Voltage -2.5 kV 
     
   
Source temperature 120°C 
  MS conditions   
   
Cone voltage 20 V 
  Instrument Micromass Quattro Ultima (Waters, 
Milford, USA) in MRM mode 
  
Cone gas flow 135 L h-1 
  Ionization mode ESI - 
    
Desolvation 
temperature 
380°C 
  Voltage - 3 kV 
    
Desolvation gas flow 575 L h-1 
  Source temperature 120°C 
     
 
  Cone voltage 55 V 
        Cone gas flow 100 L h-1 
        Desolvation 
temperature 
500°C  
        Desolvation gas 
flow 
775 L h-1 
        
          
  
Table 3: Tentative lowest observable effect concentrations (LOECs) (dm2/mL) and tentative efficacies (Emax) (%) for the 20 paper and board extracts  examined in the AR reporter gene 
assay in agonist and antagonist mode, the ER reporter gene assay and the AhR reporter gene assay.  
Extract no. Usage AR Agonism AR Antagonism AhR agonism ER agonism 
    LOEC Emax LOEC Emax LOEC Emax LOEC Emax 
S2 Plain paper 8.0*10-3 290 2.2*10-1 45 2.2*10-1 115 - - 
S3 Baking paper 6.3*10-2 73 2.3*10-3 65 6.3*10-2 73 - - 
S4 Sandwich wrapper* 7.8*10-3 532 2.3*10-2 52 2.1*10-1 81 - - 
S5 Baking paper - - 2.5*10-2 28 7.4*10-2 224 - - 
S6 Baking mold - - - - 2.0*10-2 174 - - 
S7 Flour baga - - - - 6.5*10-3 568 5.9*10-2 82 
S8 Pizza box* - - - - 4.8*10-5 1040 2.6*10-3 103 
S9 Susceptor for microwave popcorn - - - - 1.1*10-2 505 - - 
S10 Sausage tray - - - - 3.9*10-3 992 2.3*10-2 69 
S11 Microwave pizza tray 3.7*10-3 327 - - 3.7*10-3 260 - - 
S12 Frozen fish box - - - - 3.6*10-3 223 2.1*10-2 63 
S13 Cake tray - - 5.1*10-3 42 1.7*10-3 274 - - 
S14 Tomato punnet - - - - 2.3*10-5 1069 5.7*10-3 105 
S16 Imported Chinese 1  1.3*10-2 104 - - 1.4*10-3 670 1.3*10-2 160 
S17 Microwave popcorn bag - - - - 4.4*10-4 229 - - 
S18 Imported Chinese 2 1.1*10-1 141 1.1*10-1 36 3.9*10-3 701 3.5*10-2 132 
S19 Paperboard with UV print - - - - 6.5*10-4 634 1.3*10-3 245 
S20 Paperboard with water soluble print - - - - 8.9*10-4 430 1.8*10-3 226 
S21 Paper board with offset print - - - - 1.1*10-3 869 - - 
S22 Cereal boxa - - - - 4.3*10-4 329 - - 
Values are based on one representative experiment in cases where more than one was conducted. *Samples for further fractionation.
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Figure 2: Androgen receptor (AR) antagonism of sandwich wrapper (extract S4) (top, left), fractions of extract S4 (top, middle), and 
identified (ID) compounds in active fractions of extract S4 (top, right). Estrogen receptor (ER) agonism of the pizza box (extract S8) 
(bottom, left), fraction of extract S8 (bottom, middle), and identified compounds in fraction 6 alkaline and 7 acidic of extract S8 
(bottom, right). Graphs are based on one representative experiment in extract, fractions, and ID compounds. Data from extract and 
identified compounds were normalized to controls and fitted to a sigmoidal dose-response model. Error bars represent standard 
deviations (SD). 
Table 4: Estimated and measured equivalence factors (EQs) in µM of hydroxyflutamide and 17β-estradiol in the AR and ER reporter 
gene assay, respectively, for the pizza box (extract S8) and the sandwich wrapper (extract S4), as well as identified compounds 
causing changes in activity in extracts including bisphenol A (BPA), di-butylphthalate (DBP), butyl-benzylphthalate (BBP), 
dehydroabietic acid (DHAA), and abietic acid (AA). aConcentrations (µM) for identified compounds in extract at maximum 
response. 
ESTROGEN RECEPTOR ACTIVITY 
EXTRACT BPA DBP BBP TOTAL EEQ 
 
µMa EEQ µMa EEQ µMa EEQ EEQcalc EEQmeas 
S8 0.08 1.11*10-5 0.19 1.89*10-7 0.07 1.99*10-7 1.42*10-5 2.23*10-6 
         ANDROGEN RECEPTOR ACTIVITY 
EXTRACT DHAA AA 
  
TOTAL EEQ 
 
µMa AEQ µMa AEQ 
  
AEQcalc AEQmeas 
S4 3.91 2.14*10-4 485.2 1.49*10-1 
  
1.49*10-1 8.84*10-2 
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Supplementary materials: Tentatively identified compounds  
 
Data presented in this Supplementary material are the results obtained from the tentative identification process of fractions with 
positive toxicological response.   
Indicated in the columns are: 
Compound name 
CAS number: if available 
Molecular formula  
Retention time: In respective method 
Ionization mode: GC-EI, LC-ESI+ and LC-ESI- 
Customized database hit: only used for compounds identified in LC-ESI+ or LC-ESI- 
Number of ions: only used for compounds identified in LC-ESI+ or LC-ESI-. Adducts (if present) are also registered as these could facilitate localization of molecular 
ion.  
Additional information: Fragmentation, relevant usage in paper and board 
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S4 acidic fraction 8 
GC-EI 
LC-ESI+ 
LC-ESI- 
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Compound CAS number 
Molecular 
formula 
Retention 
time 
GC-
EI 
LC-
ESI+ 
LC-
ESI- 
Customized 
database hit 
Number of ions 
(for LC only) 
Additional information 
1-
Isocyanatooctadecane 112-96-9 C19H37NO 9.32 x     
Used in coatings, adhesives  and in printing 
Phthalic acid, butyl 
cyclohexyl ester 84-64-0 C18H24O4 11.12 x     
Used as plasticizer  
   
12.98 x 
    
Aliphatic fragmentation pattern 
   
13.27 x 
    
Aliphatic fragmentation pattern 
2,2-
diethoxyacetophenone C12H16O3 6175-45-7 13.38 x     
Used in resin compositions for ink jet printing 
Methyl 6-methoxy-
2,3-dihydro-1-
benzofuran-2-
carboxylate 
C11H12O4 20166-65-8 13.64 x 
    
 
   
14.48 x 
    
Aliphatic fragmentation pattern 
Propanamide, 3-(2-
benzothiazolylthio)- 
132605-19-
7 C10H10N2OS2 6.95  
x 
  
2 Fragment into C3H5NO 
   
11.67 
 
x 
  
1 m/z 300.9967 
  
C18H30N4S 12.15 
 
x 
  
1  
Dehydroabietic acid 1740-19-8 C20H28O2 12.3 
 
x 
 
x 1 Resin acid 
Abietic acid 514-10-3 C20H30O2 12.3 
 
x 
 
x 1 (-H2O adduct) Resin acid 
Isorhamnetin 480-19-3 C16H12O7 12.66 
 
x 
  
1 Naturally occurring flavonol  
Rhamnetin 90-19-7 C16H12O7 12.66 
 
x 
  
1 Naturally occurring flavonol  
  
C23H40O5 12.66 
 
x 
  
2 (NH4+ 
adduct) 
Fragments into C12H18O.  No matching structures available 
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3,6,9,12-
Tetraazaoctadeca-
14,16-dien-18-oic 
acid, 1-amino-, 
ethylester 
61347-03-3 C16H33N5O2 14.50 
 
x 
  
4 
 
4-oxo-retinoic acid 38030-57-8 C20H26O3 14.77 
 
x 
  
1  (NH4+ 
adduct) 
 
2-(8-Heptadecenyl)-2-
oxazoline  
C20H37NO 15.51 
+15.81  
x 
  
2 Fragments into C3H5NO 
   
16.60 
 
x 
  
3 Molecular ion at m/z 1120.8380, fragments at m/z 569.4367 and m/z 284.2982 (C18H37NO) 
  
C26H55NO4S 17.40 
 
x 
  
7 Fragments into C24H48O2S, C13H28S,  C11H16, C8H12, 
C7H10, C6H8 
2-
Mercaptobenzothiazol
e 
149-30-4 C7H5NS2 5.98 
  
x x 3 
Fragments into C7H5NS , used in rubber and latex production 
as well as in paper manufacturing, production of litographic 
plates and two-part cyanoacrylate adhesives 
  
C21H26N4 9.77 
  
x 
 
1  
  
C16H32N4 12.05 
  
x 
 
1  
  
C18H34N4S 12.05 
  
x 
 
1  
  
C17H30N14O 13.21 
  
x 
 
2  
  
C1736O10 13.82 
  
x 
 
2 Fragments into C13H28O8 
(2E)-3-
(Tetradecylsulfanyl)ac
rylic acid  
C17H32O2S 15.98 
  
x 
 
1 
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S4 alkaline fraction 8 
  
LC-ESI+ 
GC-EI 
LC-ESI- 
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Compound CAS number 
Molecular 
formula 
Retention 
time 
GC-
EI 
LC-
ESI+ 
LC-
ESI- 
Customized 
database hit 
Number of 
ions (for LC 
only) 
Additional information 
1-Isocyanatooctadecane 112-96-9 C19H37NO 9.32 x     Used in coatings, adhesives  and in printing 
4-hydroxy-3a,7a-dimethyl-
4,5-dihydro-3H-2-benzofuran-
1-one 
54346-06-4 C10H14O3 12.91 x      
2,2-diethoxyacetophenone C12H16O3 6175-45-7 13.39 x     Used in resin compositions for ink jet printing 
   14.7 x     Aliphatic fragmentation pattern 
   15.17 x     Aliphatic fragmentation pattern 
   15.71 x     Aliphatic fragmentation pattern 
   16.34 x     Aliphatic fragmentation pattern 
   17.07 x     Aliphatic fragmentation pattern 
  C10H10N2OS2 7.02  x   2 Fragments into C3H5NO 
Benzyl 
dimethylcarbamodithioate 
7250-18-2 C10H13NS2 8.93  x   2 Fragments into C3H5NS,used in ink compositions 
Dehydroabietic acid 1740-19-8 C20H28O2 12.3  x  x 1 (M+H) Resin acid 
Abietic acid 514-10-3 C20H30O2 12.3  x  x 1 (M+H-
H2O) 
Resin acid 
   14.55  x   4 328.2714, 286.2235, 117.0741, 75.0262 
2-(8-Heptadecenyl)-2-
oxazoline 
 C20H37NO 15.51, 15.8  x   2 Fragments into C3H5NO 
   16.6  x   3 m/z 1120.8380, fragments into m/z 569.4367 and m/z 
284.2982 (C18H37NO) 
  C26H55NO4S 17.40  x   7 Fragments into C24H48O2S, C13H28S,  C11H16, C8H12, 
C7H10, C6H8 
2-Mercaptobenzothiazole 149-30-4 C7H5NS2 5.98   x x 2 Fragments into C7H5NS, used in rubber and latex 
production as well as in paper manufacturing, production of 
litographic plates and two-part cyanoacrylate adhesives 
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S8 acidic fraction 6 
LC-ESI+ 
GC-EI 
LC-ESI- 
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Compound 
CAS 
number 
Molecular 
formula 
Retention 
time 
GC-
EI 
LC-
ESI+ 
LC-
ESI- 
Customized 
database hit 
Number of 
ions (for LC 
only) 
Additional information 
N,N-Dimethyldodecylamine 112-18-5 C14H31N 8.58 x      
Vinyl benzoate 769-78-8 C9H8O2 9.48 x     Monomer for polyvinyl 
Di-isobutyl phthalate 84-69-5 C16H22O4 10.68 x     Used in in printing inks, resin solvent, paper coatings and 
in adhesives 
Dibutyl phthalate 84-74-2 C16H22O4 11.17 (GC); 
12.25 (LC) 
x x  x 3 Used in in printing inks, resin solvent, paper coatings and 
in adhesives 
2,2-Dimethoxy-1,2-diphenylethanone 24650-42-8 C16H16O3 10.85 x     Photo initiator. Associated with printing inks. 
4a,9a-Dihydro-9,10-anthracenedione 84-65-1 C14H8O2 11.387 x     Digester additive in paper making process. Protecting 
cellulose (and hemicellulose) from alkaline degradation. 
Methyl 4-(6-methyl-4-oxo-2-
heptanyl)-1-cyclohexene-1-
carboxylate 
17904-27-7 C16H26O3 11.49 x      
Benzidine 92-87-5 C12H12N2 11.9 x     Used in production of dyes. 
Bisphenol A 80-05-7 C15H16O2 12.25 x     Used for manufacturing epoxy, polycarbonate and other 
resins 
Tributyl acetylcitrate 77-90-7 C20H34O8 12.53 x     Biodegradable plasticizer used in cellulose resin. 
4'-Methoxy-2-hydroxystilbene - C15H14O2 12.84 x     Naturally occurring substance formed in hardwood. 
Bis(2-ethylhexyl) (2E)-but-2-
enedioate 
141-02-6 C20H36O4 12.38 x     Fumarate. Possibly used to facilitate dye setting. 
Benzyl Butyl Phthalate 85-68-7 C19H20O4 13.00 x     Used in in printing inks, resin solvent, paper coatings and 
in adhesives 
1,3-Diphenyl isothianaphthene 16587-39-6 C20H14S 13.40 x     Used in  production of vinyl polymer 
2-(2-(Benzoyloxy)propoxy)propyl 
benzoate 
20109-39-1 C20H22O5 13.46 x     Naturally occurring substance formed in hardwood. 
Oxydi-2,1-ethanediyl dibenzoate 120-55-8 C18H18O5 13.52 (GC); 
9.1 (LC) 
x x   2 Fragments into C10H11O2 in LC. Naturally occurring 
substance formed in hardwood. 
Dipropyleneglycol dibenzoate 20109-39-1 C20H22O5 13.59 x     Used in photo resistant layers as well as adhesives 
Diglycol dibenzoate 120-55-8 C18H18O5 14.69 x     Used as a plasticizer, in adhesives and in ink jet inks 
Michler's ketone 90-94-8 C17H20N2O 7.1  x  x 2 Fragments into C8H11N,  intermediate in the synthesis of 
dyes and pigments for paper 
4,4-Dimethylandrost-5-ene  C21H34 10.85  x   1 (NH4+ 
adduct) 
 
2,4-Xylenol, 6,6'-isobutylidenedi- 33145-10-7 C20H26O2 11.4  x   1 Used in printing inks (for black) 
   11.6  x   3 317.2086, 295.2264, 277.2186 
Dipropylene glycol benzoate 27138-31-4 C20H22O5 11.8-12.0  x   2 Fragments into C10H11O2, used as plasticizer 
  C26H26N2O2 12.5  x   1  
 34 
 
  C31H38N2 13.2  x   1  
  C19H37NOS 14.75  x   3 (-H20 
adduct) 
Fragments into  C6H12S and C3H6S 
   14.9  x   1 m/z 298.3151 
   15.7  x   1 m/z 308.2898 
   15.9  x   1 m/z 308.3001 
  C40H36O 16.1  x   1  
   16.8  x   1 m/z 284.2992 
 
 
Stearamide 
124-26-5 C18H37NO 16.9  x  x 1 Used in toner pigments, as defoamer and in flexographic 
printing forms 
  C27H44O2 17.55  x   4 Fragments into C25H40, C16H24, C11H16 
N-Isopropylhexadecanamide 189939-61-5 C19H39NO 17.75  x   1 Used in amide containing copolymers 
2-Mercaptobenzothiazole  C7H5NS2 6.15   x  2 Fragments into C7H5NS, used  in rubber and latex 
production as well as in paper manufacturing, production 
of lithographic plates and two-part cyanoacrylate 
adhesives 
Polyglycerol ricinoleate   29894-35-7 C18H33O3 13.45   x  2 Fragments into C12H20O2, printing ink  
Nonidet P-40 11130-43-1 C18H30O3 14.03   x  2 Approved use as a component of articles intended for use 
in packaging, transporting, or holding food  (US FDA) 
Ricinoleic acid 141-22-0 C18H34O3 14.21   x x 1 (-H2O) Used in printing ink 
Methyl 9,10-Dihydroxystearate 1115-01-1 C19H38O4 14.78   x  2 Fragments into C18H34O3, used in ink jet printing 
Polyglycerol ricinoleate   29894-35-7 C18H33O3 15.31   x x 1 Used in printing ink 
12-Hydroxystearic acid  106-14-9 C18H36O3 15.82   x  1 Used as printing ink, resin composition and laminates 
Dehydroabietic acid 1740-19-8 C20H28O2 16.21   x x 1 Resin acid 
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S8 alkaline fraction 6 
LC-ESI+ 
GC-EI 
LC-ESI- 
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Compound CAS number 
Molecular 
formula  
Retention 
time 
GC-
EI 
LC-
ESI+ 
LC-
ESI- 
Customized 
database hit 
Number of 
ions (for LC 
only) 
Additional information 
          
4-Diethylaminobenzaldehyde 120-21-8 C11H15NO 9.81 x 
   
 
Used in colorants 
Isobutyl Benzoate 120-50-3 C12H16O2 9.95 x 
   
 
Used in olefin production, and in defoaming 
processes 
N-Propylbenzamide 10546-70-0 C10H13NO 10.0 x 
   
 
Found in curable compositions in printing 
Dibutyl phthalate 84-74-2 C16H22O4 11.12 (GC); 12.25 (LC) x x  x 3 
Phthalate fragment at 149.023480. Also fragment 
at 205.086153 (C12H13O3). Used in in printing 
inks, resin solvent, paper coatings and in adhesives 
Bis(2-ethylhexyl) (2E)-but-2-enedioate 142-02-6 C20H36O4 12.05 x 
   
 
Used to facilitate dye setting 
Bisphenol A 80-05-7 C15H16O2 12.27 x 
   
 
Used in resins, paper coatings and in epoxy 
adhesives 
Fumaric acid, 3-methylbut-2-yl, undecyl ester -  12.37 x 
   
 
 
Methyl 8,11,13-abietatrien-18-oate 1235-74-1 C21H30O2 13.03 x 
   
 
 
2,4-Bis(1-phenylethyl)phenol 2769-94-0 C22H22O 13.9 x     
Used in thermoplastics 
Bisomer Amine D 700  C5H13NO 1.05 
 
x   2 
Fragments into C3H9N. Used in dye-containing 
curable compositions. 
  
C20H13N5 3.35 
 
x   1 
 
  
C22H40N4O4 4.93 
 
x   
4 (+NH4+ 
adduct) 
Fragments at C9H18O3, C6H12O2,C3H6O and 
C22H43N5O4 
  
C20H23NO 5.16 
 
x   3 
Fragment: C11H13N and C8H9N 
1,3-dibenzylurea 1466-67-7 C15H16N2O 5.88 
 
x   2 
Fragments into C8H7NO 
4-Nonylphenyl dihydrogen phosphate C15H25O4P 6.23 
 
x  x 
2 (-H2O 
adduct) 
Used as surfactant and thermal transfer dye sheets 
N-Benzylbenzamide 1485-70-7 C14H13NO 7.2 
 
x   2 
Fragments into C7H4O 
  C11H15NO  7.2 
 
x   2 
Fragments into C10H15N 
Solvent Violet 8 52080-58-7 C24H27N3 7.61 
 
x  x 1 
Used as a dye 
  
C33H29N3O8 8.0 
 
x   1 
 
1-benzyl-3-tert-butyl-1H-pyrazole-5-
carboxylic acid 
100957-85-
5 C15H18N2O2 9.98 
 
x   3 
Fragments into C12H10N2O2, and C12H10N2O 
N-Benzyl-1-tetradecanamine 
 
C21H37N 10.34 
 
x   3 
Fragments into C14H29N and C7H6, used in 
thermal dye transfer 
   11.56 
 
x   3 
317.2086, 295.2264, 277.2186 
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Linolenic acid 
 
C18H30O2 12.99 
 
x   
1  (-H2O 
adduct) 
 
  
C19H37NOS 14.75 
 
x   
3 (-H2O 
adduct) 
Fragments into  C6H12S and C3H6S 
  
 14.9 
 
x    
m/z 298.3151 
  
 15.83 
 
x    
m/z 298.2812 
  
C13H22N4S 12.14 
 
 x  1 
 
Polyglycerol ricinoleate   29894-35-7 C18H33O3 13.51 
 
 x  2 
Fragments into C12H20O2, used in printing ink  
  
C21H34N4O3
S 14.23 
 
 x  1 
 
2-Dodecylbenzenesulfonic acid 27176-87-0 C18H30O3S 14.9 
 
 x  
1 (-H2O 
adduct) 
Used as binder resin in toners 
3-tetradecyldihydrofuran-2,5-dione 47165-57-1 C18H32O3 15.2-15.5 
 
 x x 1 
Used in paper size compositions 
12-Hydroxystearic acid  106-14-9 C18H36O3 15.88 
 
 x x 1 
Used as printing ink, resin composition and in 
laminates 
Ricinoleic acid 141-22-0 C18H34O3 14.2; 16.25 
 
 x x 
1 (-H2O 
adduct) 
Used in printing ink 
Dehydroabietic acid 1740-19-8 C20H28O2 16.35 
 
 x x 1 
Resin acid 
  
C23H22O3 16.95 
 
 x  2 
Fragments into C22H22O 
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